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ABSTRACT 
Bipolar disorder (BD) is a chronic and complex mood disorder with a worldwide prevalence 
of ~2%, which co-occurs with various psychiatric and medical comorbidities, and is associated 
with increased risk of suicide. About 50% of subjects with BD remain symptomatically ill 
despite treatment, with depression being the most frequent disease phase. In spite of this severe 
nature and significant medical and psychosocial burden, the precise pathophysiology of BD 
and the specific mechanisms by which bipolar disorder drugs exert their therapeutic effects are 
still obscure.  
Although current medications have some clinical efficacy, they are less than optimal in treating 
many subjects with BD. Furthermore, polypharmacy is the rule rather than exception in BD, 
however we lack understanding of the factors that underpin the efficacy of polypharmacy.  
Consequently, a more comprehensive understanding of how the currently prescribed drugs 
work at molecular and cellular levels may enable the development of new and improved 
therapeutics, and give insight into the pathophysiology of BD as well as explanations for the 
efficacy of polypharmacy. This project aims to characterise the molecular mechanisms of 
action of drugs currently used to treat bipolar disorder.  
We explored the effect of a combination of BD drugs (lithium, valproate, lamotrigine and 
quetiapine) in NT2-N (human neuronal) cells and rat frontal cortex through whole genome next 
generation sequencing and pathway analysis. We discovered that the BD drug combination 
robustly upregulated the cholesterol biosynthesis pathway in NT2-N cells (adjusted p=3.4x10-
9). All of the genes in this pathway were significantly upregulated (all p<0.001). Moreover, in 
the rats, the genes involved in cholesterol biosynthesis tended to increase as well. Gene 
expression data also revealed that the synthesised cholesterol was being utilised within the cells 
as the expression of the major gene involved in the efflux of cholesterol (ABCA1) was 
decreased by the BD drug combination. Therefore, we measured neurite outgrowth in NT2-N 
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cells treated with BD drug combination and individual drugs, and found that individually the 
drugs did not affect neurite outgrowth, however in combination they increased neurite 
outgrowth. These data suggest that one of the molecular mechanisms of action of bipolar 
disorder drugs when used in combination is increasing cholesterol biosynthesis in the brain. 
Increased cholesterol in the neuronal membranes enables the protrusion and elongation of 
neurites, thereby increasing neurite outgrowth and neuronal plasticity. This mechanism 
possibly underpins the clinical efficacy in subjects with BD when treated with polypharmacy. 
We then investigated the transcriptional effects of the BD drugs individually and identified 
possible pathways and mechanisms through which they might act to bring about efficacy in 
BD patients. We found that individual BD drugs regulated different pathways, except for 
lamotrigine, which did not appear to affect any of the pathways assessed. Lithium regulated 
the “amino acid transport across the plasma membrane” pathway, while valproate and 
quetiapine regulated “antigen processing and presentation” and “CDK5” pathways 
respectively. The pathway and differential gene expression analyses provided some 
understanding of the pathways and functions regulated by the individual BD drugs as well as 
some insight into how polypharmacy and monotherapy differ at the molecular level. However, 
this study was rather underpowered with a low number of biological replicates.  
We also investigated the differential expression of microRNAs (miRNAs) in BD drug 
combination treated NT2-N cells and rats. The BD drug combination increased the expression 
of miR-128 and miR-378 (both p<0.02). Putative target genes of these miRNAs were subjected 
to gene annotation enrichment analysis using DAVID software. miR-128 and miR-378 target 
pathways included “neuron projection development” and “axonogenesis”. A large number of 
genes that are putative targets of these two miRNAs were differentially expressed following 
treatment with bipolar drugs. We conclude that at a transcriptional level, BD drugs affect a 
number of genes in concert that would increase neurite outgrowth and hence neuronal 
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plasticity, and that this is mediated (at least in part) by modulation of the expression of these 2 
key miRNAs. 
We then created a gene expression signature (GES) to represent the overall biological effects 
of the BD drug combination on cultured human neuronal cells (NT2-N) and rat brains, focusing 
on genes that also had evidence of differential expression in individuals with BD.  We found 
that a total of 88 genes showed evidence of differential expression in response to the drug 
combination in both models, and therefore comprised the GES. Six of these genes showed 
evidence of differential expression in post-mortem brains of individuals with BD. We used this 
GES to identify new drugs that can be repurposed for BD using Connectivity Map (CMap), 
which identified 10 compounds that affected the GES in a similar manner to the BD drug 
combination. These drugs are candidates to be repurposed for BD. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction 
 
Neuropsychiatric disorders can be severe and debilitating, and constitute a high burden on 
health care systems, individuals and families. One of the most challenging neuropsychiatric 
disorders, from the perspective of the patient experience, clinical management and indeed 
research, is bipolar disorder (BD), which is chronic and characterised by recurrent episodes of 
mania or hypomania combined with periods of depression and euthymia (Figure 1.1) [1, 2]. 
Unpredictable and cyclic disruptions to the ability to think, act and feel in bipolar patients 
makes this disorder particularly incapacitating and result in a high cost in terms of morbidity, 
mortality and quality of life [3].  
 
 
 
 
 
 
 
 
Figure 1.1. The course of BD 
As per the Fourth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV) published in 1994, bipolar illness can be considered as a spectrum of disorders; type I 
bipolar disorder (BD-I), type II bipolar disorder (BD-II), cyclothymic disorder and bipolar 
disorder not otherwise specified (BD-NOS) [4-7]. However, due to the limitations of DSM-IV, 
especially the over use of BD-NOS in diagnosis, the Fifth Edition of the Diagnostic and 
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Statistical Manual of Mental Disorders (DSM-V) was released in 2013 in which the BD-NOS 
group has been renamed as Other Specified Bipolar and Related Disorders (OSBARD) [5]. The 
subtypes of BD differ in severity of episodes and create diagnostic challenges, which impact 
on clinical research [6, 8].  
BD is one of the major global health burdens with substantial mortality and morbidity 
accompanying it [9, 10]. A study on the global burden of mental disorders that was carried out 
by the World Health Organisation (WHO) in 2010 established that mental and substance use 
disorders predominate worldwide, and BD accounts for 7 % of that morbidity [9]. Moreover, 
other problems such as comorbidities, suicide, premature death and unemployment increase 
the social and economic burden of the disease on the individual as well as the community [11]. 
Compared to the general population, people suffering from psychiatric disorders experience 
more chronic medical conditions and pass away younger.  
One of the major contributors to the morbidity of BD is the inadequate treatments, which leave 
patients with significant residual symptoms and additional side effects. Particularly challenging 
in BD are the depressive symptoms, which are typically less well controlled by treatment as 
compared to manic symptoms. Consequently, there is a pressing need to discover new drugs to 
treat BD, as the drugs that are used presently are insufficient in controlling the disorder. In 
order to do so, the pathophysiology of BD must be understood more clearly to elucidate the 
biological pathways involved. The lack of understanding of the pathophysiology of BD has 
hampered de novo drug development. However, if we are able to understand the molecular 
mechanisms of action of some of the currently used BD drugs, we will be able to apply the 
concept of reverse engineering and elucidate the pathophysiology of BD. This will also enable 
us to identify drugs that are more personalised and targeted.  
 
 
3 
 
1.2 Prevalence and Epidemiology of Bipolar Disorder 
 
Aggregated cross-sectional studies show that approximately 1% of the general population meet 
lifetime criteria for BD-I [4, 12]. Although outliers exist in individual countries, the global 
prevalence still clusters around 1% [13]. An epidemiological review on BD reported the 
median prevalence of BD-II to be 1.2% [14]. 
In a study carried out by Merikangas et al. (2011) on the lifetime and twelve month prevalence 
rates of DSM-IV BD in 11 countries in the Americas, Europe and Asia, the combined lifetime 
BD prevalence was 2.4% (BD-I 0.6%, BD-II 0.4% and sub-threshold BD 1.4%). New Zealand 
and the United States had the highest lifetime prevalence rates of BD-I (1%), followed by Brazil 
(0.9%) [12]. India and Bulgaria had the lowest prevalence of BD-I (0%). With regard to BD-
II, the United States had the highest prevalence (1.1%) followed by New Zealand (0.7%) and 
then Lebanon (0.5%). A similar trend was seen in sub-threshold BD with the United States 
having the highest prevalence (2.4%) followed by New Zealand (2.1%). Among all the 
countries studied, the United States had the highest (4.4%), whereas India had the lowest 
(0.1%) lifetime prevalence of BD. To date, this is the only study that provides aggregated 
international data on the lifetime prevalence of BD-I, BD-II, and sub-threshold BD using DSM-
IV diagnosis criteria. The data on the lifetime prevalence of BD in Australia is scarce, however 
in a study carried out by Fisher et al. (2007), it was found to be 2.5%, which is comparable to 
the aforementioned findings [15]. 
According to the National Survey of Mental Health and Wellbeing carried out in 2007 in 
Australia, the twelve-month prevalence of affective disorders in individuals aged between 16 
and 85 was found to be 6.2% [16]. Of those, 1.8% had BD [17]. However, another Australian 
study reported the twelve-month prevalence of BD-I and BD-II as 0.5% and 0.4% respectively 
[18], which is comparable to the twelve-month prevalence of BD in New Zealand (BD-I 0.6%, 
BD-II 0.5%) described by Merikangas et al. (2011). The inconsistency between the national 
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survey and the other studies could be that those studies only reported BD-I and BD-II without 
the prevalence of subthreshold BD, whereas the national survey included depression, 
dysthymia and BD under the category of affective disorders.  
Fassasi et al. (2014), recently reported a community level lifetime prevalence of DSM-V BD 
in Lausanne, Italy, where the BD-I and BD-II prevalence were 1% and 0.8% respectively [5]. 
The lifetime prevalence for the OSBARD criteria was 1%. Given this study was done at a 
community level; we cannot extrapolate this data to national level. However, the data is quite 
comparable to the findings of Merikangas et al. suggesting that the slight differences in the 
DSM-IV and DSM-V diagnosis criteria do not substantially affect the overall prevalence [12].  
The majority of BD patients first present with symptoms in their late teens. In a review by 
Mitchell et al., the reported mean age of onset in three large datasets ranged from 17.4 to 22.9 
years [19]. Moreover, studies have shown that early onset of the disease has correlations with 
family history of affective disorder as well as increased severity [20, 21]. Given this disease 
affects people in the prime of their lives, it is devastating in terms of health, finance and in 
quality of life as patients often lose the healthy years of their lives to BD.  
Merikangas et al. (2007) showed that BD was inversely associated with education, and had no 
apparent link with gender, race, ethnicity or income.  Furthermore, BD is more common in 
divorced/widowed and unemployed people than those who were single/married and employed. 
Similarly, in Australia, females and males are equally affected by BD, and it is more prevalent 
among separated/divorced/widowed and unemployed individuals [22].  
The studies that were carried out prior to 2013 primarily employed DSM-IV diagnosis criteria, 
or even earlier DSM versions. However, since the publication of DSM-V, clinicians have 
adopted these new guidelines. Therefore, it might be difficult to identify the true current 
prevalence of BD based on the updated criteria given that not many studies have been 
conducted using DSM-V.  
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Moreover, methodological discrepancies in these studies should be taken into consideration 
and only when studies use a common questionnaire or methodology for the diagnosis of BD, 
can we arrive at a more reliable prevalence estimate for BD.   
The high and growing prevalence of BD also means that there is an increasing incidence of 
comorbidities and socioeconomic burden on individuals and the general community, which 
must be combated with more effective and affordable treatment options.  
1.3 Comorbidities and Outcomes in Bipolar Disorder 
 
The existence of comorbidities in mental disorders are attributable to severe progression, 
chronicity, increased incapacitation, reduced response to treatment and  poor outcomes [23]. 
The lifelong episodic nature of BD can lead to functional and cognitive impairment as well as 
poor quality of life due to various medical and psychiatric comorbidities and outcomes which 
include anxiety, behavioural and personality disorders, substance abuse and suicide [24].  
Studies from the last two decades show that BD is linked to premature death [25] with almost 
2-fold increased risk caused primarily by cardiovascular diseases, and 15-fold increased risk 
of suicide [26, 27]. A Swedish national cohort study in 2013 reported that BD patients had 
about 2-fold increased mortality and passed away 9 years prematurely when compared with 
healthy controls. These deaths were primarily due to cardiovascular diseases, diabetes, asthma, 
influenza/pneumonia, unintended injuries and suicide [28]. There is also a 15% lifetime risk of 
suicide, which is one of the leading causes of death in BD patients [29]. According to a report 
by SANE Australia, 24,001 years of healthy Australian life were lost to BD in 2003, with 4843 
years lost due to suicide and self-harm [29].   
Furthermore, findings also suggest that comorbidities are associated with higher chance of 
recurrence in patients. In a prospective study of 1000 BD patients, it was found that anxiety 
was linked to earlier recurrence and poorer recovery from a depressive episode [30]. In 
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addition, alcohol and cannabis abuse, personality disorders and medical comorbidities were 
also associated with higher recurrence rates, prolonged episodes and rapid cycling [31-33].  
1.4 Economic Burden of Bipolar Disorder 
 
In addition to social and personal impairment, BD is also associated with substantial economic 
burden to the patient, family and society [34]. The economic burden is exacerbated by 
comorbidities, suicide and the costly treatment of BD.  An American study examined health 
insurance expenditure in BD patients and established that it was the most expensive 
behavioural health care diagnosis [35]. From the claims of 1.66 million individuals that were 
examined, 7.5% were seeking payments for a behavioural health care problem. Moreover, of 
those patients, 3% were suffering from BD with an average yearly out of pocket expenditure 
of US $568. Furthermore, this study also found that the in-patient hospital admission costs 
were much higher for BD patients compared to other behavioural health care patients [35].  
A review by Laxman and co-workers (2008) looked at the effect of BD in the workplace and 
concluded that it had adverse impact on work place relationships, attendance and functioning, 
thus leading to loss of efficiency and additional expense to employers [36]. 
In Australia, mental health care costs about $3 billion annually, which is 9.6% of the entire 
health care budget [23]. One of the initial studies on the economic impacts of BD in Australia 
revealed that the direct and indirect costs of BD and associated comorbidities were extensive 
with about $1.59 billion being spent in 2003 [29]. It is likely that these costs would have 
increased in recent years. A more recent Australian study showed that the additional costs of 
BD were approximately $3.97-$4.95 billion [15].  
The comorbidities, high recurrence rates, poor outcomes and the subsequent economic burden 
posed by BD illustrate how disabling this disorder can be. This further emphasises the 
importance of understanding the pathophysiology of BD in order to identify more effective 
treatment options.  
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1.5 Aetiology of Bipolar Disorder  
 
The knowledge of the pathophysiology of BD has advanced over the years, however, definite 
causes of BD are yet to be fully elucidated [37]. BD is considered as one of the most heritable 
psychiatric illnesses; however, it is likely to be a multifactorial disorder where environmental 
and genetic factors both play a role in the aetiology [38]. Family, twin and adoption studies 
show that genetic factors are likely to play a major role in the aetiology of BD, which is among 
the most comprehensively studied psychiatric disorders with regard to genetics [39].  
Increasing evidence from studies of the biological mechanisms indicate that the genetic 
aetiology of BD could lead to pathophysiology that is related to mitochondrial dysfunction, 
neuroinflammation, circadian dysregulation, as well as disruptions in neurotransmitter 
signalling and neural plasticity [40, 41] 
1.5.1 Genetics of Bipolar Disorder 
 
High familiarity and heritability of BD have been established thorough various genetic 
epidemiology studies. In a review by Smoller and Finn (2003) it was reported that first degree 
relatives of BD patients have about 5-10 fold increased risk of being affected compared to the 
relatives of controls [39]. Moreover, one of the early familial studies showed that the close 
relatives of the BD patients have increased risk for other psychiatric disorders as well as 
substance abuse [42], which has recently been affirmed in a study by Lichtenstein and co-
workers [43]. In addition, several twin studies have established that monozygotic twins have 
high concordance for BD compared to dizygotic twins [44-46] and that the heritability of BD 
is between 79 and 93% [46-48]. Furthermore, some of the early adoption studies have also 
shown that biological parents of adoptees with BD were more likely to have the disorder than 
the adoptive parents [49-52].  
The findings from genetic linkage studies have implicated various chromosomal regions in BD 
but they have not been consistently reproducible [53, 54]. One of the most extensive meta-
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analyses of linkage studies has reported the long arms of chromosomes 6 and 8 to be implicated 
[55]. However, the specific genes from these regions are yet to be identified. The inability to 
identify genes through linkage analysis provides further evidence of the complexity and 
heterogeneity of BD, where a large number of genes might be affected along with 
environmental factors playing a role. This understanding has also shifted the focus onto 
genome wide association studies (GWAS) in BD. Several association studies have found single 
nucleotide polymorphisms (SNPs) in the genes CACNA1C, ODZ4, ANK3 and NCAN, thus 
making them potential candidate genes for BD [38, 56]. The SNP in the CACNA1C gene has 
been one of the most extensively studied genomic variants in BD [56] and is located within a 
voltage dependent calcium channel [53]. Calcium homeostasis is known to be affected in BD 
and is discussed elsewhere in this chapter.  
The aforementioned studies indicate that genetic factors play a significant role in BD.  
However, given that the concordance rate of BD is not 100% in monozygotic twins, and the 
inconsistency in identifying causative genes through linkage and association studies, it is clear 
that environmental factors also contribute to the risk of BD.   
1.5.2 The Role of the Environment in Bipolar Disorder 
  
Life events or stress can play a significant part in the onset of psychiatric disorders along with 
genetic factors, and this is also applicable to BD [57]. Various studies have established that 
negative life events such as death of a family member, severe illness of self or family members, 
financial problems, major relationship problems, sexual, physical or emotional abuse, etc. 
could trigger or increase the probability of bipolar depression and mania [57-60]. Studies have 
also shown that depending on the type of negative life event, the type of episode can also be 
affected. For instance, personal illness has been associated with bipolar depression while 
demise of a loved one has been linked to mania [57, 61, 62]. 
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The link between childhood trauma and BD has been explored recently and various studies 
have found a clear connection [63]. Romero et al. (2009) showed that children and teenagers 
affected with BD were exposed to more negative life events as opposed to healthy controls 
[64]. Moreover, another study has reported an involvement of increased rate of childhood 
trauma in BD, especially emotional abuse in childhood [65, 66]. Retrospective studies have 
also shown that trauma in childhood is implicated with severe disease progression and earlier 
disease onset, more suicidal behaviour and more depressive and manic episodes [67, 68].  
It appears clear that both genetic and environmental factors contribute to the development of 
BD. Given the lack of clarity regarding BD aetiology in terms of causative genes, it is not 
surprising that our understanding of the pathophysiology of BD is limited. However, recent 
research has implicated mitochondrial dysfunction in BD pathophysiology.  
1.6 Pathophysiology of Bipolar Disorder 
1.6.1 Mitochondrial Function 
 
Mitochondria are intracellular organelles encompassing mitochondrial DNA (mtDNA) that is 
maternally inherited. This organelle is associated with the regulation of energy production, and 
makes adenosine-5’- triphosphate (ATP) via the electron transport chain (ETC) [69]. The brain, 
although it represents only 2% of the body mass, has a high energy requirement and uses up to 
20% of resting body energy [70]; hence the brain tissue contains a large number of 
mitochondria relative to other organs [71]. These factors make the brain vulnerable to the 
effects of reduced aerobic metabolism [71].  
Mitochondria use glucose and oxygen to produce ATP through a series of events as shown in 
Figure 1.2. Glycolysis, which is a process where glucose is broken down to form pyruvate, 
occurs in the cytosol of the cell, whereas the rest of the events take place in the mitochondria 
[70]. The low energy generating anaerobic pathway converts pyruvate into lactate whereas in 
the high energy producing aerobic pathway it is transformed into acetyl-coenzyme A, which 
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crosses into the mitochondria and enters the citric acid cycle generating substrates that are 
utilised in oxidative phosphorylation in the ETC.  
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Energy production in the mitochondrion 
(Adapted from de Sousa et al. (2014) [70]) 
The ETC activity during oxidative phosphorylation produces reactive oxygen species (ROS) 
and reactive nitrogen species (RNS), such as toxic superoxide, nitric oxide (NO) and 
peroxynitrite, as by-products [70, 72].  RNS and ROS are scavenged through the action of 
catalase, glutathione (GSH), glutathione peroxidase (GSH-Px) and superoxide dismutase 
(SOD). GSH-Px and catalase transform H2O2, a by-product of ROS scavenging, to H2O in the 
cytosol. H2O2 can also produce free radicals upon interacting with iron or copper ions [70]. 
Therefore, ROS and RNS, when made excessively or not adequately removed, can cause 
oxidative and nitrosative modification of proteins, lipids and DNA contributing to oxidative 
stress and inflammation [70, 72]. Moreover, increased levels of cytoplasmic ROS can also 
trigger the activation of pro-apoptotic proteins and eventually bring about apoptosis [70].  
Mitochondrial Matrix 
ETC Complexes 
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In addition to energy production, mitochondria also buffer cytoplasmic calcium (Ca2+) 
concentration, consequently contributing to Ca2+ homeostasis and Ca2+ driven apoptosis and 
possibly ferroptosis [73, 74]. Ca2+ functions as a major secondary messenger mediating 
neurotransmission and neuronal plasticity [70, 73, 75]. An electrochemical gradient across the 
mitochondrial membrane that helps to pump hydrogen in and out drives the production of ATP 
by activating ATP synthase. This leads to a negative potential in the mitochondria as opposed 
to the cytoplasm, which generates a reservoir of Ca2+ in the cytosol. When the cytosolic Ca2+ 
increases, it can prompt stress and excitotoxicity, however, the buffering activity of 
mitochondria helps to avert these effects [70]. The mitochondria sequester the Ca2+ through 
their Ca2+ uniporter, which is then buffered or carried back out of the mitochondria via 
Na+/Ca2+ antiporter. However, cellular damage prompted by surplus flooding of Ca2+ into the 
mitochondria increases its permeability by means of opening the permeability transition pore 
[70, 76]. This results in the release of pro-apoptotic proteins such as cytochrome C and 
procaspases, which induce apoptosis [76].     
1.6.1.1 Mitochondrial Dysfunction in Bipolar Disorder 
 
Mitochondrial dysfunction denotes disruption in energy metabolism instigated by aberrations 
in either mtDNA or nuclear DNA [69]. In such cases, energy metabolism is shifted towards 
glycolysis, which increases lactate and decreases pH, phosphocreatine and ATP levels. These 
biomarkers of deficient energy metabolism are routinely used in detecting mitochondrial 
dysfunction or disorders in patients and have been implicated in the pathophysiology of BD 
[77] (Figure 1.3). BD, being periodic between mania and depression, is correlated with 
different energy usage by the brain. It has been proposed that a manic episode might be  
associated with augmented bioenergetics while depression could be characterised by the 
converse state [72]. This endorses that BD could indeed be a biphasic energy disorder and 
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therefore biomarkers implicated in bioenergetics and mitochondrial function have been widely 
studied in BD patients. 
Functional magnetic resonance imaging (fMRI) studies have shown that BD patients have 
augmented levels of lactate in the prefrontal cortex and limbic regions of the brain [70, 75]. 
Likewise, in a proton echo planar spectroscopic imaging study done on medication free BD 
patients, grey matter lactate levels were found to be higher as opposed to healthy controls [78].  
Another study further supports these findings as it reported raised cerebrospinal fluid lactate 
levels in BD patients [77]. Furthermore, studies have also established that intracellular pH in 
the brain is reduced in BD patients, which could be attributed to the shift to glycolysis due to 
mitochondrial dysfunction [78-80].  
Other biomarkers that indicate altered energy metabolism are high energy phosphates such as 
phosphocreatine and ATP. Spectroscopic studies have established diminution of these 
phosphates in the frontal and temporal lobes of BD patients [78, 81-83]. In addition, a post-
mortem study in BD patients showed decreased expression of genes coding for mitochondrial 
complexes involved in oxidative phosphorylation, and down regulation of ATP-dependent 
processes [84]. In a similar study, MacDonald et al. (2006) studied the expression levels of 
mRNA coding for creatine kinase, which acts on phosphocreatine to yield ATP and creatine. 
They reported that the expression of the brain isoform of creatine kinase was downregulated, 
providing further evidence that lower phosphocreatine and ATP levels play a role in the 
pathophysiology of BD [85]. Striking evidence shows that phosphocreatine and ATP levels are 
decreased in patients with major depression, further strengthening the finding of altered brain 
bioenergetics between the two phases of BD [86-88].  
Recent studies have shown that the activity of mitochondrial ETC complexes is reduced in the 
post-mortem brains of BD patients along with the indication that the subunits for complexes I, 
IV and V are down regulated in BD [89, 90] (Figure 1.3). Moreover, linkage studies have found 
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chromosomal region 19p13 to be implicated in BD, where many of the ETC complex I genes 
are located [91].  
Increased oxidative stress is another abnormality that has been reported in BD patients. As 
mentioned previously, the brain metabolises around 20% of total body oxygen although it is 
only 2% of our whole body by weight. This makes the brain highly susceptible to the 
production of ROS and ensuing oxidative stress [92]. Oxidative stress occurs when the pro-
oxidant levels overpower the antioxidant capacity leading to the overproduction of free radicals 
or ROS along the ETC [92]. Antioxidant capacity might become challenged upon alteration in 
the activity of antioxidant enzymes [92]. As mentioned in section 5.3.1, catalase, SOD, GSH 
and GSH-Px are such enzymes, and several studies show that their activity is altered in the 
brain of BD patients (Figure 1.3). SOD activity was established to be increased during mania 
and depression but not in euthymia, whereas catalase activity was decreased in euthymia [93]. 
In another study in unmedicated manic BD subjects, SOD and catalase activities were increased 
[94]. NO is another marker for oxidative stress that is found to be increased in BD mania and 
euthymia along with SOD [95]. Furthermore, Fullerton et al.(2010) reported that genes for 
SOD2 and GSH-Px3 can function as risk factors for BD [96].  These studies indicate that SOD, 
an antioxidant enzyme, might be increased in BD patients to combat oxidative stress. 
Collectively, the available literature is suggestive of energy metabolism shifting towards 
glycolysis and production of ROS, which could reflect a generalised pattern of compromised 
mitochondrial metabolism in BD. However, the origins of these abnormalities are yet to be 
fully elucidated.  
 
14 
 
 
 
 
Figure 1.3. Mitochondrial dysfunction and BD (Adapted from Rajasekaran et.al (2015) [97]) 
 
1.6.2 Neurobiological Disruptions in Bipolar Disorder 
 
Knowledge of the cellular and molecular basis of neuronal and glial function has advanced 
recently and shed some light into the mechanisms associated with axonal growth, synapse 
formation, neuronal plasticity and apoptosis. This has led to research into the role of 
intracellular signalling and neurotransmission mechanisms in BD.  
1.6.2.1 Structural and Functional Alterations of the Brain in Bipolar Disorder 
 
The inference of brain structure alterations in BD was brought about by the observation that 
lesions due to tumours, strokes or injuries caused manic behaviour in some patients [98]. This 
study also established that when the lesions occurred in the frontal and temporal lobes, some 
patients experienced secondary mania [98].   
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Structural neuroimaging studies have shown anatomical and neuropathological aberrations in 
BD patients, such as ventricular enlargement, reduced volume of grey matter, decreased 
neuronal integrity and levels of a mitochondrial energy production marker (N-acetyl-aspartate; 
NAA) and reduced density of neurons and glial cells [99, 100].  
Two comprehensive reviews by Cerullo et al. (2009) and Strakowski et al. (2005) on functional 
imaging studies suggest that the altered activation and metabolism observed in pre-frontal 
cortex, amygdala, basal ganglia, thalamus and anterior cingulate cortex in BD patients is highly 
significant [101, 102]. 
1.6.2.2 Neurotransmitters 
 
Many of the early studies on BD attempted to unravel the role of four main monoamine 
neurotransmitters, serotonin (5-HT), norepinephrine (NE), dopamine (DA) and acetylcholine 
(Ach) in the disease pathology [103]. It was believed that imbalance in these neurotransmitter 
systems was causing BD, however to date no particular dysfunction in these systems has been 
recognized [33]. However, in recent times attention has been shifted towards other 
neurotransmitters, especially glutamate, which is discussed in detail below. 
Glutamate is an important excitatory neurotransmitter in the cerebral cortex that binds to either 
ionotropic or metabotropic receptors and plays a significant role in synaptic plasticity, learning 
and memory [104]. Ionotropic receptors, which are subdivided into three groups (α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA), Kainate receptors (KA) and 
N-methyl-D-aspartate (NMDA) receptors) have been shown to play an important role in mood 
disorders as they regulate ion influx and efflux, thereby facilitating oxidative balance [104]. 
When AMPA or KA receptors are activated they increase the influx of sodium that prompts 
fast excitatory neurotransmission. On the other hand, NMDA receptors, which are blocked by 
magnesium ions under resting conditions, become activated when two glutamate molecules 
and two molecules of glycine or D-serine bind. When the NMDA receptor is activated it 
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increases the concentration of cytosolic Ca2+, thus triggering neurotransmission over a longer 
period of time [104]. However, in pathological circumstances/overstimulated state, glutamate 
could act as a strong neuronal excitotoxin prompting excitotoxicity [104]. When glutamate 
levels increase, the subsequent rise in Ca2+ influx leads to the collapse of the mitochondrial 
membrane potential. This may trigger the production of ROS and RNS resulting in 
excitotoxicity and apoptosis [105] (Figure 1.3). In addition, at lower levels, glutamate regulates 
mitochondrial biogenesis.  
Increased levels of glutamate [78, 106] have been extensively reported in BD patients. In a 
post-mortem study of BD patients, glutamate levels were found to be increased in the prefrontal 
cortex [107]. Moreover, in manic [108] and depressed [109] BD patients glutamate levels were 
raised. Furthermore, the findings that increased levels of RNS in BD patients and lithium, a 
first line treatment for BD, decreased the level of glutamate in the brains of BD patients support 
the involvement of glutamate in BD pathophysiology [110, 111].  
1.6.2.3 Neuroinflammation 
 
Our immune system is classified into innate and adaptive systems [112].  The innate system, 
which is the primary defence mechanism, makes use of defence cells (e.g. neutrophils, 
monocytes, monocyte derived dendritic cells, macrophages, natural killer cells and mast cells), 
and inflammatory cytokines (e.g. Interferon -IFN-α, tumour necrosis factor α – TFN- α, 
Interleukins – IL-1β, IL-6 and IL-8) and chemokines [112-114]. On the other hand, the adaptive 
immune system is stimulated by antigen presenting cells (macrophages and dendritic cells) 
which activate T cells [114]. In the case of BD, CD4 T helper (Th) cells are important, as they 
are involved in the cytokine cascade instigation. Th1 cells influence the secretion of pro-
inflammatory cytokines (e.g. IFN –γ, TNF and IL-2) while Th2 cells secrete anti-inflammatory 
cytokines (e.g. IL-4, IL-5 and IL-10) [114]. Therefore, it is essential that there is an equilibrium 
between Th1 and Th2 cells for the proper functioning of the immune system.  
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In the last decade, evidence has emerged to show that the immune system could be involved in 
the pathophysiology of BD [115, 116]. Many studies have looked at the inflammatory cytokine 
profiles in BD.  In 1992, the macrophage- T- cell theory of depression was proposed, which 
stated that continuous activation of macrophages/microglia and T-cells produces cytokines and 
inflammatory molecules that destabilise the brain [117]. Along with environmental and genetic 
predisposition, these changes in the brain can bring about the signs and symptoms of 
mania/depression [118]. 
Several studies have demonstrated that the levels of pro-inflammatory markers, such as IL-6, 
TFN- α, IL-1β, IL-1 receptor antagonist (IL-1RA), nuclear factor kB (NFkB), other cytokines 
and C-reactive protein (CRP) were augmented in BD mania and depression [40, 119-122]. 
When cytokines, especially IL-6 and TFN-α increase, the hypothalamic-pituitary-adrenal 
(HPA) axis is disrupted, increasing cortisol to neurotoxic levels. Increased cortisol levels can 
decrease the number of post-synaptic serotonin receptors and levels of brain-derived 
neurotrophic factor (BDNF), thereby disrupting neurotransmitter pathways and neuronal 
plasticity [114].  
In the brain, microglia act as macrophage-like cells [113], and when activated under 
pathological conditions they induce pro-inflammatory cytokine cascades [118]. The 
consequent increase in IL-1β results in an upsurge of NMDA receptors leading to glutamate 
excitotoxicity [40, 114]. Therefore, activated microglia have the ability to initiate the 
production of ROS as well as trigger glutamate excitotoxicity which can be harmful to neurons 
and affect synaptic plasticity and neuronal outgrowth [118].  
Glial cells and inflammatory cytokines along with neurotransmitters can modulate neuronal 
plasticity as well as mitochondrial biogenesis, and therefore influence signalling and neuronal 
outgrowth, which are essential for the proper functioning of neurons.  
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1.6.2.4 Neuronal plasticity 
 
Plasticity or neuronal plasticity is the intrinsic ability of the nervous system to modify neural 
circuitry and function in response to internal or external stimuli [123-125]. Neuronal plasticity 
can denote any short or long-term changes in intracellular signalling, gene regulation, 
alterations in synaptic number and strength, change in neurotransmitter release, shaping of 
axons and dendrites and neurogenesis [123, 126]. Synaptic plasticity denotes activity 
dependent changes in the efficiency of neurotransmission, which could be short or long term, 
and has been evidently linked to the pathophysiology of mood disorders [123, 124]. However, 
in the literature both of these terms are often used interchangeably and, in this review, both 
terms will be discussed as neuronal plasticity. Growing evidence suggests that neuronal 
plasticity plays a significant role in the pathophysiology of BD.  
Glial cells, which include microglia and astrocytes, uphold homeostasis, synaptic modulation 
and protection of neurons in the brain and peripheral nervous system, and thus contribute to 
neuronal plasticity [127, 128]. Signalling between perisynaptic glia and neurons has a 
significant role in plasticity [127]. Furthermore, microglia also regulate the production of 
serotonin, via inflammatory signalling, and ultimately lead to prolonged changes in synaptic 
function, apoptosis, excitotoxicity and neurogenesis [128]. However, pathological changes in 
the brain could interfere with microglial cells and contribute to neuronal degeneration, thus 
recent findings suggest that these cells can induce inflammation through cytokines and ROS, 
and play a role in the pathophysiology of BD [127].  
Intracellular calcium is reported to be increased in the platelets of BD patients [129, 130]. 
Calcium influx and efflux, which are controlled by mitochondria in the neurons, are imperative 
to neurite outgrowth and neuronal plasticity [131, 132] (Figure 1.3). Deficient ATP production 
due to insufficient oxidative phosphorylation and increased levels of glutamate, as mentioned 
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in section 1.6.2.2, can disrupt calcium homeostasis. This can impair neurotransmission as well 
as short and long term neuronal plasticity given the role of Ca2+ in intracellular signalling.  
Moreover, mitochondria are the major energy manufacturers in the neurons, and in order to 
cater for the neuronal energy demands, they migrate along the axons and dendrites and undergo 
fission and fusion [70, 133]. Therefore, this movement and multiplication of mitochondria are 
crucial for synapse formation and maintenance of mitochondrial mass respectively [70]. 
Pathological division and fusion of mitochondria due to increased oxidative stress or any other 
dysfunction can affect synaptic signalling and plasticity as well as initiating neuronal apoptosis 
[70, 133].  
A network of axons, neurites, dendrites and synaptic endings transmit signals and enable 
communication between neurons [134], and disruption of this network can affect neuronal 
plasticity [135]. Therefore, neuronal projections, such as axons and dendrites are essential for 
neurite outgrowth that is needed to maintain neuronal plasticity [134]. Phospholipids, which 
are major components in cell membranes, have been shown to be important in the regulation 
of neurite outgrowth in cultured neurons [136]. Neurons have a large amount of membrane 
surface formed by neuronal projections, where cholesterol is present in high amounts and its 
deficiency has been implicated in the dysregulation of dendrite outgrowth in cerebral cortical 
neurons isolated from rats [137].Therefore, cholesterol plays a significant role as a structural 
component, in neurotransmission, synaptogenesis, dendrite formation, axonal guidance and 
neurite outgrowth [138]. In the brain cholesterol is synthesised within the brain and its 
biosynthesis is separated from periphery due to the presence of blood brain barrier (BBB) 
[138]. This process requires energy and therefore, oxidative phosphorylation and mitochondrial 
pathways have to be regulated properly in the brain.  
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Be it mitochondrial or neurological dysfunction, it is clear that all of these pathways and 
mechanisms are interrelated, and all the above-mentioned pathways could be potential targets 
in understanding the pathophysiology of BD. Moreover, dysfunction in one pathway could 
downregulate or upregulate another function (Figure 1.3) and this could be another reason why 
we are still unable to pinpoint an exact pathophysiological mechanism responsible for the 
symptoms and signs of BD. Therefore, looking at drug mechanisms of action can pave way to 
elucidating the pathophysiological mechanisms in BD. That way, we might be able to elucidate 
pathways that are affected by the drugs early in the cascade and thus affect other pathways 
downstream. The pathways or functions the BD drugs act on could represent a major 
pathophysiological nexus in BD. In order to understand how the BD drugs work or affect the 
pathways, we could study the transcriptional effects of the drugs on mRNA and microRNAs 
(miRNAs) in cellular models. The expression of miRNAs and mRNA are interconnected where 
a certain miRNA could downregulate or upregulate the translation of single or multiple mRNAs 
[126]. Therefore, studying the transcriptional changes would enable us to identify differentially 
expressed genes and miRNAs following BD drug treatment and via pathway analysis of these 
genes and miRNAs, we can elucidate affected pathways.  
1.6.3 miRNAs 
 
In recent years, the role of miRNAs has been of interest in psychiatric disorders. miRNAs are 
involved in various pathways such as the development, differentiation, proliferation, apoptosis 
and immune response throughout the organism, including the nervous system [139-142]. 
Neurons are rich in miRNA expression, and many neuronal and brain specific miRNAs have 
been reported [143, 144]. MicroRNAs play important roles in brain function, including 
neuronal differentiation, neurogenesis and synaptic plasticity [145, 146].  
Several promising studies suggest differential expression of miRNAs in the post-mortem brains 
of BD patients. A recent study by Choi et al. (2017) found that miR-149 was increased in 
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anterior cingulate cortex-derived (ACC) exosomes of BD patients [147]. The same group has 
previously showed that miR-29c was highly expressed in the prefrontal cortex (PFC) of BD 
patients [148]. Moreover, in another study on PFCs of BD patients, it was reported that miR-
17-5p, miR-579, miR-106b-5p and miR-29c-3p were upregulated while miR-145-5p, miR-
485-5p, miR-370, miR-500a-5p and miR-34a-5p were downregulated [149]. 
In BD, miR-134 has shown to be a potential biomarker.  miR-134 suppresses the translation of 
the Limk1-mRNA, which codes for an enzyme that regulates dendrite size [126]. This 
repression of Limk1 can be reversed by BDNF, which has been shown to be involved in 
neuronal plasticity and connectivity [150]. Furthermore, the plasma levels of miR-134 has also 
been shown to be inversely correlated with severity of mania in BD patients compared to 
healthy controls [151]. These findings collectively suggest that miRNAs are important as 
therapeutic targets as well as markers that can be used to understand the pathophysiology of 
BD.  
Furthermore, studies have also shown that the commonly prescribed mood stabilisers, lithium 
and valproate, regulate miRNAs in humans and rats [152]. Chen et al. (2009) showed that 
lithium increased the expression of four miRNAs (miR-34a, miR-152, miR-155 and miR-221) 
in lymphoblastoid cell lines derived from BD patients compared to their discordant siblings 
[153]. In rat hippocampus, chronic treatment with lithium and valproate altered the expression 
of 37 and 31 miRNAs respectively, of which nine were affected by both drugs [152].  
Given that many miRNAs are highly expressed in the human brain, it is conceivable that 
dysregulation of miRNAs could be involved in the pathophysiology of BD.  
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1.7 Management of Bipolar Disorder 
1.7.1 Drug Therapies  
 
The available BD drug therapies have not been highly successful in treating the underlying 
causes, in spite of the considerable development of BD research in the last two decades. This 
is mainly due to incomplete understanding of the pathophysiology of BD, leading to a lack of 
validated pharmacological targets and a lack of well-established  animal models for the disorder 
[154].  Therefore, most of the current BD drugs have been repurposed from another disorder 
such as epilepsy or schizophrenia (SZ) [154]. For example, antipsychotics are used for the 
management of mania while antidepressants are used in depressed phases. However, many of 
the currently available BD treatments emphasise acute stabilisation of the patients where the 
objective is to bring them back to euthymic mood, and maintenance in order to prevent 
recurrence and improve quality of life and re-establish psychosocial functioning [154, 155]. 
Furthermore, treatments that improve depression could induce mania or rapid cycling in 
patients, while typical antipsychotic treatments could trigger depression [154]. Given the 
chronicity of BD, it is crucial that the safety and tolerability of the drug interventions are 
weighed against efficacy while taking into consideration the long-term management. 
Therefore, the treatment options must be well-thought-out for each patient, episode and stage 
of the disease [155].  
In BD, depressive episodes are more recurrent and difficult to treat compared to hypomanic 
episodes, therefore, patients mostly seek treatment for depression [156]. In addition, physicians 
more easily diagnose depression rather than mania or subthreshold BD characteristics. 
Therefore, BD is at times misdiagnosed as unipolar major depressive disorder (MDD) [156]. 
These patients might not respond to antidepressant therapy, which could prompt a manic or 
hypomanic episode, thus reducing the quality of life and increasing the risk of self-harm [157]. 
In such cases, mood stabilisers or atypical antipsychotics are more suitable.  
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Conventionally, first-line mood stabilizers such as lithium and valproate have been used in 
treating BD, however, in recent years the treatment options have been extended to include 
atypical antipsychotics [158]. Some of the currently available drugs for treating mania are 
lithium, quetiapine, valproate, olanzapine and aripiprazole, while bipolar depression is treated 
with quetiapine, asenapine, lamotrigine and olanzapine-fluoxetine combination [158, 159]. The 
Canadian Network for Mood and Anxiety Treatment (CANMAT) guidelines recommend 
lithium, valproate or quetiapine as first line monotherapy for acute mania whereas for 
depression lithium, lamotrigine or quetiapine are advocated [160]. Moreover, for maintenance 
treatment of BD, CANMAT suggests lithium, valproate, quetiapine or lamotrigine as first line 
monotherapy [160]. Often patients are managed with polytherapy throughout all the phases of 
BD. 
1.7.1.1 Lithium and Valproate 
Lithium and valproate are US Food and Drug Administration (FDA) approved mood 
stabilisers, which are used in the treatment and maintenance of BD. Lithium, a monovalent 
cation, was first introduced as an effective treatment for mania in 1949 by John Cade, and since 
has been used as a gold standard treatment for BD due to its neuroprotective and neurotrophic 
actions [158, 161]. Valproate has been used as an alternative and adjunctive treatment to 
lithium since 1966. Valproate is obtainable in various forms such as sodium valproate, valproic 
acid and valproate semi-sodium, however they all circulate in the body as the valproate ion.  
Lithium is beneficial in treating all stages of BD and it is also linked to reduced suicidal risk in 
patients [162, 163]. Additionally, lithium therapy appears to be more effective against bipolar 
mania compared to depression and has a prophylactic efficacy against relapse [164, 165]. 
Valproate has been widely used in treating acute episodes of mania and depression, however, 
studies show that it is more effective for the treatment of acute mania [166] and is possibly 
superior to lithium in treating mixed state patients [167]. Lithium can be used as first line 
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monotherapy for both mania and depression while valproate can be used as a monotherapy for 
mania [168].  
It should be noted that how lithium and valproate bring about these effects is still not 
understood fully; however, it has been proposed that these drugs could affect various enzymatic 
pathways that affect mitochondrial function, neuronal plasticity, inflammation and axonal 
guidance.  
The high levels of intracellular calcium and sodium seen in BD patients, which are thought to 
be responsible for the increased neurotransmitter release, have been shown to be reversed with 
lithium therapy, possibly by displacing these ions [169]. However calcium antagonists such as 
verapamil are of no value in the treatment of mania [170]. Another mechanism that could 
account for the therapeutic effect of lithium is its action on various neurotransmitter systems. 
Action of lithium has been established in the serotonergic system, which has long been thought 
to be involved in the pathophysiology of BD [169]. Different studies have shown that lithium 
increased the release of serotonin at the synaptic level and that this could lead to anti-manic 
activity in patients [169, 171]. Therefore, these studies show that lithium could be attaining 
these therapeutic and prophylactic outcomes by affecting neurotransmitter-signalling 
pathways.  
Further evidence shows that lithium and valproate bring about neuroprotective effects in BD 
patients. MRI studies have shown that lithium treatment increased the cerebral gray matter 
volume and NAA, which are reduced in BD patients as mentioned in section 5.4.1 [172, 173]. 
Neurotrophins are regulatory molecules that facilitate the differentiation, regulation and 
survival of neurons and modify synaptic transmission and plasticity, thereby preventing cell 
death and promoting neurogenesis [174].  One such molecule, B-cell lymphoma/leukaemia -2 
protein (Bcl-2) was increased in the frontal cortex, hippocampus and striatum of BD patients, 
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and in cultured cells of rodents and human neuronal cells in vitro, when treated with lithium 
[172, 175] and valproate [175, 176].  
Moreover, BDNF is another neurotrophin that is involved in the efficacy of lithium and 
valproate therapy. Studies have established that lithium raised BDNF levels and that BDNF is 
required for lithium to extend its neuroprotective effects, as blocking BDNF lead to glutamate 
excitotoxicity [105]. In vitro studies have established that lithium therapy is neuroprotective 
against AMPA and KA receptors, which are also involved in glutamate excitotoxicity [105]. 
Similarly, lithium’s protective effects against glutamate toxicity has also been shown in studies 
where pre-incubation or chronic treatment with lithium safeguarded neurons [105]. Likewise, 
valproate has been shown to inhibit the action of NMDA receptors and therefore could 
potentially reduce glutamate excitotoxicity and increase BDNF [177]. 
In addition, lithium and valproate have been shown to increase mitochondrial ETC complex 
activities in human brain tissue and improve mitochondrial movement along axons to facilitate 
synaptic plasticity, which also reinforces the notion that mitochondrial dysfunction may play a 
role in the pathophysiology of BD [178, 179].  
However, lithium treatment is associated with neurological, cardiovascular, renal and 
haematological related side effects and needs close monitoring of its plasma concentration due 
to its narrow therapeutic index [155, 180]. If the plasma concentration of lithium increases, it 
can lead to impairment of renal excretion thus leading to toxic effects and even death [180]. 
Furthermore, lithium has a fairly slow onset of action, therefore patient’s symptoms usually 
only improve after 1-3 weeks of treatment [155]. Prolonged use of this drug has been linked to 
progressive renal failure that could be irreversible [180]. Recent findings show that the efficacy 
of lithium therapy has fallen significantly compared to its early days, especially in patients who 
present with mixed or dysphoric mania, rapid cycling, comorbid substance abuse and anxiety 
disorders, and an episode pattern of depression-mania-euthymia [181]. On the other hand, some 
26 
 
patients develop tolerance over time or become treatment refractory at discontinuation [155, 
181] .  
Valproate is better tolerated in the sodium form but can still cause dosage related 
gastrointestinal side effects, such as vomiting, diarrhoea and bloating [167]. Although rare, 
more severe side effects are also possible with valproate treatment, for example 
thrombocytopenia, platelet dysfunction, pancreatitis, and sometimes hepatic failure and death 
in children [167].  
Regardless of the side effects, lithium and valproate have established efficacy in treating BD 
mania. Both of these drugs bring about neuroprotective actions by affecting glutamate 
signalling, mitochondrial function and neurotrophins. When we comprehensively elucidate the 
mode of action of these drugs at the molecular level, we will be able to better understand the 
pathophysiology of BD and possibly find better drug targets for BD. 
1.7.1.2 Lamotrigine and Quetiapine 
 
There is a paucity of data available on the mechanisms of how lamotrigine and quetiapine are 
therapeutic for BD. Nevertheless, from the available literature it is clear that lamotrigine and 
quetiapine have some efficacy in treating BD, and they affect monoamine neurotransmitter 
activity, glutamate activity and mitochondrial function.  
Lamotrigine, a phenyltriazine derivative, is an anti-convulsant and has been shown to be 
effective in depression and rapid cycling in BD as monotherapy and as adjunctive therapy to 
lithium or valproate [168, 182, 183]. The best recognized mechanism of  lamotrigine is its 
action on Na+ and Ca2+ channels [184], which are involved in glutamate neurotransmission. It 
is proposed that lamotrigine acts as an Na+ and Ca2+ ion blocker, subsequently reducing the 
release of glutamate and excitotoxicity [182, 184, 185].  Moreover, lamotrigine affects 
serotonin reuptake, and this could contribute to anti-depressant effects in BD [185, 186].  
Another likely candidate mechanism that has been proposed for lamotrigine is its ability to 
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subdue unusual neuronal activities while maintaining the basal neurophysiological state and 
neuronal stability [185].   
Lamotrigine is well tolerated but the most concerning side effect of this drug is the cutaneous 
manifestation of Stevens-Johnson syndrome [184], however, successful re-introduction of this 
drug through slow titration has been possible in these patients [187].  Moreover, a case study 
reported a BD patient to develop manic symptoms while being treated for depression as an 
adjunctive therapy with valproate, emphasising that the prescriber must be cautious with 
titration rate and dosage of lamotrigine [188].  
Quetiapine, an atypical anti-psychotic drug, is the first FDA approved monotherapy for BD 
depression and mania [168, 189].  It is also emerging as a first line adjunctive therapy for BD 
mania with either lithium or valproate [168]. Yet again, as with other BD drugs, the mechanism 
of action for quetiapine is not clear-cut but it has been shown than it could act as an antagonist 
for several monoamine neurotransmitter receptors, such as serotonin, dopamine and 
norepinephrine [190]. Therefore, it is possible that quetiapine could be exerting its mood 
stabilising and anti-depressant effects through acting on these neurotransmitters. In addition, 
quetiapine has been also shown to act on the ETC complex I. Therefore, it could play a role in 
improving mitochondrial function, reducing oxidative stress and apoptosis [191].  
Quetiapine is quite well tolerated, and several clinical trials have documented that most of the 
patients only reported mild adverse effects such as sedation, gastrointestinal discomfort, 
anxiety and agitation [192]. 
The aforementioned four drugs, lithium, valproate, lamotrigine and quetiapine have proven 
clinical efficacy in treating BD depression and mania as monotherapy as well as polytherapy. 
Although CANMAT guidelines recommend monotherapy as a first line treatment for BD, in 
reality BD patients are often prescribed with more than one drug [193]. Consequently, 
polypharmacy is a rule rather than exception in BD. However, we do not fully understand how 
28 
 
these drugs work alone and in combination to understand why polytherapy works better for 
most of the patients. Therefore, single and synergistic effects of these drugs are yet to be fully 
understood to develop better BD drugs with less prescription burden.  
Moreover, these drugs also have side effects that must be considered when prescribing. This 
also signifies the need to identify better, well tolerated drugs that could target most of the 
candidate pathophysiological mechanisms for BD. Ideally, an efficient monotherapy for all the 
BD phases would be valuable with regard to costs and patient’s quality of life, nevertheless, 
that might not be possible in the near future as we still have a long way to go in understanding 
the pathophysiology of BD.  
1.8 Significance 
 
The available BD drugs have substantial medical burden, side effects and inadequacies in 
improving the symptoms, especially BD depression. This results in highly incapacitated 
patients with frequent medication non-adherence. These factors make BD a potentially 
devastating disorder, and therefore there is a pressing necessity to find new drugs to curtail the 
costs and improve patient outcomes.  A major limitation in identifying new drugs is the lack of 
clear understanding of both the pathophysiology of BD and the mechanism of action of 
commonly used therapeutics, alone and in combination. Consequently, drugs that have been 
developed to target single receptors that are thought to be involved in the pathophysiology of 
BD have generally been ineffective.  
Therefore, understanding the pathophysiology of BD is important, however, the lack of 
validated animal models hinders progress. Currently, BD is being investigated in separate 
rodent animal models for either mania or depression, and it has been difficult to mimic the 
cyclical nature of the disorder in the same animal [194]. Therefore, the unknown 
pathophysiology, poor understanding of the BD drug mechanisms and the lack of animal 
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models to mimic the human BD compels this thesis to take an explorative direction rather than 
hypothesis driven.  
In this thesis, we discuss various methods that can be employed to understand the molecular 
mechanisms of some of commonly prescribed BD drugs when they are used in combination 
and individually. We know that some of the BD drugs have proven efficacy in BD patients, 
however, we do not know how the effects are exerted. Therefore, if we work backwards by 
treating human neuronal cells and rat brains with BD drugs and by capturing the transcriptional 
effects following drug treatment, we will be able to understand the gene expression changes 
induced by the drugs. Moreover, the differentially expressed genes can be used in various 
bioinformatic analyses that can shed light into potential target pathways associated with BD 
pathophysiology. Collectively, this information will help us to understand the molecular 
mechanisms of action of the used BD drugs.  
Although the models used in this study do not represent the BD disease state, we believe that 
they will be able to enlighten us to some extent how these drugs work. The human neuronal 
cells will enable us to understand the basic biological and other neurological pathways affected 
by the BD drugs. Moreover, in the rodent model the frontal cortex will be used, which is 
considered equivalent to the prefrontal cortex in humans and implicated in BD [195, 196] and 
several other neuropsychiatric disorders [197, 198]. Furthermore, several studies have looked 
at frontal cortex of rodent models in understanding SZ and MDD, and psychiatric drugs [199-
203]. Therefore, studying this brain region in the rats will enable us to understand the effects 
of the BD drugs in a living animal and the brain as an organ that could be, to some extent, 
compared to humans. 
Moreover, this project also tried to evade the obstacle of poor pathophysiological 
understanding of BD as it uses an advanced bench to bedside approach known as GES 
technology, which has already been a proven success in diabetes and oncology [204, 205]. 
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GES, a screening tool, is a cluster of differentially expressed genes, which best describes the 
global biological response of a cell or tissue to its environment [204, 206].  
1.9 Objectives 
 
The objectives of this study are as below: 
1. To characterise the global transcriptional effects and molecular mechanisms of a 
combination of currently marketed and commonly prescribed FDA approved BD drugs 
(lithium, valproate, quetiapine and lamotrigine) in human neuronal cells and rat brains, 
and to use the differentially expressed genes to identify pathways regulated by this drug 
combination.  
2. To identify transcriptional effects of the individual BD drugs in human neuronal cells 
to identify the pathways and molecular mechanisms regulated by them.  
3. To generate a gene expression signature (GES) that represents the overall 
transcriptional effects of the combination of drugs rather than a single drug effect in 
both human neuronal cells and rat brains and use this GES and various databases such 
as the Connectivity Map (CMap) as a tool to identify similarly acting drugs. 
4. To identify differentially expressed microRNAs following BD drug combination 
treatment in human neuronal cells and rat brains and identify their target genes and 
possible pathways they affect to understand the molecular mechanisms of these drugs.  
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CHAPTER 2 
GENERAL METHODS 
2.1 NT2 cells 
 
NTera2/cloneD1 (NT2) is a pluripotent cell line that is derived from human testicular 
embryonic carcinoma cells [207, 208]. They can be grown in large quantities and have the 
ability to differentiate into post-mitotic neurons (NT2-N) following retinoic acid (RA) 
treatment [207, 208].  NT2 cells have been used for studying CNS biology in various human 
disorders. In our lab, we recently showed that NT2-N cells could be used to study the effects 
of BD drugs on markers of inflammation and mitochondrial function, which are postulated to 
be dysregulated in BD patients [209]. Moreover, a recent study looked at the neurological 
manifestations in Lesch-Nyhan disease using NT2 cells, where the effects of 5-
aminoimidazole-4-carboxamide-1-β-D-ribotide on neuronal differentiation was studied [210]. 
Moreover, microRNA studies have also been carried out in NT2 cells to study neuronal 
differentiation, cell cycle progression and apoptosis [211]. Given the lack of validated 
experimental models for BD, NT2-N cells will enable us to study the neuronal transcriptional 
changes that occurs when treated with BD drugs and possibly provide an element of 
physiological applicability to BD patients 
2.1.1 NT2 Cell Culture  
2.1.1.1 NT2 Cell Culture Conditions 
NT2 (ATCC, Manassas, USA) cells were cultured in Dulbecco’s modified Eagle’s Medium 
(DMEM; Life Technologies, Melbourne, Australia) supplemented with 10% (v/v) foetal 
bovine serum (FBS; Thermo Fisher Scientific, Melbourne, Australia) and 1% (v/v) 
antibiotic/antimycotic solution (Life Technologies) to prevent contamination. These cells were 
grown at 37o C in 5% CO2 and passaged at 80-90% confluency.  
The vial of purchased NT2 cells from ATCC was stored in liquid nitrogen until use. When 
required the vial was thawed as specified on the product sheet. Briefly, the vial was gently and 
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rapidly agitated in a 37o C water bath. Once the contents were thawed, the vial was 
decontaminated with 70% ethanol and moved to a biosafety cabinet. The contents of the vial 
were transferred to a sterile 15 ml centrifuge tube (Corning®; Sigma-Aldrich, Sydney, 
Australia) containing 9 ml of growth medium as described above and centrifuged for 5 minutes 
at 125 x g. The pellet was then resuspended in 1 ml of growth medium and added to a 75 cm2 
cell culture flask (Interpath, Melbourne, Australia) containing 14 ml growth medium. When 
confluent, the adhered cells were washed with phosphate buffered saline (PBS) and trypsinsed 
for 3-5 minutes at 37o C with Trypsin/ Ethylenediaminetetraacetic acid (EDTA) in PBS (TEP) 
in order to dislodge them. Once the cells were non-adhered to the flask, 4 ml of fresh growth 
medium was added to the flask to inactivate trypsin and the cells were collected into a 15 ml 
centrifuge tube and centrifuged at 125 x g for 5 minutes. The cells were resuspended in 1 ml 
of fresh growth medium and split into required number of flasks and stored in an incubator at 
37o C with 5% CO2 (Figure 2.1a).  
2.1.1.2 Differentiation of NT2 Cells into Neuronal-like Cells and Replating #1 
As described by Pleasure et al. (1992), once the NT2 cells were adequately confluent they were 
seeded at 2x106 cells/flask in 75 cm2 cell culture flasks. After 24 hours, the cells were treated 
with 10µM RA (Sigma-Aldrich) in growth medium to start the differentiation process. The RA 
media was refreshed 3 times per week for 28 days. 
RA, a vitamin A derivative, is known to regulate neuronal differentiation and growth in tumour 
cell lines [212]. When NT2 cells are treated with RA, it results in growth inhibition and 
neuronal differentiation. This process can be confirmed by measuring neuronal markers such 
as Ngn1, Mash1, NeuroD, Math1, GluR and Tau, which are known to be expressed in 
differentiated NT2 cells [207]. This confirmation and monitoring had been carried out 
previously at different time points during the 28 days of differentiation (data not shown), in the 
Walder Laboratory; therefore, it was not done every time the NT2 cells were differentiated.  
33 
 
Following 28 days of differentiation, the cell culture contained differentiated (NT2-N) cells on 
and undifferentiated cells, and appeared to have large, dark patches demonstrating successful 
differentiation (Figure 2.1b). In order to release the NT2-N cells that were buried among layers 
of cells, and to enrich this cell population, the differentiated cells were replated (replate #1) 1:6 
in RA-free growth medium in 75 cm2 flasks.  
2.1.1.3 Replating #2 and Mitotic Inhibitor Treatment 
On the day following replating #1, the cells were mechanically dislodged in 5 ml of fresh 
growth media by striking the culture flasks 10 times on either side. After the first replate, the 
NT2-N cells are loosely attached to a layer of undifferentiated NT2 cells and through 
mechanical dislodgement, the culture was further enriched for NT2-N cells as reported by 
Pleasure et al. (1992).  For replating #2, 24-well plates (VWR, Brisbane, Australia) were coated 
with 10 μg/ml poly-d-lysine (PDL) and 10 μg/ml laminin (LAM) (Sigma-Aldrich). The 
mechanically dislodged cells were collected into centrifuge tubes and centrifuged at 125 x g 
for 5 minutes. The cell pellet was resuspended in fresh growth medium and seeded onto 10 pre-
coated 24-well plates at the density of 2x105 cells/well. 
One hour after seeding, the cells were treated with mitotic inhibitors (MI; 1µM cytosine-β- 
arabinofuranoside (Sigma-Aldrich) and 10µM uridine (Sigma-Aldrich)) in growth medium. 
MIs restrain the growth of dividing NT2 cells that might still be present in the culture and at 
the same time do not affect NT2-N cells. This, yet again, enhances the proportion of NT2-N 
cells in culture.  The MI treatment was refreshed three times within 7 days (Figure 2.1c).   
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Figure 2.1. Differentiation process of human NT2 cells 
(a) Confluent undifferentiated NT2 cells before starting retinoic acid treatment (b) Mixed 
population of NT2 cells and differentiated NT2-N cells during retinoic acid treatment for 28 
days(c) Differentiated NT2-N cells during mitotic inhibitors treatment for 7 days. 
2.1.2 Drug Treatments 
Following the MI treatment, cells were treated with either the BD drug combination or single 
drugs and their respective vehicle controls.  The BD drug combination contained 2.5 mM 
lithium chloride (mood stabiliser), 0.5 mM valproate (mood stabiliser), 50 µM lamotrigine 
(anti-convulsant) and 50 µM quetiapine (atypical anti-psychotic; all four drugs were purchased 
from Sigma-Aldrich) in serum starvation media (DMEM with 0.2% (v/v) bovine serum 
albumin (BSA; Sigma-Aldrich)). Serum starvation media helps to synchronize the cell cycle 
and thus eliminates variability between cells. The optimal doses were determined from dose 
response studies in GT1-7 (mouse neuronal cells) through studies done previously in the 
Walder Laboratory (see appendix 1 in Chapter 3). The final doses of the drugs used in this 
study were balanced to make sure that an individual drug would neither dominate the overall 
effects of the drugs in some of the tested genes nor be toxic to the NT2-N cells, but rather 
represent the combinatorial effect. It should be noted that these drug response studies were 
carried out in GT1-7 cells and not NT2 cells. However, when the doses were chosen for 
treatment in NT2 cells, we used the data from GT1-7 studies as well as literature available for 
NT2 cells.  These studies were carried out prior to the start of my PhD by Briana Spolding. The 
BD drug combination was used in this study in order to imitate the widely used polypharmacy 
in the treatment of BD. Moreover, the drugs that were selected to make up the combination are 
a b  
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mechanistically different from each other, thereby possibly enabling us to understand different 
downstream effects and pathways in the NT2-N cells. 
The same concentrations of the drugs described above were used when the cells were treated 
with single drugs. Lamotrigine and quetiapine are soluble in dimethyl sulfoxide (DMSO), 
whereas lithium and valproate are H2O soluble. Therefore, the vehicle controls for BD drug 
combination were treated with MilliQ H2O and 0.2% DMSO (Sigma-Aldrich), whereas for 
individual drugs, the controls were treated with either MilliQ H2O (lithium and valproate) or 
0.1% DMSO (lamotrigine and quetiapine).   
Drug and vehicle treatments were applied in the coated 24 well plates with a final volume of 
500 µl/well for 24 hours after which the cells were harvested. In the BD combination study 
each treatment group had n=100, while in BD individual drug study each treatment group had 
n=16 including the duplicates which were pooled (section 2.1.3).  
2.1.3 Cell Harvesting  
The media was removed in each well was washed once with 500 µl of PBS after which 200 µl 
of Trizol reagent (Life Technologies) was added. After 5 minutes, the cells were collected from 
each well into 1.5 ml (Pacific Laboratory Products, Melbourne, Australia) tubes. Duplicate 
wells were pooled to get sufficient RNA for next generation sequencing (NGS). Therefore, 
each treatment group in the BD combination study had n=20 samples (pooled five wells per 
sample, so 1 ml of Trizol in total) and BD individual study had n=4 (pooled four wells per 
sample, so 800 µl of Trizol in total) in the end.  
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2.2 Rat Study 
2.2.1 Animal Conditions 
 
All animal procedures were approved by the ethics committee of Deakin University, Australia 
(Approval number - G31-2014, 06/10/2014) and conducted according to the code of practice 
for the care and use of animals for scientific purposes (National Health and Medical Research 
Council, Australia). Eight-week-old male Sprague-Dawley® rats were housed (21 ± 2°C, 40–
70% humidity, 12-h light/dark cycle) with unrestricted access to food and water (n=8 per 
group).  
2.2.2 Drug Treatments and Tissue Collection 
 
The drug treated group received the same BD drug combination as the NT2-N cells via 
intraperitoneal injection (lithium 10 mg/kg, valproate 50 mg/kg, quetiapine 2 mg/kg and 
lamotrigine 10 mg/kg) while the vehicle group was treated with 6% DMSO. The drug dosages 
were determined based on published literature describing the minimal effective doses needed 
to affect gene expression in the brains of rats and mice. The frontal cortex and hippocampus of 
the rats were dissected and frozen in liquid nitrogen 6 hours after the injection as the Cmax for 
the drugs overlay at 4 hours with plasma half-lives between 7-24 hours.   
Treatments and handling of the animals were carried out by Briana Spolding. 
2.3 RNA Extraction 
2.3.1 Cell Preparation for RNA Extraction 
 
The tubes containing the harvested cells described in section 2.1.3 were vortexed thoroughly 
and chloroform equivalent of 20% of the total volume of Trizol was added to the tube. BD 
combination drug study samples contained 1 ml of Trizol, so 200 µl of chloroform was added, 
while for the BD individual drug samples, which contained 800 µl of Trizol, 160 µl of 
chloroform was added. The samples were vortexed well for 15 seconds and left to sit at room 
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temperature (RT) for 2 minutes. The tubes were then centrifuged in a microcentrifuge at 12,000 
xg for 15 minutes at 4°C. 
2.3.2 Rat Brain Tissue Preparation for RNA Extraction 
 
Approximately 20-30mg of the dissected frontal cortex of the rats (section 2.2.2) was weighed 
on liquid nitrogen and added into a 2 ml (Pacific Laboratory products) tube containing 1 ml of 
Trizol and homogenised using a micro-homogenizer at speed 10. The homogenised samples 
were left on ice for 5 minutes, after which 200 µl of chloroform (equivalent of 20% of the total 
volume of Trizol) was added to the tube and vortexed vigorously for 15 seconds. The samples 
were then left to sit at RT for 1 minute and centrifuged in a microcentrifuge at 12,000 xg for 
15 minutes at 4°C. 
2.3.3 RNA Extraction Procedure  
 
RNeasy® mini kits (Qiagen, Melbourne, Australia) were used to extract RNA from the NT2-
N and rat frontal cortex samples as per manufacturer’s protocol. Briefly, following 
centrifugation of the samples as described in sections 2.3.1 and 2.3.2, the supernatant from the 
samples was collected into a fresh 2 ml tube without disturbing the interface or the organic 
layer. An equal volume of 70% ethanol was added to the supernatant and mixed well by 
pipetting. A maximum of 700 µl of the sample was placed into RNeasy® spin columns 
(Qiagen) and centrifuged at 12,000 xg for 30 seconds at RT in a microcentrifuge. If there was 
leftover supernatant and ethanol mixture, the excess was added again to the RNeasy® spin 
columns and centrifuged again at 12,000 xg for 30 seconds. The flow through was discarded 
and the columns were washed once with 700 µl Buffer RW1 (Qiagen), and centrifuged at 
12,000 xg for 30 seconds at RT. After disposing the flow-through, the columns were washed 
twice with 500 µl Buffer RPE (Qiagen), and centrifuged at 12,000 xg for 30 seconds for the 
first wash, and two minutes for the second wash at RT. The flow-through was discarded after 
each wash, and at the end of the RPE wash, the columns were placed in new 1.5ml collection 
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tubes provided with the kit. Into each column 30 µl of RNase-free water was added and 
centrifuged at 12,000 xg for one minute to elute the RNA, which was then stored at -80°C until 
use. 
2.4 Next Generation Sequencing  
2.4.1 Library Preparation and Sequencing  
2.4.1.1 mRNA sequencing 
 
The cDNA library preparation was conducted at the Metabolic Research Unit, Deakin 
University and the sequencing was contracted to Macrogen, South Korea. Briefly, the quality 
of the extracted RNA from the NT2-N samples (n=20 per group in BD combination drug study 
and n=4 per group in BD individual drug study) and the rats (n=8 per group in BD combination 
drug study) was determined using Agilent 2100 Bioanalyzer and RNA 6000 Nano Kit (Agilent 
Technologies, USA). The quantity of the RNA was assessed using NanoDrop 1000 (Thermo 
Fisher Scientific). RNASeq libraries were prepared for all the samples from 1 µg of total RNA 
using Illumina TruSeq®  RNA Sample Preparation Kit  V2 (Illumina) as per the manufacturer’s 
instructions. The prepared libraries for NT2-N cells and rats were then run on an Illumina 
HiSeq platform generating 50 bp single-end reads (HiSeq 2500 rapid 50bpSE; 1 flow cell).  
2.4.1.2 microRNA sequencing 
To measure microRNA (miRNA) expression TruSeq® Small RNA Library Prep Kit (Illumina) 
was used. The same RNA samples that were used for the RNASeq library preparation were 
used for miRNA analysis. The first six NT2-N cell samples from the 20 samples in each 
treatment group (n=6 per group) and all the rat frontal cortex samples (n=8 per group) from the 
BD combination drug study were chosen for this analysis. The library preparation was carried 
out as per the manufacturer’s instructions.    
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2.4.2 Next Generation Sequencing Data Analysis – Bipolar Disorder Drug Combination 
Study 
The output of raw sequence reads were downloaded in FASTQ format for bioinformatics 
analysis. The raw sequence reads in FASTQ format were filtered for quality and any technical 
sequences such as adapters and primers were removed using the FastQC program   
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The reads were then filtered 
based on quality scores (Phred), and base calls with a Phred of 20 or lower were discarded. 
The cell and rat sequences were then aligned to human and rat reference genomes respectively 
using Bowtie 2/TopHat 2 (http://ccb.jhu.edu/software/tophat/index.shtml). The differential 
expression of the genes and miRNAs between drug treated and vehicle groups in NT2-N cells 
and rat frontal cortex were assessed using the software package edgeR (mRNA; 
http://bioconductor.org/packages/release/bioc/html/edgeR.html) or DESeq (miRNA; 
https://bioconductor.org/packages/release/bioc/html/DESeq2.html) in R.  
In edgeR, the differential expression is determined with empirical Bays estimation procedure 
and exact tests based on a negative binomial distribution model [213]. The data set is 
normalised using the weighted trimmed mean of M-values (TMM) and the p-values are 
adjusted for multiple testing using Benjamini and Hochberg approach [214] to control the false 
discovery rate (FDR). On the cell dataset from edgeR analysis, we first applied an adjusted p-
value of 0.001 to filter out statistically insignificant genes. On the other hand, for the rat dataset 
from edgeR analysis, a less stringent p-value of 0.05 was applied to remove statistically 
insignificant genes in order to account for potential biological variability between the animals 
and not to omit biologically meaningful data. The resultant statistically significant cell and rat 
genes were aligned against each other and all the common genes were filtered out to be used 
in downstream analysis. 
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As edgeR analysis did not generate any statistically significant differentially expressed 
miRNAs, we wanted to check if similar results would be produced with DEseq. This approach 
also employs a negative binomial model to determine differential expression, however, DEseq 
uses the observed relationship between the mean and variance when estimating dispersion [213, 
215]. This allows for a more general, data-driven parameter estimation. DESeq uses a similar 
scaling factor normalisation approach to edgeR to account for sequencing depth variation 
between the samples, and FDR is controlled with the Benjamini and Hochberg approach. From 
the DESeq analysis, an adjusted p value of <0.05 and total reads of >100 were used to identify 
statistically significant miRNAs of interest. 
2.4.3 Next Generation Sequencing Data Analysis– Individual Bipolar Disorder Drug Study 
The output of raw sequence reads were downloaded in FASTQ format for bioinformatics 
analysis. For this study, we employed a different approach to what is described in section 2.4.2 
for data analysis. We used an RNAseq data analysis pipeline developed by Dr. Mark 
Richardson (https://github.com/m-richardson/RNASeq_pipe). This is a different approach to 
how the BD drug combination data was analysed mainly because the individual BD drug study 
was carried out at a later point in time, and the bioinformatics approaches to analysing NGS 
data had changed and improved during that period. This new pipeline incorporates the 
following steps and tools: 
1. Raw read quality filtering and adapter trimming with Trimmomatic  
2. Building the genome/transcriptome index with STAR 
3. Mapping to the reference genome/transcriptome of choice using STAR 2-pass 
4. Quantification of expression - i.e. getting the counts 
5. Collating individual sample counts into a m x n matrix for differential abundance testing 
using R 
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As all the steps required in NGS data analysis are incorporated into this pipeline, it reduces the 
time required for obtaining differential expression data. Moreover, the STAR alignment 
program is comparatively faster and in some cases more accurate than the Bowtie /TopHat 
approach [216]. The final output from STAR in the form of read counts per gene was collated 
in R and produced in a format that can be used in differential gene expression analysis using 
edgeR.  
Differential gene expression analysis was carried out using edgeR and an adjusted p-value of 
0.05 was used to identify miRNAs of interest.  
2.5 Gene Set Enrichment Analysis 
Gene Set Enrichment Analysis (GSEA) was carried out on the complete gene lists obtained 
from NGS for both NT2-N cells in combination and individual BD drug studies, and rat brains. 
GSEA is a computational method developed by the Broad Institute, USA (available at 
software.broadinstitute.org/gsea/index.jsp) [217]. This method was founded on the idea that 
gene expression could be altered at the level of biological pathways rather than specific genes. 
Through GSEA, the genes are ranked relative to the difference in expression based on signal-
to-noise ratio (SNR).  
Firstly, the duplicates as well as any genes with total read counts of <0 were removed. This file 
was then converted to a Text (Tab delimited) (*.txt) format. The phenotype information and 
labels were written into a CLS file. The text and CLS files were loaded onto the GSEA software 
and the analysis was run with phenotype as the permutation type.  
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2.6 Database for Annotation, Visualization and Integrated Discovery 
Analysis 
The identified differentially expressed genes were annotated using  using Database for 
Annotation, Visualization and Integrated Discovery (DAVID) Bioinformatics Resources V6.7 
[218] (National Institutes of Health, Bethesda, Maryland, USA). DAVID employs a gene set 
based algorithm that identifies functionally connected genes in the input gene sets. This tool 
can examine of functionally related genes based on the Gene Ontology terms biological 
processes, cellular components and molecular functions. 
Firstly, the list of genes or their IDs were submitted to DAVID and converted to a compatible 
format. Using the functional annotation tools, enriched Gene Ontology (GO) terms were 
searched. GO terms that were with a p-value of <0.05 were considered statistically significant 
following Benjamini correction for multiple testing. 
2.7 Connectivity Map Analysis 
A set of genes with evidence of differential expression  were analysed using into Connectivity 
Map (CMap build 2; publicly available at https://portals.broadinstitute.org/cmap/). This set of 
genes was identified based on evidence of differential expression following BD drug 
combination treatment in NT2-N cells and rats, as well as relevance to human BD, and the 
output was considered to be a gene expression signature (GES). The potential relevance of the 
GES genes to human BD was assessed through a literature search on PubMed and through a 
post-mortem brain study in BD patients, which was carried out by our collaborators at The 
Florey Institute of Neuroscience and Mental Health, Melbourne, Australia.  
For each gene in the GES, we identified the corresponding feature set ID from the 22,283 probe 
sets on the HG-U133A array that are recognized by CMap. These ID’s were collated into tag 
sets of “up” or “down” genes, and analyzed using the CMap software. This tool measured the 
similarity between the input query gene set and a reference microarray dataset containing 
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human cell line derived expression profiles treated with approximately 1300 compounds [219]. 
The similarity was reported as connectivity score ranging from +1 to -1 based on non-
parametric rank ordered Kolmogorov-Smirnov statistics. When the connectivity score is 
positive, it denotes increased similarity or connection between the expression patterns induced 
by the compounds in the CMap database and the query gene set. Negative connectivity score 
means inverse similarity between reference profiles and query signatures. 
2.8 Quantification of Free Cholesterol in NT2-N cells and Rats 
2.8.1 Lipid Extraction 
2.8.1.1 NT2-N Cells 
 
NT2-N cells were grown and treated as described above (Section 2.1) with the drug 
combination or with individual drugs, and their respective vehicle controls, at the density of 
400,000 cells/well in coated 24 well plates (n=6 per group). After 24 hours of treatment, the 
cells were washed in 500μl of cold PBS three times. Into each well 500μl of PBS was added, 
and the cells were scraped using a cell scraper (13 mm; TPP, Switzerland) and the contents 
were transferred into a 1.5 ml tube (pre-weighed) and centrifuged at 15,000 x g for 10 minutes. 
The supernatant was discarded and the cell pellet was homogenised using a micro-homogenizer 
at speed 10 with 200 μl of  lipid extraction buffer (chloroform:isopropanol:NP-40 at 7:11:0.1 
ratio) for 20 seconds. The homogenised cell pellet was centrifuged at 15,000 x g for 10 minutes, 
and the organic phase was transferred into a new tube without disturbing the pellet and left 
overnight to air dry. The tubes containing the pellet were also air dried and weighed again to 
determine the pellet weight. Then the samples containing the extracted lipid were placed under 
vacuum for 30 minutes to remove any trace amounts of organic solvent. 
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2.8.1.2 Rats 
 
The rat hippocampus tissues obtained from the study described in 2.2 were used for the 
cholesterol assay, as there was not sufficient frontal cortex tissue left.  Firstly, approximately 
10 mg of rat hippocampus tissue was weighed into a 2 ml tube on liquid nitrogen and 
homogenised using the lipid extraction buffer (chloroform:isopropanol:NP-40 at 7:11:0.1 ratio) 
at speed 10 for 20 seconds with a micro-homogeniser. The rest of the procedure was carried 
out as described in section 2.8.1.1.  
2.8.2 Quantification of Free Cholesterol 
 
A fluorometric total cholesterol assay kit (Cell Biolabs, San Diego, USA) was used to measure 
the amount of free cholesterol in lipids extracted from NT2-N cells and rats. The dried lipids 
obtained from the lipid extraction procedure described in section 2.8.1, were dissolved by 
vortexing in 200μl of 1X assay buffer that was supplied by the manufacturer of the cholesterol 
assay kit. 
The cholesterol assay was carried out in a 96-well microtiter plate as per manufacturer’s 
instructions and incubated at 37°C for 45 minutes. As we did not want to measure total 
cholesterol, but only free cholesterol, cholesterol esterase was not added to the reactions. 
Following the incubation the plate was immediately scanned in a Flex Station II 384 (Molecular 
Devices, Victoria, Australia) fluorescence plate reader using an excitation of 550 nm and 
emission of 595 nm. 
The free cholesterol per well was calculated using the cholesterol standard curve and for the 
NT2-N cells the results were normalised to pellet weight, whereas for the rat hippocampus 
samples they were normalised to tissue weight.  
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2.9 Neurite Outgrowth Assay – Immunocytochemistry 
 
NT2-N cells were grown and treated with individual drugs, drug combination and vehicle 
controls as described above (section 2.1), but in black 96 well clear bottom plates (Corning®; 
Sigma-Aldrich) at a density of 15,000 cells/well (n=8 per group). After 24 hours of treatment, 
immunocytochemistry was performed as described previously [220]. In brief, the NT2-N cells 
were rinsed in ice cold PBS, and fixed with 4% paraformaldehyde (Electron Microscopy 
Sciences, Pennsylvania, USA) for 15 minutes at room temperature followed by 3 washes in 
PBST (PBS containing 0.1% Triton X-100). Blocking buffer (5% horse serum in PBST) was 
then applied and incubated for 1 hour at room temperature. A monoclonal antibody β-III-
Tubulin (1:10,000; Sigma-Aldrich) was applied and incubated overnight at 4°C. The next day, 
the cells were washed 3 times for 5 minutes each with PBST, and treated with a biotinylated 
secondary antibody horse-anti mouse (1:250; Vector Laboratories, California, USA), and 
incubated for 1 hour at room temperature. The cells were then washed 3 times for 5 minutes 
each with PBST, and streptavidin coupled Cy3 (Sigma-Aldrich) was added and incubated for 
1 hour at room temperature. Subsequently, the cells were washed once with PBST, and 
counterstained with DAPI at a concentration of 0.1 μg/ml for 5 minutes. The cells were then 
washed and left in PBST for imaging. 
Images were captured using a ZOE™ Fluorescent Cell Imager (Bio-Rad, New South Wales, 
Australia). For each well 5 images were captured (middle, top, right, bottom and left). The 
images were processed in Adobe Photoshop CC (Version 14.2). Images that did not have any 
cells were excluded from the analysis. The captured images were analysed using ImageJ 
(National Institutes of Health) using the NeuronJ plugin [221] to trace the neurites and measure 
their lengths. Neurites were measured from the soma of the cell to the tip. The number of nuclei 
was counted using the Multi-point tool in ImageJ.  
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2.10 miRNA Analysis 
 
2.10.1 miRNA Target Prediction and Gene Annotation Enrichment Analysis 
 
Target prediction for the differentially expressed miRNAs was conducted by means of 
bibliographic search on PubMed and accessing the open source microRNA.org database 
(http://www.microrna.org/microrna/home.do). 
Using the resulting target genes for each miRNA, the potential individual and combinatorial 
effect of the miRNAs on regulation of biological pathways was studied using DAVID 
Bioinformatics Resources. 
2.10.2 miRNA TaqMan Assay 
 
The NT2-N cells were cultured as above (section 2.1), and treated for 24 hours with individual 
drugs, drug combination or vehicle controls (n=6 per group). The RNA was extracted as above 
(section 2.3) and quantified using a NanoDrop 1000.   
To confirm and validate the differentially expressed miRNAs derived from sequencing data, 
Reverse Transcription (RT)-qPCR analyses of miRNAs (miR-128 and miR-378) were carried 
out using TaqMan microRNA assays (Applied Biosystems, Life Technologies, Australia). RT 
reactions were performed  in 15 μl reactions with 9.15 μl of total RNA, 0.15 μl of 100mM 
dNTP mix,  1.5 μl of 10X RTbuffer, 1 μl of 50U Multiscribe RT enzyme, 0.2 μl  of 20U RNAse 
inhibitor and 3 μl of  pooled 1X primers (miR-128 – UCACAGUGAACCGGUCUCUUU and 
miR-378-CUCCUGACUCCAGGUCCUGUGU) (Applied Biosystems, Life Technologies). 
RT reactions were performed at 16°C for 30 minutes, 42°C for 30 minutes, and 85°C for 5 
minutes using a GeneAmp® PCR System 9700 thermocycler (Applied Biosystems, Life 
Technologies). 
The qPCR was performed with miRNA specific TaqMan miRNA Assay probes using a 
PikoReal™ qPCR machine (Thermo Fisher Scientific) at 95°C for 10 minutes, followed by 40 
cycles of 95°C for 15 seconds and 60°C for 60 seconds. All samples were run in duplicate and 
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included no template controls. Cycle threshold (Ct) values were automatically determined by 
the Pikoreal software. 
2.10.3 cDNA Quantification Using OliGreen Method 
 
The Quant-iT™ OliGreen® ssDNA Assay Kit (Life Technologies, USA) was used to quantify 
the cDNA concentration in each sample. The provided nucleotide standard (100µg/ml) was 
diluted in 1x Tris-EDTA (TE) buffer to prepare the oligonucleotide standards of 15, 12.5, 10, 
7.5, 5, 2.5, 1.25 and 0 µg/ml. 5 µl of each standard and cDNA samples were loaded in triplicate 
in an opaque 96-well plate (Greiner, Hamburg, Germany), into which 95 µl of 1x TE buffer 
and 100 µl of 1x ssDNA reagent were added.  The plate was covered with aluminium foil to 
protect it from light and incubated at room temperature for 5 minutes. Then the plate was 
scanned in a Flex Station II 384 fluorescence plate reader that is connected to a computer with 
Softmax Pro v5 software.  Using this software, the protocol was configured to read the plate 
from the top with an initial mixing for 10 seconds followed by excitation at 485 nm and 
emission at 538 nm.  
The subsequent data was used to produce a standard curve and calculate the relative ssDNA 
concentration in each sample. miRNA expression data from the TaqMan assay was then 
normalised to the derived ssDNA concentration of each sample. This corrects for any deviance 
in miRNA expression that could result from variability in the starting RNA concentration 
between samples. 
2.10.4 miR-128 and miR-378 Inhibition  
In order to see the effect of the BD drug combination when miR-128 and miR-378 are inhibited, 
we carried out the study described below. The NT2 cells were cultured and grown as previously 
described in section 2.1 and seeded at a density of 475,000 cells/well in coated 24 well plates. 
The cells were transfected with  10μM miRCURY LNA microRNA inhibitors for hsa-miR-
128-3p and hsa-miR-378a-5p simultaneously  or negative control A (Qiagen) using 
Lipofectamine RNAiMAX reagent (Life Technologies) as per the manufacturer’s protocol. 
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Briefly, the Lipofectamine RNAiMAX reagent and 10 μM inhibitors/negative control were 
diluted in Opti-Mem medium (Thermo Fisher Scientific). The inhibitors or negative control 
were added to the diluted Lipofectamine RNAiMAX reagent at 1:1 ratio and incubated for 5 
minutes at RT. Then the inhibitors/negative control-lipid complex was added to the cells at a 
final concentration of 10nM in serum starvation media (DMEM with 0.2% (v/v) BSA) per well 
and incubated for 24 hours.  After 24 hours of transfection, the cells were washed with 500 µl 
of serum starvation media and the drug combination or vehicle treatments were applied for 24 
hours.  
After 24 hours of drug treatment, the RNA was extracted using RNeasy® mini kits (Qiagen). 
Each well was washed once with 500 μl of 1X PBS and to it 200 μl of RLT buffer (Qiagen) 
was added. The cells were pipetted up and down few times and were transferred to a fresh 1.5 
ml tube and vortexed. An equal volume (200 μl) of 70% ethanol was added to the samples, 
mixed and added to RNeasy® mini columns. From here onwards the RNA extraction protocol 
followed as previously described in section 2.3.3. The extracted RNA samples were stored at -
80°C until use. 
2.10.5 Expression of target genes in NT2 cells treated with miRNA inhibitors 
2.10.5.1 cDNA synthesis 
The extracted RNA from NT2-N cells transfected with miRNA inhibitors were reverse-
transcribed to produce cDNA using a Maxima H Minus first strand cDNA synthesis kit 
(Thermo Fisher Scientific, Australia). The reaction mixture (15 µl) in each thermocycler tube 
was made up with 1µl of 10 mM dNTP mix, 1 µl of  100 µM oligo (dT) 18 primer, 10 µl of 
total RNA (1pg -5 µg total RNA) and 3 µl of nuclease free water. The tubes were then incubated 
for 65°C for 5 minutes in a GeneAmp® PCR System 9700 thermocycler (Applied Biosystems, 
Life Technologies). After 5 minutes, the tubes were placed on ice briefly to stop the reaction, 
and span briefly. In the meantime, a master mix of 5x RT buffer and Maxima H minus enzyme 
mix was prepared and 5 µl was added to each tube. The contents (final volume of 20 µl) of the 
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tubes were gently mixed by pipetting and spun briefly. The tubes were then incubated in the 
same thermocycler for 30 minutes at 50°C; 5 minutes at 85°C; 5 minutes at 4°C. The resulting 
cDNA was diluted to 1:10 with nuclease free water, and stored at -20°C until use. 
2.10.5.2 Real-time PCR  
All primer sequences for the genes used in Real-time PCR (qPCR) were designed using 
Thermo Fisher Scientific’s OligoPerfect™ Designer tool, and their complementarity and 
specificity were confirmed with Primer-BLAST (NCBI; Table 2.1). The designed primers were 
supplied by Integrated DNA Technologies (New South Wales, Australia). The primer pairs 
were optimised to ensure the amplification of the desired product as well as to determine the 
optimal template cDNA concentrations required for the reaction.  
qPCR was conducted using SYBR Green fluorescence. qPCR reaction mix was prepared for 
each primer pair with 0.11 µM of forward and reverse primers, 56% Luminaris HiGreen Low 
ROX qPCR Master Mix (Thermo Fisher Scientific) and topped up with nuclease free water. 
This reaction mixture (9 µl in each well) was pipetted into a 96-well qPCR plate after which 1 
µl of the diluted cDNA (1:10) was added in duplicate for each sample making the final volume 
10 µl. Duplicates of no template controls (NTC) were also prepared. The prepared plate was 
sealed with an optical adhesive cover and centrifuged briefly for 30 seconds at 125xg. The 
reactions were carried out in a PikoReal™ qPCR machine with the following protocol: 95°C 
for 7 minutes, 40 cycles of 95°C for 30 seconds and 60°C for 1 minute followed by data 
acquisition, 60°C for 30 seconds, 55-95°C – data acquisition and 20°C for 10 seconds.  
The cDNA was quantified using the Quant-iT™ OliGreen® ssDNA Assay Kit as described in 
section 2.10.3. Gene expression data from the miRNA target genes was then normalised to the 
derived ssDNA concentration of each sample. 
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Table 2.1. All primer sequences used in this study. 
Gene Species Forward Primer (5’-3’) Reverse Primer (5’-3’) 
NOVA1 Human AAT GTG GCC AAG ACA GAA CC 
 
TGG GAT CAG ATG GAG AGG AC 
 
GRIN3A Human CTG CTG CTA CCA CGA ATC AA 
 
TTG GTC TTG AAA TGC TGC TG 
 
VIM Human GAG AAC TTT GCC GTT GAA GC 
 
TCC AGC AGC TTC CTG TAG GT 
 
SIRT3 Rat AGG CGG CTT TGG ATG TGG AG ACT GCT GAA GGT TGC TGT AGA GG 
SIRT4 Rat TGA CTC GCT GCT GGT GGT G GTG GGT CCG ATG TTC AGA ATG G 
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2.11 Statistical Analysis 
All statistical analyses were carried out using Statistical Package for the Social Sciences 
version 24 (SPSS) software. A Shapiro–Wilk test was used to check whether the data were 
normally distributed. Levene’s Test was used to decide whether equal variances could be 
assumed between treatment groups. Drug treatment groups were compared to their 
corresponding controls using independent samples t-test for normally distributed data and non-
parametric test (Mann-Whitney U test) for data not normally distributed. Significance levels 
were set at p<0.05 or determined for individual experiments following correction for multiple 
testing as appropriate. 
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CHAPTER 3 
 
EFFECTS OF BIPOLAR DISORDER DRUGS ON 
CHOLESTEROL BIOSYNTHESIS - A POSSIBLE 
THERAPEUTIC MECHANISM 
 
3.1 Introduction 
Bipolar disorder (BD) is a chronic and complex mood disorder with a worldwide prevalence 
of ~2% [12]. This difficult to diagnose disorder co-occurs with various psychiatric and medical 
comorbidities, and is associated with increased risk of suicide [222]. Moreover, about 50% of 
subjects with BD remain symptomatically ill despite treatment, with depression being the most 
frequent disease phase [223].   
In spite of its severe nature and significant medical and psychosocial burden, the precise 
pathophysiology of BD is still obscure. However, several theories pertaining to epigenetics, 
mitochondrial dysfunction, oxidative stress, inflammation and dysregulation in neural 
plasticity have been proposed for BD.  
The clinical reality of BD led to the employment of complex treatment regimens in BD. 
Monotherapy or prescription of a single drug is uncommon in BD as there is still no well-
controlled clinical trial based evidence that shows efficacy in all phases of BD. While lithium, 
the gold standard treatment, has been shown to be effective in reducing relapse and suicide 
[224], its narrow therapeutic index and side effects hinder its use as monotherapy [222].  
Therefore, many subjects with BD are treated with complex and lifelong combinations of 
pharmacological agents, a process known as polypharmacy [225]. Consequently, in BD, 
polypharmacy has become the rule rather than the exception, with at least 18% of subjects with 
BD taking four or more drugs [226]. However, similar to monotherapy, polypharmacy also 
suffers from a lack of clinical trial based evidence to support its use. 
The lack of validated BD animal models contributes to the scarcity of knowledge in this area 
[222]. Consequently, we have little knowledge about how the current BD drugs bring about 
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their therapeutic outcomes in subjects with BD. There is also a paucity of evidence to support 
the biological mechanisms behind the efficacy of polypharmacy in subjects with BD. These 
gaps need to be addressed in order to further advance the management of BD. Therefore, there 
is a pressing need to identify how BD drugs bring about their efficacy in subjects with BD.  
Due to the lack of knowledge in this area, we employed a reverse engineering approach to 
identify biological pathways associated with BD in this study. Using this technique, gene 
expression data which represents the overall effects of commonly used BD drugs was generated 
using unbiased whole genome sequencing. A combination of drugs was used in this study in 
order to address the wide use of polypharmacy to treat subjects with BD and to understand their 
effects collectively, rather than individual drug effects. 
Therefore, this chapter aims to characterise the effects of a combination of BD drugs currently 
used to treat BD on gene expression using unbiased genome wide gene expression profiling, 
which will be used in pathway analysis.  
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3.2 Materials and Methods 
3.2.1 Cell Culture 
Ntera2 (NT2) human teratocarcinoma (ATCC, Manassas, USA) cells were cultured and 
maintained in Dulbecco’s modified Eagle’s Medium (DMEM; Life Technologies, Melbourne, 
Australia) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, 
Melbourne, Australia) and 1% antibiotic/antimycotic solution (Life Technologies) at 37o C in 
a 5% CO2 atmosphere. At 80-90% confluency, the cells were seeded at 2x10
6 cells/flask in 75 
cm2 cell culture flasks (Interpath, Melbourne, Australia). After 24 hours, the cells were treated 
with 10µM retinoic acid (Sigma-Aldrich, Sydney, Australia) in media for 28 days to induce 
differentiation to express neuron like morphology [208], with media replenished every 2-3 
days.  
The differentiated cells (NT2-N) were mechanically dislodged and seeded onto poly-D-lysine 
and laminin coated 24-well plates at 2x105 cells/well and treated with mitotic inhibitors (1µM 
cytosine-β-arabinofuranoside and 10µM uridine; Sigma-Aldrich) for 7 days. 
Following the mitotic inhibitor treatment, the cells were treated with either the BD drug 
cocktail (2.5 mM lithium chloride, 0.5 mM valproate, 50 µM lamotrigine and 50 µM 
quetiapine; Sigma-Aldrich) or vehicle control (0.2% DMSO; Sigma-Aldrich) in serum 
starvation media (DMEM with 0.2% bovine serum albumin; Sigma-Aldrich) for 24 hours 
(n=20 per group). The drugs that were chosen are widely used in treating BD and are considered 
to be mechanistically different. The doses were determined empirically through dose response 
studies in GT1-7 (mouse neuronal cells) such that no single drug dominated overall effects on 
gene expression (Appendix 1). These studies were carried out prior to the start of my PhD by 
Briana Spolding. It should be noted that these drug response studies were carried out in GT1-
7 cells and not NT2 cells. However, when the doses were chosen for treatment in NT2 cells, 
we used the data from GT1-7 studies as well as literature available for NT2 cells.  
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3.2.2.RNA Isolation and Quality Control 
Following the 24-hour treatment, the cells were harvested and total RNA was extracted using 
TRIzol (Thermo Fisher Scientific) and purified with RNeasy® mini kits (Qiagen, Melbourne, 
Australia) as per the manufacturer’s instructions. The quality of the extracted RNA from the 
NT2-N cells was determined using an Agilent 2100 Bioanalyzer and RNA 6000 Nano Kit 
(Agilent Technologies, Melbourne, Australia). The quantity of the RNA was assessed using a 
NanoDrop 1000 (Thermo Fisher Scientific). 
3.2.3 Animal Study  
 
All animal procedures were approved by the ethics committee of Deakin University, Australia, 
and conducted according to the Australian code of practice for the care and use of animals for 
scientific purposes as specified by the National Health and Medical Research Council 
(NHMRC, Australia). Eight week old male Sprague-Dawley® rats (Animal Resource Centre, 
Perth, Australia), housed with unrestricted access to food and water, were used for this part of 
the study (n=8 per group). The room temperature was maintained at 21 ± 2°C with 40–70% 
humidity and a 12-h light/dark cycle. The drug treated group was treated with the same BD 
drug cocktail as the NT2 cells (lithium 10 mg/kg, valproate 50 mg/kg, quetiapine 2 mg/kg and 
lamotrigine 10 mg/kg; Sigma-Aldrich) while the vehicle group was treated with 6% DMSO. 
The drug dosages were determined based on published literature describing the minimal 
effective doses needed to affect gene expression in the brains of rats and mice. The treatments 
were administered through intraperitoneal injection. As the Cmax for the drugs overlay at 4 hrs 
with plasma half-lives between 7-24 hrs, after 6 hours, the animals were anesthetized using 
isoflurane and an incision was made in the abdomen to dissect the diaphragm, and the 
descending aorta was clamped. 10 ml of ice cold saline was administered through the left 
ventricle, which flushed the blood out of the central nervous system (CNS). The frontal cortex 
of the rats was dissected and snap frozen in liquid nitrogen.   
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Total RNA was extracted from the frontal cortex of all rats (n=16) by homogenizing 20-30 mg 
of frozen tissue in TRIzol and purifying with RNeasy® columns according to the 
manufacturer’s protocol. The quality and the quantity of the extracted RNA were determined 
as described above. 
3.2.4 Next Generation Sequencing– Bipolar Disorder Drug Combination Study 
RNAseq libraries were prepared for all NT2-N cells and rat samples from 1 µg total RNA using 
a TruSeq RNA Sample Preparation Kit v2 (Illumina, Victoria, Australia) as per the 
manufacturer’s instructions. The prepared libraries for NT2-N cells and rats were checked on 
an Agilent DNA 1000 chip using an Agilent 2100 Bioanalyzer. The concentrations of the 
samples were normalized to 10 nM and pooled.  The validated and pooled libraries were then 
run on an Illumina HiSeq platform (HiSeq 2500 rapid 50bpSE; 1 flow cell) to measure genome 
wide mRNA. 
3.2.5 Data and Pathway Analyses 
The raw data were obtained in fastq format from the HiSeq platform for the NT2-N cells and 
rats, and were aligned to reference genomes using Bowtie 2/TopHat 2. Firstly, the genes with 
no reads in all samples were filtered out, and the data set was normalized using the weighted 
trimmed mean of M-values. The differential expression of genes between the drug treated and 
vehicle groups in NT2-N cells and rat brains was assessed using edgeR in R. Gene Set 
Enrichment Analysis (GSEA) was carried out on the datasets using publically available 
software developed by the Broad Institute, USA (available at 
software.broadinstitute.org/gsea/index.jsp). 
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3.2.6 Cholesterol Assay  
3.2.6.1 NT2-N Cells 
 
A fluorometric total cholesterol assay kit (Cell Biolabs, San Diego, USA) was used to measure 
the amount of free cholesterol in treated (individual drugs or drug combination) and untreated 
NT2-N cells (DMSO 0.1% or 0.2%). Briefly, NT2-N cells were grown and treated as described 
above with the drug combination or with individual drugs, and their vehicle controls, at  the 
density of 400,000 cells/well in 24 well plates (n=6). After 24 hours of treatment, the cells were 
washed in 500μl of cold PBS three times. Into each well 500μl of PBS was added, and the cells 
were scraped using a cell scraper (13 mm; TPP, Switzerland) and the contents were transferred 
into a 1.5 ml tube (pre-weighed) and centrifuged at 15,000 x g for 10 minutes. The supernatant 
was discarded and the cell pellet was homogenised using a micro-homogenizer at speed 10 
with 200μl of lipid extraction buffer (chloroform: isopropanol: NP-40 at 7:11:0.1 ratio) for 20 
seconds. The homogenised cell pellet was centrifuged at 15,000 x g for 10 minutes, and the 
organic phase was transferred into a new tube without disturbing the pellet and left overnight 
to air dry. The tubes containing the pellet were also air dried and weighed again to determine 
the pellet weight. Then the samples containing the extracted lipid were placed under a vacuum 
for 30 minutes to remove any trace amounts of organic solvents. The dried lipids were then 
dissolved by vortexing in 200μl of 1X assay buffer that was supplied by the manufacturer of 
the kit. The cholesterol assay was carried out in a 96-well microtiter plate as per manufacturer’s 
instructions and incubated at 37°C for 45 minutes. As we did not want to measure total 
cholesterol, but only free cholesterol, cholesterol esterase was not added to the reactions. 
Following the incubation the plate was immediately scanned in a Flex Station II 384 (Molecular 
Devices, Victoria, Australia) fluorescence plate reader using an excitation of 550 nm and 
emission of 595 nm. The free cholesterol per well was calculated using the cholesterol standard 
curve and was normalised to pellet weight. 
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3.2.6.2 Rats 
 
The rat hippocampus tissues obtained from study the described in 1.2.3 were used for the 
cholesterol assay. Firstly, approximately 10 mg of rat hippocampus tissue was homogenised 
using the lipid extraction buffer at speed 10 for 20 seconds. The rest of the procedure was 
carried out as described in section 1.2.6.1. The free cholesterol in each rat hippocampus sample 
was calculated using the cholesterol standard curve and was normalised to tissue weight.  
3.2.7 Neurite Outgrowth Assay – Immunocytochemistry 
 
NT2-N cells were grown and treated with individual drugs, drug combination and vehicle 
controls as described above, but in black 96 well clear bottom plates (Corning®; Sigma-
Aldrich, New South Wales, Australia) at 15,000 cells/well density (n=8). After 24 hours of 
treatment, immunocytochemistry was performed as described previously [220]. In brief, the 
NT2-N cells were rinsed in ice cold PBS, and fixed with 4% paraformaldehyde (Electron 
Microscopy Sciences, Pennsylvania, USA) for 15 minutes at room temperature followed by 3 
washes in PBST (PBS containing 0.1% Triton X-100). Blocking buffer (5% horse serum in 
PBST) was then applied and incubated for at least 1 hour at room temperature. Monoclonal 
antibody β-III-Tubulin (1:10,000; Sigma-Aldrich) was applied and incubated overnight at 4°C. 
The next day, the cells were washed 3 times for 5 minutes each with PBST, and applied with 
biotinylated secondary antibody horse-against mouse (1:250; Vector Laboratories, California, 
USA), and incubated for 1 hour at room temperature. The cells were then washed 3 times for 
5 minutes each with PBST, and streptavidin coupled Cy3 (Sigma-Aldrich) was added and 
incubated for 1 hour at room temperature. Subsequently, the cells were washed once with 
PBST, and counterstained with DAPI at a concentration of 0.1 μg/ml for 5 minutes. The cells 
were then washed and left in PBST for imaging. 
Images were captured using a ZOE™ Fluorescent Cell Imager (Bio-Rad, New South Wales, 
Australia). For each well 5 images were captured (middle, top, right, bottom and left). The 
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images were processed in Adobe Photoshop CC (Version 14.2). Images that did not have any 
cells were excluded from the analysis. The captured images were analysed on ImageJ (National 
Institutes of Health) using NeuronJ plugin [221] to trace the neurites and measure their lengths. 
Neurites were measured from the soma of the cell to the tip. The number of nuclei was counted 
using the Multi-point tool in ImageJ. Normality of the data was checked using a Shapiro–Wilk 
test. Levene’s Test was used to decide whether equal variances could be assumed between 
treatment groups. Drug treatment groups were compared to their corresponding controls using 
independent samples t-test for normally distributed data and non-parametric test (Mann-
Whitney U test) for data not normally distributed. Significance levels were set at p<0.05. 
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3.3 Results 
3.3.1 NGS Output 
 
3.3.1.1 NT2-N Cells 
 
A total of 255 million (mean of 6.4 million reads per sample) raw reads with 12,998 million 
total bases (mean of 325 million bases per sample) were generated from 40 libraries for the 
NT2-N cells treated with the BD drug cocktail or vehicle control. Aggregated RNAseq data 
was obtained for 19,211 features that included mRNAs, microRNAs and redundant features. 
3.3.1.2 Rats 
A total of 273.8 million (mean of 17.1 million reads per sample) raw reads with 13,965 million 
total bases (mean of 873 million bases per sample) were generated from 16 libraries from the 
frontal cortex of the rats treated with the BD drug cocktail or vehicle control. Aggregated 
RNAseq data was obtained for 13,332 features that included mRNAs, microRNAs and 
redundant features. 
3.3.2 GSEA 
In order to better understand the biological significance of the sequencing data we used gene 
set enrichment analysis. This tool enables the understanding of pathways that correlate with a 
certain phenotype, in this case treatment with BD drugs, and evaluates how genes in various 
pathways are distributed and ranked in the next generation sequencing data.  
3.3.2.1 NT2-N Cells 
From the 19,211 features we obtained from NGS, we removed redundant features and 
duplicates after which 18,263 genes were recognised that had a unique identifier (Table 3.1). 
The analysis returned 403 enriched gene sets or pathways. Of these gene sets, 398 were used 
in the analysis after applying the gene set size filter of a minimum of 5 genes. 118 pathways 
were enriched in vehicle treated cells, whereas 280 pathways were enriched in drug treated 
cells as shown in Table 3.1. The steroid biosynthesis pathway was the most significantly 
enriched Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway (Enrichment score = 
-0.85, normalised enrichment score = -2.10, p-value<0.001) followed by the terpenoid 
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backbone biosynthesis pathway (Enrichment score = -0.86, normalised enrichment score = -
1.97, p-value<0.001) in the drug treated cells. 
3.3.2.2 Rats 
From the 13,332 features we obtained from NGS, we filtered and removed redundant features 
and recognised 12,921 genes that had a unique identifier (Table 3.1). The analysis returned 
1077 enriched gene sets or pathways. Of these gene sets, 728 were used in the analysis after 
applying the gene set size filter of a minimum of 5 genes. 502 pathways were enriched in 
vehicle treated rats, whereas 226 pathways were enriched in drug treated rats as shown in Table 
3.1. The oxidative phosphorylation pathway was the most significantly enriched KEGG 
pathway (Enrichment score = -0.57, normalised enrichment score = -2.46, p-value<0.001). 
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Table 3.1. Summary of Gene Set Enrichment Analysis results in NT2-N cells and rat brains 
 
NT2-N Cells Rat Brains 
 
Vehicle Drug treated Vehicle Drug treated 
Number of Genes 18,263 12,921 
Total number of enriched gene 
sets 
403 1,077 
Number of enriched gene sets 
used in analysis 
398 728 
Number of upregulated gene 
sets 
118 280 502 226 
Number of gene sets with False 
Discovery Rate  of < 25% 
5 44 68 58 
Number of  gene sets with p 
value < 0.01 
9 22 47 41 
Number of  gene sets with p 
value < 0.05 
17 59 90 59 
Most significant  pathway Steroid Biosynthesis Oxidative Phosphorylation 
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Table 3.2. Top 50 pathways with gene sets showing evidence of enrichment for higher expression in drug-treated NT2-N cells compared to vehicle 
treated control NT2-N cells. (ES = enrichment score, NES = normalised enrichment score, NOM p-val = nominal p-value, FDR q-val = false 
discovery rate adjusted p-value, FWER p-val = family wise error rate, Max rank = position in the ranked list at which the maximum enrichment 
score occurred). 
Name of Pathway Size ES NES 
NOM 
 p-val 
FDR  
q-val 
FWER  
p-val 
Max  
rank 
Steroid biosynthesis 17 -0.85 -2.10 <0.001 <0.001 <0.001 1985 
Terpenoid backbone biosynthesis 12 -0.86 -1.97 <0.001 0.004 0.009 832 
Il10 pathway 16 -0.75 -1.86 <0.001 0.022 0.072 3561 
Glycine serine and threonine metabolism 27 -0.65 -1.80 0.001 0.049 0.195 1828 
Vegf signalling pathway 66 -0.55 -1.76 <0.001 0.070 0.317 1701 
Arachidonic acid metabolism 44 -0.58 -1.75 0.002 0.075 0.391 4457 
Biosynthesis of unsaturated fatty acids 22 -0.64 -1.70 0.004 0.134 0.629 544 
Dc pathway 10 -0.77 -1.69 0.007 0.117 0.630 3486 
Fc epsilon ri signalling pathway 62 -0.53 -1.68 0.002 0.129 0.716 2761 
Alpha linolenic acid metabolism 12 -0.72 -1.68 0.006 0.119 0.728 1701 
Tryptophan metabolism 31 -0.59 -1.67 0.009 0.120 0.764 2745 
Selenoamino acid metabolism 24 -0.62 -1.66 0.004 0.121 0.799 3270 
Lysosome 118 -0.48 -1.66 <0.001 0.120 0.831 5293 
Long term depression 63 -0.52 -1.64 0.002 0.129 0.876 2900 
Calcium signalling pathway 160 -0.47 -1.63 <0.001 0.142 0.902 3224 
Glutathione metabolism 42 -0.54 -1.62 0.005 0.149 0.926 4881 
Arginine and proline metabolism 51 -0.52 -1.62 0.003 0.141 0.926 5091 
Vascular smooth muscle contraction 105 -0.47 -1.60 0.001 0.157 0.954 2505 
Nkcells pathway 17 -0.63 -1.59 0.023 0.170 0.971 2567 
Porphyrin and chlorophyll metabolism 23 -0.60 -1.59 0.014 0.170 0.976 3693 
B24:b45pentose and glucuronate 
interconversions 
13 -0.67 -1.58 0.024 0.167 0.979 3693 
Metabolism of xenobiotics by cytochrome p450 
43 -0.53 -1.58 0.011 0.172 0.985 
 
4881 
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Name of Pathway Size ES NES 
NOM  
p-val 
FDR 
q-val 
FWER 
p-val 
Max 
rank 
Linoleic acid metabolism 21 -0.59 -1.57 0.023 0.180 0.992 2786 
Glycosphingolipid biosynthesis globo series 14 -0.66 -1.57 0.016 0.178 0.992 1665 
Ether lipid metabolism 25 -0.58 `-1.56 0.019 0.174 0.993 2912 
Antigen processing and presentation 49 -0.51 -1.56 0.010 0.179 0.994 4900 
Neuroactive ligand receptor interaction 207 -0.43 -1.55 <0.001 0.186 0.997 3036 
Fructose and mannose metabolism 32 -0.53 -1.53 0.026 0.209 1.000 3222 
Gnrh signaling pathway 91 -0.46 -1.53 0.003 0.220 1.000 2478 
Primary immunodeficiency 23 -0.56 -1.52 0.022 0.215 1.000 2651 
Ppar signaling pathway 58 -0.49 -1.52 0.013 0.210 1.000 3415 
Sppa pathway 20 -0.58 -1.52 0.022 0.210 1.000 2478 
Thelper pathway 5 -0.82 -1.52 0.024 0.205 1.000 1450 
Folate biosynthesis 8 -0.73 -1.52 0.044 0.203 1.000 3153 
Lym pathway 9 -0.70 -1.50 0.031 0.220 1.000 1280 
Tight junction 122 -0.44 -1.50 0.002 0.218 1.000 1818 
Nicotinate and nicotinamide metabolism 23 -0.57 -1.50 0.040 0.221 1.000 998 
Pgc1a pathway 22 -0.56 -1.50 0.037 0.216 1.000 2991 
Toll like receptor signaling pathway 79 -0.46 -1.50 0.012 0.213 1.000 3490 
Cytokine pathway 10 -0.67 -1.49 0.044 0.217 1.000 1591 
Asthma 9 -0.68 -1.49 0.047 0.211 1.000 746 
Pyruvate metabolism 35 -0.52 -1.49 0.027 0.212 1.000 4129 
Glycerolipid metabolism 43 -0.49 -1.47 0.025 0.249 1.000 3332 
Natural killer cell mediated cytotoxicity 86 -0.45 -1.46 0.022 0.263 1.000 4067 
Cell adhesion molecules cams 103 -0.43 -1.46 0.005 0.259 1.000 2272 
Amino sugar and nucleotide sugar metabolism 42 -0.49 -1.45 0.039 0.258 1.000 5146 
Hematopoietic cell lineage 51 -0.47 -1.45 0.043 0.258 1.000 4013 
Glycosaminoglycan biosynthesis keratan sulfate 15 -0.59 -1.45 0.068 0.253 1.000 2779 
Glycerophospholipid metabolism 69 -0.45 -1.45 0.024 0.251 1.000 3332 
Phosphatidylinositol signaling system 72 -0.44 -1.45 0.027 0.247 1.000 3490 
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Table 3.3. Top 50 pathways with gene sets showing evidence of enrichment for lower expression in drug-treated NT2-N cells compared to vehicle 
treated control NT2-N cells. (ES = enrichment score, NES = normalised enrichment score, NOM p-val = nominal p-value, FDR q-val = f, FDR 
q-val = false discovery rate adjusted p-value , FWER p-val = family wise error rate, Max rank = position in the ranked list at which the maximum 
enrichment score occurred). 
Name of Pathway Size ES NES 
NOM  
p-val 
FDR  
q-val 
FWER  
p-val 
Max  
rank 
Systemic lupus erythematosus 96 0.550 2.520 <0.001 <0.001 <0.001 2443 
Tel pathway 17 0.580 1.800 0.008 0.309 0.378 4996 
Mcalpain pathway 24 0.530 1.780 0.004 0.254 0.442 2242 
Wnt pathway 25 0.520 1.740 <0.001 0.277 0.579 1730 
Tgf beta signaling pathway 79 0.400 1.730 <0.001 0.245 0.614 2742 
Carm er pathway 34 0.470 1.720 0.005 0.218 0.633 1776 
Spliceosome 125 0.360 1.710 <0.001 0.204 0.663 4341 
Carm1 pathway 13 0.600 1.660 0.024 0.247 0.777 2242 
Mcm pathway 18 0.530 1.610 0.008 0.309 0.860 1405 
Dna replication 35 0.430 1.580 0.015 0.336 0.913 1127 
Alk pathway 34 0.430 1.540 0.017 0.401 0.961 1674 
Ctcf pathway 22 0.470 1.540 0.045 0.372 0.963 2742 
P53 signaling pathway 65 0.350 1.510 <0.001 0.400 0.984 2522 
Ranms pathway 10 0.590 1.490 0.095 0.407 0.988 3977 
Vip pathway 26 0.450 1.490 0.025 0.382 0.988 2893 
Thyroid cancer 29 0.430 1.490 0.045 0.368 0.989 1550 
Akapcentrosome pathway 15 0.500 1.440 0.061 0.454 0.998 2242 
Tgfb pathway 19 0.470 1.440 0.079 0.432 0.999 3812 
P35alzheimers pathway 11 0.540 1.400 0.096 0.507 1.000 6086 
Plce pathway 12 0.520 1.390 0.121 0.494 1.000 2242 
Shh pathway 16 0.480 1.380 0.104 0.488 1.000 2242 
Gata3 pathway 13 0.490 1.380 0.117 0.474 1.000 2242 
Akap95 pathway 12 0.510 1.380 0.117 0.460 1.000 2390 
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Name of Pathway Size ES NES 
NOM  
p-val 
FDR  
q-val 
FWER  
p-val 
Max  
rank 
Arap pathway 15 0.480 1.360 0.098 0.474 1.000 2931 
P53hypoxia pathway 22 0.420 1.360 0.077 0.458 1.000 2051 
Cell cycle 121 0.300 1.360 0.016 0.441 1.000 2355 
Pitx2 pathway 14 0.450 1.310 0.179 0.536 1.000 1611 
Cftr pathway 12 0.470 1.300 0.135 0.555 1.000 2242 
G1 pathway 28 0.370 1.300 0.120 0.537 1.000 1145 
No1 pathway 28 0.360 1.270 0.134 0.590 1.000 1585 
Ribosome 84 0.280 1.270 0.048 0.574 1.000 13172 
Cardiacegf pathway 18 0.400 1.240 0.169 0.618 1.000 1571 
Tob1 pathway 11 0.470 1.240 0.203 0.616 1.000 3717 
Csk pathway 14 0.420 1.230 0.171 0.617 1.000 2242 
Colorectal cancer 61 0.300 1.220 0.132 0.614 1.000 1796 
Base excision repair 33 0.330 1.210 0.158 0.630 1.000 2850 
Eif pathway 16 0.400 1.200 0.222 0.650 1.000 1617 
Ubiquitin mediated proteolysis 129 0.250 1.200 0.063 0.639 1.000 4128 
Lysine degradation 44 0.310 1.190 0.174 0.626 1.000 2513 
Mtor pathway 23 0.360 1.190 0.204 0.611 1.000 3177 
Salmonella pathway 13 0.430 1.190 0.222 0.599 1.000 3579 
Vdr pathway 12 0.430 1.190 0.239 0.605 1.000 3989 
Chronic myeloid leukemia 71 0.270 1.170 0.178 0.636 1.000 2766 
Prostate cancer 82 0.270 1.170 0.143 0.627 1.000 1915 
Wnt signaling pathway 145 0.240 1.150 0.121 0.652 1.000 1683 
Nfat pathway 50 0.280 1.130 0.240 0.689 1.000 1585 
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Name of Pathway Size ES NES 
NOM  
p-val 
FDR  
q-val 
FWER  
p-val 
Max  
rank 
Gcr pathway 16 0.370 1.130 0.295 0.689 1.000 4803 
Il2rb pathway 34 0.310 1.130 0.244 0.678 1.000 1937 
Dream pathway 14 0.380 1.120 0.302 0.689 1.000 2242 
Ps1 pathway 13 0.400 1.110 0.346 0.708 1.000 1047 
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Table 3.4. Top 50 pathways with gene sets showing evidence of enrichment for higher expression in drug-treated rats compared with vehicle 
treated control rats. (ES = enrichment score, NES = normalised enrichment score, NOM p-val = nominal p-value, FDR q-val = , FDR q-val = 
false discovery rate adjusted p-value , FWER p-val = family wise error rate, Max rank = position in the ranked list at which the maximum 
enrichment score occurred). 
Name of Pathway Size ES NES 
NOM 
p-val 
FDR 
q-val 
FWER 
p-val 
Max rank 
Atp Synthesis By Chemiosmotic Coupling And Heat Production 
Uncoupling Proteins  
73 -0.619 -2.532 <0.001 <0.001 <0.001 3898 
Oxidative Phosphorylation 103 -0.574 -2.462 <0.001 <0.001 <0.001 3907 
Respiratory Electron Transport 58 -0.623 -2.400 <0.001 <0.001 <0.001 4198 
Tca Cycle And Respiratory Electron Transport 109 -0.499 -2.191 <0.001 0.001 0.006 4040 
Ribosome 84 -0.495 -2.022 <0.001 0.013 0.062 4201 
3 Utr Mediated Translational Regulation 100 -0.468 -1.996 <0.001 0.014 0.093 4457 
Formation Of The Ternary Complex And Subsequently The 43s Complex 46 -0.540 -2.000 <0.001 0.015 0.089 4745 
Peptide Chain Elongation 82 -0.465 -1.944 <0.001 0.020 0.177 3804 
Activation Of The Mrna Upon Binding Of The Cap Binding Complex And 
Eifs And Subsequent Binding To 43s 
53 -0.521 -1.949 
<0.001 
0.021 0.162 4745 
Pyruvate Metabolism 34 -0.542 -1.916 <0.001 0.022 0.224 2783 
Nonsense Mediated Decay Enhanced By The Exon Junction Complex 97 -0.445 -1.905 <0.001 0.022 0.246 3804 
Influenza Viral Rna Transcription And Replication 96 -0.459 -1.918 <0.001 0.023 0.220 3921 
Srp Dependent Cotranslational Protein Targeting To Membrane 104 -0.438 -1.880 <0.001 0.026 0.307 3804 
Cdt1 Association With The Cdc6 Orc Origin Complex 53 -0.489 -1.847 0.003 0.032 0.404 4329 
Scf Beta Trcp Mediated Degradation Of Emi1 48 -0.497 -1.851 0.003 0.033 0.393 4329 
Parkinsons Disease 102 -0.433 -1.834 <0.001 0.034 0.443 4198 
Translation 139 -0.403 -1.827 <0.001 0.035 0.468 3804 
Apc C Cdh1 Mediated Degradation Of Cdc20 And Other Apc C Cdh1 
Targeted Proteins In Late Mitosis Early G1 
62 -0.457 -1.799 <0.001 0.041 0.555 4329 
Assembly Of The Pre Replicative Complex 61 -0.448 -1.782 <0.001 0.042 0.611 4329 
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Name of Pathway Size ES NES 
NOM 
p-val 
FDR 
q-val 
FWER 
p-val 
Max rank 
Vif Mediated Degradation Of Apobec3g 47 -0.478 -1.785 0.003 0.043 0.602 4329 
Proteasome Pathway 28 -0.547 -1.790 <0.001 0.043 0.583 4778 
Influenza Life Cycle 125 -0.391 -1.765 <0.001 0.044 0.674 4039 
Apc C Cdc20 Mediated Degradation Of Mitotic Proteins 62 -0.458 -1.768 <0.001 0.045 0.663 4329 
Proteasome 42 -0.486 -1.759 0.003 0.046 0.695 4283 
Autodegradation Of Cdh1 By Cdh1 Apc C 55 -0.451 -1.744 0.004 0.050 0.739 4329 
Regulation Of Ornithine Decarboxylase Odc 47 -0.463 -1.731 0.007 0.052 0.773 4329 
Mitochondrial Protein Import 42 -0.478 -1.731 0.003 0.054 0.770 3211 
Peroxisome 70 -0.415 -1.700 <0.001 0.062 0.866 3543 
Destabilization Of Mrna By Auf1 Hnrnp D0 47 -0.457 -1.691 0.003 0.063 0.881 4329 
Er Phagosome Pathway 52 -0.443 -1.694 0.003 0.063 0.874 4329 
Mrna Capping 25 -0.532 -1.701 0.014 0.065 0.866 3879 
Prefoldin Mediated Transfer Of Substrate To Cct Tric 21 -0.542 -1.677 0.011 0.068 0.911 5064 
Formation Of Transcription Coupled Ner Tc Ner Repair Complex 24 -0.522 -1.655 0.011 0.078 0.945 4893 
Formation Of The Hiv1 Early Elongation Complex 25 -0.505 -1.631 0.011 0.085 0.967 3883 
Pentose Phosphate Pathway 22 -0.527 -1.634 0.034 0.085 0.964 2444 
Huntingtons Disease 145 -0.358 -1.638 <0.001 0.086 0.964 4147 
Orc1 Removal From Chromatin 64 -0.414 -1.618 0.007 0.091 0.976 3063 
Autodegradation Of The E3 Ubiquitin Ligase Cop1 46 -0.433 -1.614 0.010 0.091 0.980 4329 
Tryptophan Metabolism 30 -0.482 -1.600 0.012 0.099 0.988 1187 
Regulation Of Mitotic Cell Cycle 74 -0.385 -1.574 <0.001 0.114 0.996 3063 
Signaling By Wnt 58 -0.405 -1.575 0.003 0.116 0.996 4698 
Cytosolic Trna Aminoacylation 24 -0.483 -1.566 0.032 0.117 0.996 4570 
Scfskp2 Mediated Degradation Of P27 P21 53 -0.408 -1.561 0.010 0.119 0.998 4396 
Cholesterol Biosynthesis 18 -0.523 -1.551 0.037 0.124 0.998 2958 
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Name of Pathway Size ES NES 
NOM 
p-val 
FDR 
q-val 
FWER 
p-val 
Max rank 
Formation Of Tubulin Folding Intermediates By Cct Tric 17 -0.529 -1.547 0.045 0.125 0.998 5064 
Cdk Mediated Phosphorylation And Removal Of Cdc6 45 -0.417 -1.536 0.016 0.132 0.999 4329 
Host Interactions Of Hiv Factors 107 -0.350 -1.526 0.004 0.134 1.000 4651 
Abortive Elongation Of Hiv1 Transcript In The Absence Of Tat 17 -0.526 -1.522 0.034 0.135 1.000 3883 
Hiv Infection 168 -0.328 -1.517 <0.001 0.137 1.000 4651 
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Table 3.5 Top 50 pathways with gene sets showing evidence of enrichment for lower expression in drug-treated rats compared with vehicle treated 
control rats. (ES = enrichment score, NES = normalised enrichment score, NOM p-val = nominal p-value, FDR q-val = false discovery rate, 
FWER p-val = family wise error rate, Max rank = position in the ranked list at which the maximum enrichment score occurred). 
Name of Pathway Size ES NES NOM p-val 
FDR q-
val 
FWER 
p-val 
Max 
rank 
Collagen Formation 37 0.675 2.138 <0.001 0.001 0.001 2259 
Integrin Cell Surface Interactions 58 0.605 2.058 <0.001 0.008 0.015 1889 
Pathways In Cancer 273 0.482 2.024 <0.001 0.008 0.024 3076 
Cell Junction Organization 60 0.581 2.004 <0.001 0.008 0.031 3510 
Hedgehog Signaling Pathway 48 0.606 2.003 <0.001 0.006 0.031 1802 
Focal Adhesion 164 0.502 1.995 <0.001 0.005 0.032 3131 
Alk Pathway 31 0.650 1.987 <0.001 0.005 0.035 3076 
Basal Cell Carcinoma 49 0.594 1.977 <0.001 0.006 0.045 1802 
Extracellular Matrix Organization 54 0.576 1.971 <0.001 0.006 0.049 2259 
Nitric Oxide Stimulates Guanylate Cyclase 21 0.703 1.960 <0.001 0.006 0.062 2124 
Smooth Muscle Contraction 21 0.702 1.958 <0.001 0.006 0.063 1841 
Mcalpain Pathway 24 0.645 1.881 <0.001 0.018 0.195 2326 
Immunoregulatory Interactions Between A Lymphoid And A 
Non Lymphoid Cell 
31 0.610 1.870 <0.001 0.019 0.223 2048 
Vascular Smooth Muscle Contraction 94 0.498 1.835 <0.001 0.028 0.330 1967 
ECM Receptor Interaction 56 0.538 1.827 <0.001 0.029 0.355 2259 
Myosin Pathway 24 0.638 1.820 <0.001 0.030 0.388 1860 
Platelet Homeostasis 64 0.512 1.789 <0.001 0.043 0.515 2124 
Adherens Junction 62 0.508 1.754 <0.001 0.062 0.666 3856 
Cgmp Effects 15 0.679 1.740 0.005 0.069 0.726 2124 
Cell Cell Communication 97 0.467 1.732 0.001 0.072 0.756 3652 
Drug Metabolism Cytochrome P450 31 0.576 1.717 0.002 0.081 0.816 1326 
Cell Cell Junction Organization 42 0.523 1.709 0.001 0.085 0.846 3812 
U calpain Pathway 17 0.645 1.706 0.003 0.085 0.857 2858 
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Name of Pathway Size ES NES NOM p-val 
FDR q-
val 
FWER  
p-val 
Max 
rank 
Gap Junction 77 0.472 1.698 0.001 0.089 0.875 3392 
Tnfr2 Pathway 16 0.643 1.695 0.005 0.088 0.882 2596 
Muscle Contraction 40 0.536 1.693 0.001 0.084 0.888 1386 
Melanoma 58 0.497 1.682 0.001 0.091 0.912 2184 
Cell Surface Interactions At The Vascular Wall 71 0.477 1.676 <0.001 0.094 0.929 2109 
Keratan Sulfate Biosynthesis 22 0.591 1.669 0.008 0.097 0.939 2106 
Tight Junction Interactions 20 0.596 1.658 0.008 0.106 0.957 3812 
Shh Pathway 15 0.639 1.650 0.015 0.112 0.973 1747 
Bladder Cancer 36 0.530 1.645 0.003 0.114 0.978 1842 
Yap1 And Wwtr1 Taz Stimulated Gene Expression 19 0.605 1.643 0.014 0.113 0.981 3162 
Signaling By Hippo 17 0.621 1.635 0.013 0.118 0.986 2848 
Keratan Sulfate Keratin Metabolism 26 0.553 1.625 0.017 0.129 0.991 2106 
Transport Of Glucose And Other Sugars Bile Salts And Organic Acids 
Metal Ions And Amine Compounds 
66 0.460 1.617 0.003 0.136 0.994 2468 
Par1 Pathway 28 0.550 1.615 0.012 0.135 0.994 1860 
Primary Immunodeficiency 23 0.561 1.613 0.012 0.133 0.995 615 
Small Cell Lung Cancer 69 0.456 1.613 0.003 0.130 0.995 2945 
Pancreatic Cancer 65 0.457 1.612 0.006 0.128 0.995 2007 
Amino Acid Transport Across The Plasma Membrane 27 0.545 1.611 0.027 0.126 0.995 888 
Signaling By Fgfr1 Mutants 19 0.593 1.608 0.029 0.127 0.997 4094 
Calcium Signaling Pathway 155 0.403 1.608 0.001 0.124 0.997 3008 
Glycosaminoglycan Metabolism 92 0.431 1.599 0.001 0.133 0.998 2106 
Regulation Of Actin Cytoskeleton 172 0.398 1.595 <0.001 0.134 0.998 3796 
Vegf Pathway 26 0.550 1.593 0.011 0.134 0.998 4207 
Wnt Signaling Pathway 128 0.409 1.589 0.001 0.137 0.999 3156 
Heparan Sulfate Heparin Hs Gag Metabolism 41 0.491 1.586 0.015 0.138 0.999 3777 
Hemostasis 346 0.370 1.582 <0.001 0.140 1.000 2131 
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3.3.3 Cholesterol Biosynthesis Pathway 
3.3.3.1 NT2-N Cells 
Pathway analysis in the NT2-N cells revealed that the BD drug cocktail increased steroid and 
terpenoid backbone biosynthesis. Therefore, we looked more closely at the genes in the 
cholesterol biosynthesis pathway in our sequencing data from the NT2-N cells. It was found 
that all 15 genes in the cholesterol biosynthesis pathway were upregulated following the BD 
drug treatment in the NT2-N cells (GSEA Adj. p-value= 3.4x10-9, Figure 3.1a) Moreover, 
expression of intracellular cholesterol transport genes were also increased (NPC1 p = 6.7x10-
23, NPC2 p = 3.2x10-19, APOE p = 1.9x10-13), while the major gene involved in cellular 
cholesterol efflux was decreased (ABCA1 p =1.2x10-6, Figure 3.2).  
We then looked at how individual BD drugs affected the cholesterol biosynthesis pathway 
genes in NT2-N cells in our whole genome sequencing data (methods and results are described 
in Chapter 2 and 4 in more detail). We looked at the expression of the 15 cholesterol 
biosynthesis pathway genes in lithium, valproate, lamotrigine and quetiapine treated cells 
(Figu). In lithium treated cells, there was no overall change in the pathway. In valproate treated 
cells, the overall cholesterol biosynthesis pathway had decreased expression by 3.8 ± 2.4%. 
Similarly, in lamotrigine treated cells, the pathway had lower expression by 6.7 ± 2.6%. 
However, in quetiapine treated cells, the pathway had an overall increase of 23 ± 2.7% 
(p<0.001, z-test). 
3.3.3.2 Rats 
 
Although steroid and terpenoid backbone biosynthesis pathways did not appear in the GSEA 
analysis of rat data, we looked at the cholesterol biosynthesis pathway genes from this data set. 
From the 15 genes, data was available for 14 genes (no data for MVK), and of these genes 12 
had increased expression compared to vehicle (Figure 3.1b). However, only one gene was 
significantly increased (PMVK; p<0.05). The overall pathway was significantly upregulated 
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(p<0.01, z-test) however the average increase in the expression was much lower (3.2 ± 6.5%) 
than the NT2-N cells (75 ± 3.5%).  
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Figure 3.1. Genes involved in cholesterol pathway and their expression in the BD drug 
treated NT2-N cells (a) and rat brains (b) (*p<0.05). 
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Figure 3.2. Evidence for increased mobilisation and intracellular transport (NPC1, NPC2 
and APOE), but not efflux of cholesterol (ABCA1) in BD drug treated NT2-N cells (n=20;  
*** p<0.001) 
 
In order to validate these findings, we measured the amount of free cholesterol in individual 
and BD drug combination treated NT2-N cells and their vehicle controls and normalised it to 
the total amount of protein. The findings showed that the free cholesterol levels tended to 
increase by 39 ± 18% (Figure 3.4) in BD drug combination treated cells. Individually lithium 
and valproate tended to increase free cholesterol, whereas lamotrigine and quetiapine appeared 
to decrease it. However, these findings were not statistically significant.   
In the rats treated with BD drug combination, the free cholesterol levels tended to increase, 
however not statistically significant (Figure 3.5). 
 
 
  
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Genes involved in cholesterol pathway and their expression in the individual bipolar disorder drug treated NT2-N cells derived from 
whole genome sequencing. 
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Figure 3.4. Effects of individual and combination of bipolar disorder drugs on the amount of free cholesterol in NT2-N cells relative to their 
respective vehicles after 24 hours of treatment. 
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Figure 3.5. Effects of combination of bipolar disorder drugs on the amount of free cholesterol in rat hippocampus following 6 hours treatment 
relative to vehicle. 
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3.3.4 Oxidative Phosphorylation Pathway and Expression of Sirtuins 
3.3.4.1 Rats 
Data were obtainable for 103 genes in the oxidative phosphorylation pathway acquired from 
GSEA in the rats (Table 3.6). Of these, 90 (87.4%) had higher expression in the drug-treated 
rats, while 13 (12.6%) were lower expressed. The average increase in expression across the 
103 genes was 4.8 ± 1.4%, which was highly significant (p<0.001, z-test). We then assigned 
the genes to their appropriate electron transport chain complex and carried out a similar 
analysis. The "Other" category consists mostly of lysosomal and vacuolar ATPases. The genes 
in Complexes I (p<0.001), III (p<0.002) and V (p<0.001; Figure 3.6) were significantly 
upregulated. In all the complexes there were an increased proportion of upregulated genes in 
the drug treated rats, and this was statistically significant for Complexes I and V (Figure 3.6).  
Given a seemingly coordinated higher level of oxidative phosphorylation gene expression in 
the drug-treated rats, we then examined the global gene expression database for potential 
upstream regulators of mitochondrial function. The expression of the PGC1α gene, a master 
regulator of mitochondrial biogenesis [227], was not different between the drug treated rats 
and vehicle treated controls. Nonetheless, two of the most differentially expressed genes in the 
dataset encoded sirtuins, which are established regulators of mitochondrial function and have 
been linked to aging and longevity [228]. SIRT3 and SIRT4 were both upregulated in the drug 
treated rats compared to the vehicle treated control rats (p=0.04 and p=0.02, respectively; 
Figure 3.8). 
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3.3.4.2 NT2-N Cells 
 
Given the increase of oxidative phosphorylation genes in the rat frontal cortex, we then looked 
at the expression of these genes in NT2-N cells. We looked for the same 103 genes from the 
rat study; however, data was only available for 100 genes in our whole genome sequencing 
dataset for NT2-N cells (Table 3.6). Of these, 70 (70%) had higher expression in the drug-
treated NT2-N cells, while 30 (30%) were lower expressed. The average increase in expression 
across the 100 genes was 12.1 ± 4.1%, which was highly significant (p<0.002, z-test). We then 
allocated the genes to their appropriate electron transport chain complex and completed a 
similar analysis to the rat genes. The average increase in gene expression in drug-treated rats 
was significant for complex IV (p<0.05) and “Other” (p<0.005; Figure 3.7). In all cases, there 
were an increased proportion of genes with higher expression in the drug-treated NT2-N cells 
and this was statistically significant for Complexes IV and “Other” (Figure 3.7). 
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Table 3.6. The Oxidative Phosphorylation (OXPHOS) pathway is upregulated by the cocktail of bipolar drugs in rat frontal cortex (GSEA – FDR 
q<0.001, FWER p<0.001), particularly genes in Complexes I and V. The majority of the OXPHOS genes are also upregulated by the drug cocktail 
in the NT2-N cells, especially in Complex IV (data derived from next generation sequencing) (n.s-not significant) 
  
NT2-N Cells Rat Brains 
Total 
Number 
of Genes 
Number of genes 
higher in drug 
treated NT2-N 
cells 
Number of genes 
lower in drug 
treated NT2-N 
cells 
p-value Total Number 
of Genes 
Number of 
genes higher 
in drug 
treated rats 
Number 
of genes 
lower in 
drug 
treated 
rats 
p-value 
OXPHOS Pathway 100 70 30 <0.002 103 90 13 <0.001 
Complex I 32 18 14 n.s. 33 30 3 <0.001 
Complex II 4 3 1 n.s. 4 3 1 n.s. 
Complex III 9 6 3 n.s. 9 7 2 <0.002 
Complex IV 15 13 2 <0.05 16 13 3 <0.05 
Complex V 15 8 7 n.s. 15 14 1 <0.001 
Other 25 22 3 <0.05 26 22 4 n.s 
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Figure 3.6. Increased OXPHOS gene expression in the frontal cortex of rats by complex in the mitochondrial electron transport chain (fold change 
compared to vehicle) following treatment with BD drugs. *p<0.05, **p<0.002, ***p<0.001. 
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Figure 3.7. Increased OXPHOS gene expression in the NT2-N cells by complex in the mitochondrial electron transport chain (fold change 
compared to vehicle) following treatment with BD drugs. *p<0.05, **p<0.002 
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Figure 3.8. Gene expression of SIRT3 and SIRT4 in drug-treated frontal cortex of rats relative to vehicle. *p<0.05 
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3.3.5 Neurite Outgrowth 
The individual and combination of BD drugs tended to have varying effects on neurite 
outgrowth (Figure 3.9). Individually the drugs did not have any effects on neurite outgrowth. 
However, as a combination the drugs tended to increase neurite outgrowth by 20.3±10.7%. 
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Figure 3.9. Effects of individual and combination of BD drugs on neurite outgrowth in NT2-N 
cells relative to vehicle. 
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3.4 Discussion 
 
In this study, we analysed the effects of a combination of BD drugs on gene expression in NT2-
N cells and rat frontal cortex. Data were obtained for 19,211 and 13,332 genes/transcripts in 
NT2-N cells and rats respectively and were used for GSEA pathway analysis.  
GSEA on genes expressed in the rat frontal cortex following BD drug treatment indicated that 
the oxidative phosphorylation pathway was significantly increased. There is extensive 
evidence to show that mitochondrial dysfunction is involved in the pathophysiology of BD 
[229]. Altered bioenergetics was first observed in 1956 by Altschuler and co-workers [230], 
and Kato and Kato first proposed the mitochondrial dysfunction hypothesis for BD in 2000 
[231]. Since then several publications have presented evidence supporting the role of 
mitochondrial dysfunction in the pathophysiology of BD. Impaired oxidative phosphorylation, 
increased glycolytic energy production, a general decrease in ATP production, abnormalities 
in the morphology and intracellular distribution of mitochondria and increased mitochondrial 
generated oxidative stress are some of the mechanisms that have been put forward [232].  
One of the most robust findings is downregulation of genes encoding subunits of the electron 
transport chain complexes, particularly the subunits of complex I [90]. Decreased expression 
of genes coding for subunits of complex I in post-mortem, prefrontal cortex [233, 234] and 
hippocampus [84] have been described. Furthermore, there have been evidences to show that 
the expression of mRNA for subunits of complexes III and IV [90], and complex V [84, 90] 
are downregulated. In one study, reduced expression of NDUFS7, which is a subunit of 
complex I, in the prefrontal cortex was connected to decreased complex I activity and increased 
oxidative damage in subjects with BD [233].  
Therefore, we looked more closely at the oxidative phosphorylation pathway, which contained 
103 genes from our dataset, and had an overall increase in expression. When we allocated the 
differentially expressed genes to their respective electron transport chain complexes, the 
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majority of them were present in Complexes I, III and V, suggesting a potential effect of these 
drugs on mitochondrial respiratory chain function when used in combination. Significant 
increases in gene expression were seen in complex I, III, IV and V in the rats, and complex IV 
in the NT2-N cells. In line with the evidence mentioned above regarding mitochondrial 
dysfunction in BD, this finding shows that one of the possible mechanisms by which the BD 
drugs bring about efficacy in BD patients, could be through increasing mitochondrial function 
and reducing oxidative stress, especially through increasing the expression of various genes in 
the complexes in the electron transport chain. 
Furthermore, various studies investigating the mechanism (s) of action of the mood stabiliser 
lithium established effects on mitochondria. Lithium upregulated the expression of complex I 
subunits in subjects with BD [90] and rodents [235]  as well as enhanced complex I activity in 
the frontal cortex of subjects with BD [178] and leukocytes of depressed subjects with BD 
[236]. However, for valproate, downregulation of NDUFS7 was seen in patients with BD [90]. 
Another study conducted in human liver cells also found that valproate inhibited mitochondrial 
activity [237]. This contradicting finding suggests that the mechanism of action of valproate 
might be via a different pathway, or given valproate’s antimanic properties, it may act to reduce 
energy metabolism associated with mania. Moreover, lamotrigine, which is an antidepressant, 
has been shown to increase the activities of complexes II, III and IV in rats, however not 
complex I [238]. Adding to that, another study showed that antidepressants could potentially 
inhibit the activities of complex I and IV [239].  It is possible that the overall effects of 
lamotrigine on the electron transport chain complexes are positive as the decrease of complex 
I activity has been shown to be compensated by the increase in other complexes. Considering 
the impairment in energy metabolism or lower energy associated with BD depression, it is 
possible that lamotrigine acts to increase energy metabolism through effects on mitochondrial 
function.  Furthermore, quetiapine has also been shown to increase the electron transport chain 
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activity in rat brains [240].  These findings further attest to the pathway analysis data we 
obtained from our rat study, which showed increased expression of genes involved in oxidative 
phosphorylation in the BD drug combination treated rats. 
Moreover, three members of the sirtuin family, known as mitochondrial sirtuins, SIRT3, SIRT4 
and SIRT5, act as deacetylases that play significant roles in the regulation of post-translational 
modifications essential for mitochondrial homeostasis. In this study, SIRT3 and SIRT4 were 
among the most differentially expressed genes, and they were both upregulated in the frontal 
cortex of the drug treated rats. Our findings suggest that BD drugs when used in combination 
might induce a synchronized increase in the expression of genes involved in the oxidative 
phosphorylation pathway, and increase mitochondrial electron transport chain activity, which 
could be a possible mechanism underpinning the efficacy of polypharmacy in BD.  
Little is known about the potential effects of BD drugs on sirtuins. Wang et al. (2013) (Wang 
et al., 2013) demonstrated that lithium at 5mmol/L, valproic acid at 1mmol/L and the 
combination of lithium plus valproic acid increased the protein levels of SIRT3 and coactivator-
associated arginine methyltransferase1 (CARM1) in an oxidative stress (H2O2) induced cellular 
injury model. Our findings suggest that sirtuins may be a molecular target of BD drugs when 
used in combination, leading to a highly coordinated transcriptional effect resulting in 
increased oxidative phosphorylation.  
On the other hand, in NT2-N cells, the GSEA implicated the steroid and terpenoid backbone 
biosynthesis pathways, which were robustly increased by the BD drug cocktail. Both of these 
pathways are closely connected to cholesterol biosynthesis. The terpenoid backbone 
biosynthesis pathway provides precursor molecules for cholesterol biosynthesis [241] whereas 
steroids are produced from cholesterol [242]. Upregulation of these pathways in neuronal cells 
suggests increased cholesterol biosynthesis. Therefore, we examined our next generation 
sequencing dataset and found that all of the genes involved in the cholesterol biosynthesis 
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pathway had strikingly increased expression in the neuronal cells following BD drug treatment. 
In addition, in the rats, most of the genes in the cholesterol biosynthesis pathway showed trends 
for an increase. In addition to increased synthesis of cholesterol, we also found evidence that 
the synthesised cholesterol appeared to be being utilised within the cells and not being removed 
from the cells. NPC1, NPC2 and APOE genes were increased by the BD drug cocktail 
compared to vehicle. These genes are involved in intracellular transport of cholesterol. 
Furthermore, the major gene involved in the efflux of cholesterol (ABCA1), was decreased by 
the drugs, which suggests that the newly synthesised cholesterol is being retained within the 
cells.  
We then validated the next generation sequencing finding and quantified free cholesterol in 
individual and combination drug and vehicle treated cells and rat brains.  Although not 
statistically significant, the drug combination tended to increase the amount of free cholesterol 
in the cells as expected, however, surprisingly the individual drugs showed opposing effects. 
In the rats, there was a trend for increased cholesterol in the hippocampus, however the findings 
were not statistically significant.  
The brain is the most cholesterol rich organ, containing about 25% of whole body cholesterol 
[243]. The brain cholesterol is synthesised exclusively in the brain, and is isolated from 
cholesterol biosynthesis in the periphery due to the presence of the BBB [138]. Unesterified or 
free cholesterol is the predominant sterol in the human brain (>99.5%), and is largely present 
in myelin sheaths formed by oligodendrocytes and plasma membranes in neurons and 
astrocytes [243]. Neurons have a large amount of membrane surface formed by their axons, 
dendrites and synapses where cholesterol is present in high amounts. Therefore, cholesterol 
plays a significant role as a structural component, in neurotransmission, synaptogenesis, 
dendrite formation and axonal guidance [138]. 
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There is a growing body of evidence showing association between mood disorders and 
cholesterol levels [244, 245]. In a post mortem study of cholesterol levels in the brains of 
subjects with BD, it was found that the cholesterol levels were 10% lower than those of controls 
[245]. Moreover, the same study also found reduced synapses in subjects with BD, which could 
be due to reduced neural plasticity in association with cholesterol depletion. Cholesterol 
exhaustion can lead to increased membrane permeability and therefore affect serotonin 
neurotransmission by impairing the function of serotonin receptors [246] and thus reducing 
serotonin activity, which is characteristic of BD [247]. Consequently, cholesterol is implicated 
in the pathophysiology of BD. 
The role of the nervous system is to transmit signals and communicate between neighbouring 
neurons through a network of axons, neurites, dendrites and synaptic endings [134]. When the 
anatomy of this network is disrupted, neural plasticity or the ability to adapt to new challenges 
such as environmental changes and brain lesions is disrupted [135]. At a cellular level, neural 
plasticity disruption is characterized by structural changes in the brain network such as reduced 
dendrite and neurite outgrowth [134], which diminishes neural connections. Brain-derived 
neurotrophic factor (BDNF) is a key mediator of neural plasticity [248] and has been shown to 
be decreased in BD manic and depressive episodes [249].  
Neuronal projections, such as axons and dendrites are essential for neurite outgrowth, and there 
is evidence to show that phospholipids regulate this function in cultured neurons [136], as well 
as cholesterol deficiency inhibiting dendrite outgrowth in cerebral cortical neurons isolated 
from rats [137]. Furthermore, Ko et al. (2005) showed that either loading or depleting 
cholesterol in hippocampal and cortical neurons reduced neurite outgrowth, which suggest that 
there may be an optimal concentration of cholesterol at which the neurons display neurite 
outgrowth, as well as the importance of the maintenance of cholesterol concentration in 
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neuronal cells [250]. These lines of data suggest that membrane lipids have substantial roles in 
neurite and dendrite outgrowth, and thereby affect neural plasticity.  
This line of evidence leads us to believe that the drugs when used in combination might affect 
the cholesterol biosynthesis pathway and increase cholesterol production, thereby increasing 
neurite outgrowth and neural plasticity. Therefore, we measured neurite outgrowth in BD drug 
treated cells. As we saw variable effects by individual drugs on cholesterol synthesis, we also 
wanted to see how the drugs affected neurite outgrowth individually. It was found that the BD 
drug cocktail increased neurite outgrowth, whereas individually the drugs decreased it. This 
suggests that an increase in cholesterol is potentially required for the increase in neurite 
outgrowth, and it could be a summative effect of the BD drug combination rather than an 
individual drug effect. 
This study suggests that BD drugs increase oxidative phosphorylation and mitochondrial 
function in order to provide more energy to increase cholesterol biosynthesis. The produced 
cholesterol is retained within the cells and used by plasma membranes to produce more 
neuronal projections, thereby increasing neurite outgrowth, which increases neural plasticity. 
We postulate that these mechanisms together represent pathophysiological elements of BD that 
interfere with neural plasticity. Moreover, the study also gives us some insight into mechanisms 
of action of some of the commonly used BD drugs when used concurrently, which is to increase 
cholesterol synthesis and thereby increase neurite outgrowth. It could be at least in part through 
this mechanism that the BD drug combination exerts its therapeutic activity in subjects with 
BD. These findings provide insight into why polypharmacy is efficacious in subjects with BD. 
However, further studies should be done in suitable models, such as iPSCs derived from 
subjects with BD, and with various drug combinations widely prescribed to subjects with BD 
to validate this finding. 
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We acknowledge there are some limitations in this study. The neuronal cells used in this study 
do not represent a bipolar state or phenotype, however, due to the lack of established model 
systems this was considered the best model in which to examine how the BD drugs affect global 
gene expression. Moreover, a more robust assay to quantify cholesterol in neuronal cells with 
higher number of replicates might give us a better understanding of the postulated molecular 
mechanism in this study. The cholesterol pathway genes showed clear increase in expression 
from the sequencing data, however we do not know how long it takes for the cells to make 
cholesterol following gene expression. Therefore, measuring cholesterol levels in NT2-N cells 
at different time points is warranted.  
3.5 Conclusion 
In conclusion, a combination of BD drugs increased mitochondrial function and biosynthesis 
of cholesterol compared to single drugs, which in turn increased neurite outgrowth. Increased 
neurite outgrowth increases neural plasticity and helps the brain to form new and better 
connections between neurons. This could be a potential mechanism by which polypharmacy 
brings about its therapeutic efficacy in subjects with BD.   
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Figure i. All the genes that were tested in the dose response study for lithium, valproate, 
quetiapine and lamotrigine in GT1-7 cells. 
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CHAPTER 4 
TRANSCRIPTIONAL EFFECTS OF DRUGS USED TO 
TREAT BIPOLAR DISORDER 
 
4.1 Introduction 
 
As previously discussed in Chapters 1 and 3, the available BD drug therapies are not 
particularly successful in treating the underlying pathophysiology of the disorder, in spite of 
the considerable development of BD research in recent decades. This is mainly due to 
incomplete understanding of the molecular and cellular aetiology of BD, leading to a lack of 
validated pharmacological targets and a lack of well-established  animal models for the disorder 
[154]. 
Conventionally, first-line mood stabilizers such as lithium and valproate were used in treating 
BD, however, in recent years the treatment options have been extended to include atypical 
antipsychotics [158].  The Canadian Network for Mood and Anxiety Treatment (CANMAT) 
guidelines recommend lithium, valproate or quetiapine as first line monotherapy for acute 
mania whereas for depression lithium, lamotrigine or quetiapine are advocated [160]. 
Moreover, for maintenance of BD, CANMAT suggests lithium, valproate, quetiapine or 
lamotrigine as first line monotherapy [160]. 
Lithium, valproate, lamotrigine and quetiapine have proven clinical efficacy in treating BD 
depression and mania as monotherapy as well as in polytherapy. Lithium has been used as a 
gold standard treatment for BD due to its neuroprotective and neurotrophic actions [158]. 
Valproate has been used as an alternative adjunctive treatment to lithium. Lamotrigine, has 
been shown to be effective in depression and rapid cycling in BD as a monotherapy and as an 
adjunctive therapy to lithium or valproate (Calabrese, Bowden et al. 1999, Ketter, Manji et al. 
2003, Yatham, Kennedy et al. 2013). Quetiapine, is the first FDA approved monotherapy for 
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BD depression and mania (Thase 2008, Yatham, Kennedy et al. 2013).  It is also emerging as 
a first line adjunctive therapy for BD mania with either lithium or valproate (Yatham, Kennedy 
et al. 2013). Although CANMAT guidelines recommend monotherapy as a first line treatment 
for BD, in reality BD patients are often prescribed with more than one drug [193]. 
Consequently, polypharmacy is the rule rather than the exception in BD. However, we do not 
fully understand how these drugs work either alone or in combination. It has been proposed 
that these drugs could affect various pathways that affect neurotransmitters, mitochondrial 
function, neuronal plasticity, inflammation, axonal guidance and glutamate activity. 
In chapter 3 we explored the combinatorial effects of the four aforementioned BD drugs, and 
found that in the NT2-N cells, the drugs increased steroid biosynthesis and thereby cholesterol 
biosynthesis. On the other hand, in rats the oxidative phosphorylation pathway was upregulated 
by the BD drug combination. This suggests that there are multiple functions and biological 
processes that could be affected by these BD drugs when they are given as polytherapy. 
However, it would be interesting and enlightening to see the transcriptional effects of these 
drugs individually. Therefore, in this chapter we have explored the transcriptional effects of 
the BD drugs individually in order to identify possible pathways and mechanisms through 
which they might act to bring about efficacy in BD patients.  
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4.2 Materials and Methods 
Detailed methods and materials for this chapter can be found in Chapter 2 of this thesis. 
4.2.1 Cell Culture 
Ntera2 human teratocarcinoma cells (NT2) were cultured and differentiated as previously 
described [208]. The differentiated neuronal-like cells (NT2-N) were treated with individual 
BD drugs (2.5 mM lithium chloride, 0.5 mM valproate, 50 µM lamotrigine and 50 µM 
quetiapine; Sigma-Aldrich) or vehicle control (0.1% DMSO for lamotrigine and quetiapine and 
H2O for lithium and valproate) in serum starvation media (DMEM with 0.2% bovine serum 
albumin; Sigma-Aldrich) for 24 hours (n=16 per group, pooled later during RNA isolation to 
make n=4 per group).  
4.2.2. RNA Isolation and Quality Control 
Following the 24-hour treatment, the cells were harvested (4 wells were pooled to make up one 
replicate) and total RNA was extracted using TRIzol (Thermo Fisher Scientific) and purified 
with RNeasy® mini kits (Qiagen, Melbourne, Australia) as per the manufacturer’s instructions. 
The quality of the extracted RNA from the NT2-N cells was determined using an Agilent 2100 
Bioanalyzer and RNA 6000 Nano Kit (Agilent Technologies, Melbourne, Australia). The 
quantity of the RNA was assessed using NanoDrop 1000 (Thermo Fisher Scientific). 
4.3. Next Generation Sequencing (NGS) 
RNAseq libraries were prepared for all NT2-N cell samples from 1 µg total RNA using a 
TruSeq RNA Sample Preparation Kit v2 (Illumina, Victoria, Australia) as per the 
manufacturer’s instructions. The prepared libraries for NT2-N cells and rats were checked on 
an Agilent DNA 1000 chip using an Agilent 2100 Bioanalyzer. The concentrations of the 
samples were normalized to 10 nM and pooled.  The validated and pooled libraries were then 
run on an Illumina HiSeq platform (HiSeq 2500 rapid 50bpSE; 1 flow cell) to measure genome 
wide mRNA. 
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4.3.1 Next Generation Sequencing Data Analysis 
The output of raw sequence reads were downloaded in FASTQ format for bioinformatics 
analysis. For this study, we employed a different approach to what is described in section 2.4.2 
for data analysis. We used an RNAseq data analysis pipeline developed by Dr. Mark 
Richardson (https://github.com/m-richardson/RNASeq_pipe). This is a different approach to 
how the BD drug combination data was analysed mainly because the individual BD drug study 
was carried out at a later point in time, and our bioinformatics approach to analysing NGS data 
had improved significantly during that period.  
As all the steps required in NGS data analysis are incorporated into this new pipeline, it reduces 
the time required for obtaining differential expression data. Moreover, the STAR alignment 
program is comparatively faster and in some cases more accurate than the Bowtie /TopHat 
approach [216]. The final output from STAR in the form of read counts per gene was collated 
in R and produced in a format that can be used in differential gene expression analysis using 
edgeR.  
Differential gene expression analysis was carried out using edgeR and an adjusted p-value of 
0.05 was used to identify genes of interest.  
4.4 Gene Set Enrichment Analysis 
Gene Set Enrichment Analysis (GSEA) was carried out on the complete gene lists obtained 
from NGS for individual BD drug study in NT2-N cells. GSEA is a computational method 
developed by the Broad Institute, USA (available at software.broadinstitute.org/gsea/index.jsp) 
[217]. This method was founded on the idea that gene expression could be altered at the level 
of biological pathways rather than specific genes. Through GSEA, the genes are ranked relative 
to the difference in expression based on signal-to-noise ratio (SNR).  
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Firstly, the duplicates as well as any genes with total read counts of 0 were removed. This file 
was then converted to a Text (Tab delimited) (*.txt) format. The phenotype information and 
labels were written into a CLS file. The text and CLS files were loaded onto the GSEA software 
and the analysis was run with phenotype as the permutation type. 
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4.5 Results 
4.5.1 NGS Output 
 
A total of 249 million (mean of 10.3 million reads per sample) raw reads with 12,717 million 
total bases (mean of 529 million bases per sample) were generated from 24 libraries for the 
NT2-N cells treated with individual BD drugs or their respective vehicle control (n=4 per 
group).  
4.5.2 Next Generation Sequencing Data Analysis 
 
After carrying out RNASeq pipeline analysis on the raw data, we obtained data for a total of 
58,051 genes regardless of the treatment group, which included duplicates and redundant 
features. After cleaning and filtering the dataset, each BD drug treatment had approximately 
36,000 genes (total reads >1; exact numbers given in Table 4.1).  
4.5.3 Gene Set Enrichment Analysis  
 
In order to better understand the biological significance of the sequencing data we used gene 
set enrichment analysis. This tool enables the understanding of pathways that correlate with a 
certain phenotype, in this case treatment with BD drugs, and evaluates how genes in various 
pathways are distributed and ranked in the next generation sequencing data.  
In lithium treated cells, the “amino acid transport across the plasma membrane” pathway was 
the most significantly enriched (Enrichment score= -0.59, normalised enrichment score= -1.84, 
p-value<0.001; Tables 4.1 and 4.2). In valproate treated cells the most significant pathway was 
“antigen processing and presentation” (Enrichment score= -0.48, normalised enrichment 
score= -2.2, p-value<0.001; Tables 4.1 and 4.3). In lamotrigine treated cells, none of the 
pathways were significantly enriched. In quetiapine treated cells the most enriched pathway 
was “CDK5 pathway” (Enrichment score= -0.51, normalised enrichment score= -1.49, p-
value<0.001; Tables 4.1 and 4.4) 
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Table 4.1. Summary of Gene Set Enrichment Analysis results in NT2-N cells treated with individual drugs. 
  Lithium Valproate Lamotrigine Quetiapine 
Total number of genes 36,132 36,305 35,570 35,750 
Number of upregulated gene 
sets in the drug treated cells 
731 988 26 157 
Number of gene sets with False 
Discovery Rate  of < 25% 
1 458 0 0 
Number of gene sets with False 
Discovery Rate  of < 5% 
0 115 0 0 
Number of  gene sets with 
nominal p value < 0.01 
37 240 0 6 
Number of  gene sets with 
nominal p value < 0.05 
61 340 0 14 
Most significant pathway Amino acid transport 
across the plasma 
membrane 
Antigen processing and 
presentation 
- CDK5 pathway 
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Table 4.2..Top 50 pathways with gene sets showing evidence of enrichment for higher expression in lithium treated NT2-N cells compared to 
vehicle treated control NT2-N cells based on NOM p-val. (ES = enrichment score, NES = normalised enrichment score, NOM p-val = nominal p-
value, FDR q-val = false discovery rate, FWER p-val = family wise error rate, Max rank = position in the ranked list at which the maximum 
enrichment score occurred). 
Name Number 
of 
Genes 
ES NES NOM 
p-val 
FDR 
q-val 
FWER  
p-val 
Max 
rank 
Reactome amino acid transport across the plasma membrane 28 -0.599 -1.838 <0.001 0.240 0.164 5274 
Reactome traf6 mediated induction of tak1 complex 13 -0.565 -1.673 <0.001 0.265 0.614 3736 
Reactome hyaluronan metabolism 14 -0.580 -1.692 <0.001 0.265 0.533 1247 
Reactome base free sugar phosphate removal via the single nucleotide 
replacement pathway 
10 -0.652 -1.660 <0.001 0.268 0.627 5175 
Kegg riboflavin metabolism 14 -0.659 -1.696 <0.001 0.271 0.506 10583 
Reactome hormone ligand binding receptors 9 -0.663 -1.644 <0.001 0.273 0.686 5838 
Reactome activation of genes by atf4 24 -0.519 -1.703 <0.001 0.278 0.491 1104 
Reactome mitotic prometaphase 78 -0.479 -1.647 <0.001 0.286 0.686 14412 
Reactome receptor ligand binding initiates the second proteolytic 
cleavage of notch receptor 
12 -0.623 -1.723 <0.001 0.296 0.369 1204 
Reactome keratan sulfate degradation 11 -0.522 -1.706 <0.001 0.308 0.474 11481 
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Name Number 
of 
Genes 
ES NES NOM 
 p-val 
FDR  
q-val 
FWER  
p-val 
Max 
rank 
Reactome hyaluronan uptake and degradation 10 -0.590 -1.597 <0.001 0.361 0.766 4879 
Kegg glycine serine and threonine metabolism 31 -0.404 -1.585 <0.001 0.391 0.793 5395 
Reactome perk regulated gene expression 27 -0.535 -1.771 <0.001 0.397 0.315 1104 
Biocarta cellcycle pathway 23 -0.407 -1.576 <0.001 0.405 0.820 14136 
Reactome activation of chaperones by atf6 alpha 12 -0.553 -1.855 <0.001 0.416 0.139 5426 
Reactome e2f enabled inhibition of pre replication complex formation 10 -0.624 -1.541 <0.001 0.425 0.865 13298 
Reactome recycling of bile acids and salts 9 -0.644 -1.518 <0.001 0.509 0.878 2102 
Kegg homologous recombination 26 -0.442 -1.514 <0.001 0.516 0.878 9929 
Kegg aminoacyl trna biosynthesis 41 -0.525 -1.496 <0.001 0.517 0.889 10515 
Reactome downstream tcr signaling 31 -0.409 -1.504 <0.001 0.529 0.878 12639 
Reactome trna aminoacylation 42 -0.515 -1.467 <0.001 0.533 0.913 10515 
Reactome cytosolic trna aminoacylation 24 -0.593 -1.451 <0.001 0.542 0.913 2910 
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Name Number 
of 
Genes 
ES NES NOM 
 p-val 
FDR  
q-val 
FWER  
p-val 
Max 
rank 
Reactome copi mediated transport 9 -0.545 -1.192 <0.001 0.810 1.000 14157 
Reactome mitotic g2 g2 m phases 78 -0.442 -1.346 <0.001 0.840 0.982 17059 
Reactome loss of nlp from mitotic centrosomes 56 -0.451 -1.224 <0.001 0.852 1.000 14071 
Reactome transport of mature transcript to cytoplasm 51 -0.482 -1.225 <0.001 0.866 1.000 15973 
Biocarta fas pathway 29 -0.435 -1.299 <0.001 0.878 1.000 15802 
Reactome recruitment of mitotic centrosome proteins and complexes 63 -0.451 -1.262 <0.001 0.899 1.000 18176 
Biocarta atrbrca pathway 19 -0.439 -1.315 <0.001 0.905 1.000 15333 
Biocarta raccycd pathway 26 -0.447 -1.267 <0.001 0.913 1.000 14407 
Reactome apc cdc20 mediated degradation of nek2a 22 -0.513 -1.251 <0.001 0.924 1.000 5624 
Reactome insulin receptor signalling cascade 82 -0.397 -1.492 0.010 0.514 0.889 15249 
Reactome pi 3k cascade 53 -0.365 -1.419 0.009 0.617 0.928 15249 
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Table 4.3. Top 50 pathways with gene sets showing evidence of enrichment for higher expression in valproate treated NT2-N cells compared to 
vehicle treated control NT2-N cells based on NOM p-val. (ES = enrichment score, NES = normalised enrichment score, NOM p-val = nominal p-
value, FDR q-val = false discovery rate, FWER p-val = family wise error rate, Max rank = position in the ranked list at which the maximum 
enrichment score occurred). 
Name Number 
of Genes 
ES NES NOM 
 p-val 
FDR  
q-val 
FWER  
p-val 
Max 
rank 
Kegg antigen processing and presentation 61 -0.479 -2.215 <0.001 0.016 0.000 6924 
Reactome amino acid transport across the plasma membrane 29 -0.615 -1.993 <0.001 0.020 0.032 5485 
Reactome interferon gamma signaling 59 -0.566 -2.000 <0.001 0.021 0.032 6946 
Reactome cell surface interactions at the vascular wall 81 -0.439 -1.905 <0.001 0.021 0.082 5020 
Reactome transport of vitamins nucleosides and related 
molecules 
29 -0.569 -1.923 <0.001 0.021 0.072 7419 
Kegg complement and coagulation cascades 60 -0.567 -1.906 <0.001 0.021 0.082 6451 
Reactome neuronal system 271 -0.603 -1.933 <0.001 0.021 0.072 8107 
Reactome gaba b receptor activation 38 -0.557 -1.908 <0.001 0.021 0.082 6449 
Reactome hemostasis 419 -0.416 -1.933 <0.001 0.022 0.072 8809 
Biocarta toll pathway 37 -0.494 -1.842 <0.001 0.022 0.158 5751 
Reactome potassium channels 94 -0.628 -1.864 <0.001 0.022 0.140 6449 
Reactome platelet calcium homeostasis 15 -0.630 -1.839 <0.001 0.022 0.158 8561 
Reactome ca dependent events 28 -0.558 -1.843 <0.001 0.022 0.158 6996 
Kegg cytokine cytokine receptor interaction 212 -0.463 -2.017 <0.001 0.022 0.032 3163 
Reactome transmission across chemical synapses 184 -0.585 -1.934 <0.001 0.022 0.072 7565 
Reactome gpcr ligand binding 342 -0.498 -1.845 <0.001 0.022 0.158 6481 
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Name Number 
of Genes 
ES NES NOM 
 p-val 
FDR  
q-val 
FWER  
p-val 
Max 
rank 
Reactome slc mediated transmembrane transport 230 -0.459 -1.846 <0.001 0.022 0.158 8670 
Reactome gpcr downstream signaling 499 -0.474 -1.865 <0.001 0.023 0.140 9547 
Kegg vascular smooth muscle contraction 111 -0.454 -1.848 <0.001 0.023 0.158 6342 
Biocarta il10 pathway 17 -0.699 -1.868 <0.001 0.023 0.140 2848 
Reactome phospholipase c mediated cascade 50 -0.589 -1.947 <0.001 0.023 0.072 6342 
Reactome signaling by rho gtpases 111 -0.491 -1.849 <0.001 0.023 0.158 8520 
Reactome g alpha i signalling events 167 -0.493 -1.868 <0.001 0.023 0.140 8174 
Reactome bile salt and organic anion slc transporters 10 -0.694 -1.851 <0.001 0.023 0.158 2430 
Reactome traf6 mediated nfkb activation 20 -0.640 -1.873 <0.001 0.023 0.140 4461 
Reactome g alpha z signalling events 44 -0.573 -1.860 <0.001 0.023 0.158 7940 
Reactome g0 and early g1 24 -0.518 -1.981 <0.001 0.023 0.061 2894 
Kegg cell adhesion molecules cams 123 -0.511 -1.951 <0.001 0.023 0.072 6008 
Reactome voltage gated potassium channels 41 -0.742 -1.874 <0.001 0.024 0.140 2075 
Reactome g alpha s signalling events 106 -0.533 -1.834 <0.001 0.024 0.189 6559 
Reactome interferon signaling 141 -0.506 -1.874 <0.001 0.024 0.140 7313 
Reactome peptide ligand binding receptors 153 -0.518 -1.829 <0.001 0.024 0.210 5063 
Reactome amino acid and oligopeptide slc transporters 46 -0.595 -1.825 <0.001 0.024 0.210 7293 
Reactome transmembrane transport of small molecules 399 -0.430 -1.820 <0.001 0.024 0.224 8670 
Kegg tryptophan metabolism 39 -0.609 -1.952 <0.001 0.024 0.072 3008 
Reactome transport of glucose and other sugars bile salts and 
organic acids metal ions and amine compounds 
85 -0.447 -1.808 <0.001 0.024 0.239 9187 
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Name Number 
of Genes 
ES NES NOM 
 p-val 
FDR  
q-val 
FWER  
p-val 
Max 
rank 
Kegg type ii diabetes mellitus 45 -0.445 -1.827 <0.001 0.024 0.210 6329 
Reactome plc beta mediated events 40 -0.581 -1.875 <0.001 0.024 0.140 6996 
Reactome ion channel transport 54 -0.531 -1.822 <0.001 0.024 0.224 8609 
Reactome transport of inorganic cations anions and amino 
acids oligopeptides 
89 -0.515 -1.814 <0.001 0.024 0.239 7293 
Reactome cytokine signaling in immune system 244 -0.437 -1.883 <0.001 0.024 0.129 7362 
Kegg neuroactive ligand receptor interaction 251 -0.534 -1.815 <0.001 0.024 0.239 8995 
Reactome neurotransmitter receptor binding and downstream 
transmission in the postsynaptic cell 
135 -0.587 -1.982 <0.001 0.025 0.061 6571 
Reactome platelet activation signaling and aggregation 189 -0.394 -1.875 <0.001 0.025 0.140 8126 
Reactome platelet homeostasis 75 -0.484 -1.816 <0.001 0.025 0.239 8561 
Reactome o linked glycosylation of mucins 49 -0.489 -1.806 <0.001 0.025 0.255 7204 
Reactome opioid signalling 75 -0.510 -1.884 <0.001 0.025 0.129 6996 
Kegg calcium signaling pathway 171 -0.559 -1.962 <0.001 0.025 0.072 8812 
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Table 4.4.Top pathways with gene sets showing evidence of enrichment for higher expression in quetiapine treated NT2-N cells compared to 
vehicle treated control NT2-N cells based on NOM p-val. (ES = enrichment score, NES = normalised enrichment score, NOM p-val = nominal p-
value, FDR q-val = false discovery rate, FWER p-val = family wise error rate, Max rank = position in the ranked list at which the maximum 
enrichment score occurred). 
Name Number 
of Genes 
ES NES NOM 
 p-val 
FDR  
q-val 
FWER  
p-val 
Max rank 
Biocarta cdk5 pathway 11 -0.509 -1.493 <0.001 0.639 0.922 593 
Reactome cholesterol biosynthesis 21 -0.764 -1.526 <0.001 0.677 0.922 4614 
Reactome trafficking of glur2 containing ampa 
receptors 
15 -0.386 -1.432 <0.001 0.912 0.963 786 
Kegg vegf signaling pathway 71 -0.340 -1.648 <0.001 1.000 0.766 545 
Kegg steroid biosynthesis 16 -0.611 -1.570 <0.001 1.000 0.885 4528 
Reactome transport of organic anions 10 -0.662 -1.538 <0.001 1.000 0.907 496 
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Table 4.5.All the genes from the “amino acid transport across the plasma membrane” pathway from BROAD Gene Set Enrichment Analysis, and 
the expression of the genes from edgeR analysis for each drug treatment in NT2-N cells in log fold change compared to their respective vehicle 
(FDR adjusted p-value <0.05). The highlighted genes in grey represent the genes that have core enrichment in the pathway denoting that they 
contribute most to the enrichment of the pathway. This pathway was enriched in valproate (p<0.001) and quetiapine treated (non-significant) 
NT2-N cells. 
  
Genes in the amino acid transport 
across the plasma membrane pathway 
Expression of the genes from edgeR analysis in log fold change compared to 
their vehicle (FDR adjusted p-value <0.05) 
Lithium Valproate Lamotrigine Quetiapine 
SLC38A3 - - - - 
SLC6A12 - - - - 
SLC16A10 - 0.617 - - 
SLC7A2 - - - - 
SLC6A15 - 0.366 - - 
SLC43A2 - -0.367 - 0.931 
SLC36A2 - - - - 
SLC7A7 - - - - 
SLC7A6 - - - - 
SLC6A20 - - - - 
SLC6A6 - - - - 
SLC38A4 - - - - 
SLC38A2 - -0.197 - -0.268 
SLC7A5 - -0.155 - -0.256 
SLC38A5 - 1.032 - 0.708 
SLC1A5 - - - - 
SLC7A9 - - - - 
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Genes in the amino acid transport 
across the plasma membrane pathway 
Expression of the genes from edgeR analysis in log fold change compared to 
their vehicle ( adjusted p-value <0.05) 
Lithium Valproate Lamotrigine Quetiapine 
SLC3A1 - - - - 
SLC38A1 0.163 - - -0.177 
SLC36A1 0.274 0.349 - - 
SLC3A2 0.298 - - 0.583 
SLC7A10 - - - - 
SLC7A8 0.334 0.236 - 0.550 
SLC1A4 0.347 -0.200 - 0.179 
SLC7A11 - - - 0.884 
SLC7A3 - 1.152 - 1.190 
SLC43A1 - 0.724 - - 
SLC7A1 0.715 0.297 - 0.178 
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Table 4.6. All the genes from the “antigen processing and presentation” pathway from BROAD 
Gene Set Enrichment Analysis, and the expression of the genes from edgeR analysis for each 
drug treatment in NT2-N cells in log fold change compared to their respective vehicle (FDR 
adjusted p-value <0.05). The highlighted genes in grey represent the genes that have core 
enrichment in the pathway denoting that they contribute most to the enrichment of the pathway 
in Valproate treated NT2-N cells. This pathway was not enriched in other drug treated NT2-N 
cells.  
Genes in the antigen 
processing and 
presentation pathway 
Expression of the genes from edgeR analysis in log fold 
change compared to their vehicle 
( FDR adjusted p-value <0.05) 
Lithium Valproate Lamotrigine Quetiapine 
HSPA1L -1.404 -1.229 - - 
CD74 - - - - 
HLA-G - - - - 
CTSS -1.541 -1.360 - - 
KLRC3 - - - - 
HSPA6 - - - - 
HLA-DQA2 - - - - 
KIR2DL4 - - - - 
KIR2DS4 - - - - 
IFNA21 - - - - 
HLA-DQA1 - - - - 
IFI30 - - - - 
HLA-DOB - - - - 
HLA-DMB - - - 0.434 
NFYA - - - - 
NFYC - - - - 
TAPBP - - - - 
CD8A - - - - 
HSP90AB1 - -0.136 - - 
HSPA8 -0.128 -0.126 - - 
PSME3 - - - -0.315 
HSP90AA1 - -0.127 - 0.212 
RFXANK - - - - 
NFYB - - - - 
CIITA - - - - 
KLRD1 - - - - 
HLA-DOA - - - - 
HSPA1B - - - 0.466 
HSPA4 - - - -0.101 
HLA-DPA1 - - - - 
HLA-DRA - - - - 
RFXAP - - - - 
CANX - - - 0.132 
PDIA3 - - - - 
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Genes in the antigen 
processing and 
presentation pathway 
Expression of the genes from edgeR analysis in log fold 
change compared to their vehicle 
( FDR adjusted p-value <0.05) 
Lithium Valproate Lamotrigine Quetiapine 
CREB1 - - - - 
HLA-DMA - - - 0.249 
CTSB - - - 
 
HSPA5 - - - 0.205 
CALR - 0.130 - 0.083 
HLA-C - - - -0.220 
KLRC4 - - - - 
RFX5 - 0.185 - - 
B2M - 0.172 - - 
HLA-DRB5 - - - - 
HLA-B -0.245 0.217 - -0.176 
HLA-A - 0.225 - - 
HSPA1A - - - 0.508 
PSME1 - - - - 
HLA-E -0.364 - - -0.183 
PSME2 - 0.260 - - 
CD4 - - - - 
TAP1 -0.678 - - -0.486 
TAP2 - - - - 
HLA-DQB1 - - - - 
LTA - - - - 
HLA-DPB1 - 0.497 - 0.309 
LGMN - 0.419 - - 
CD8B - 
 
- - 
HLA-F - 0.769 - - 
HLA-DRB1 - 1.094 - - 
HSPA2 - 1.457 - - 
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Table 4.7. All the genes from the “CDK5 pathway” pathway from BROAD Gene Set 
Enrichment Analysis, and the expression of the genes from edgeR analysis for each drug 
treatment in NT2-N cells in log fold change compared to their respective vehicle (FDR adjusted 
p-value <0.05). The highlighted genes in grey represent the genes that have core enrichment 
in the pathway denoting that they contribute most to the enrichment of the pathway in Valproate 
treated NT2-N cells. This pathway was not enriched in other drug treated NT2-N cells. 
 
Genes in the 
CDK5 pathway 
Expression of the genes from edgeR analysis in log fold 
change compared to their vehicle 
( FDR adjusted p-value <0.05) 
Lithium Valproate Lamotrigine Quetiapine 
RAF1 - -0.203 - -0.143 
MAPK1 - - - - 
NGF - 0.479 - - 
MAP2K1 - - - - 
CDK5 - - - - 
MAP2K2 - - - - 
CDK5R1 - -0.198 - - 
HRAS - - - - 
MAPK3 - - - 0.168 
NGFR - 0.382 - 0.688 
EGR1 0.682 0.779 - 0.934 
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4.6 Discussion 
 
After analysing the effects of the BD drug combination in NT2-N cells and rat frontal cortex 
as described in Chapter 3, in this study, we analysed the effects of individual BD drugs on gene 
expression in NT2-N cells. Data were obtained for approximately 36,000 genes and were used 
for GSEA pathway analysis. Lithium, lamotrigine and quetiapine did not have any significantly 
enriched pathways after adjusting p-values for multiple testing using FDR (<5%), whereas 
valproate had 115 enriched pathways. 
4.6.1 Amino Acid Transport across the Plasma Membrane 
 
Based on nominal p-values, in lithium treated cells the most significantly enriched pathway 
was “amino acid transport across the plasma membrane” (p<0.001). This pathway was also 
enriched in valproate (p<0.001) and quetiapine (non-significant) treated NT2-N cells. Amino 
acids play a vital role as building blocks of proteins, energy sources, precursors for metabolites 
and signalling molecules, and membrane transport carriers enable the transport of amino acids 
in and out of cells [251]. Therefore, when amino acid transport is affected, it can lead to 
pathophysiological changes.  
Although the pathophysiology of BD is not well understood, it has been suggested that 
alterations in neurotransmitter regulation could play a significant role [252, 253]. The synthesis 
of the neurotransmitters dopamine, norepinephrine and serotonin in the CNS are partly reliant 
on precursor amino acids [254]. Tyrosine is the precursor of dopamine and norepinephrine, 
while tryptophan is the precursor of serotonin, and these amino acids are actively transported 
across the cell membranes by various amino acid transport systems including solute carrier 
families (SLCs) [255]. Tyrosine is transported by several proteins coded by SLC1A5, SLC38A1 
and SLC7A5, SLC7A8, SLC7A9, SLC16A10 and SLC6A14  [256]. Of these genes, SLC7A8 and 
SLC38A1 were upregulated in the lithium treated cells, which shows that the drug maybe 
increasing tyrosine transport across the plasma membranes in the neuronal cells. Aberrant 
116 
 
amino acid transport has been reported in fibroblasts of BD and SZ patients [252, 257, 258]. 
This suggests that abnormal amino acid transport in the brains of BD patients could result in 
reduced levels of essential neurotransmitters and ultimately affect neuronal communication.  
When we looked more closely at the genes involved in the “amino acid transport across plasma 
membrane” pathway in the lithium treated cells, it consisted of 28 genes from the SLCs, which 
code for carrier proteins that frequently have amino acids as substrates [259]. The amino acid 
transporter coding genes include those in the SLC1, SLC3, SLC6, SLC7, SLC16, SLC17, 
SLC18, SLC25, SLC32, SLC36, SLC38, and SLC43 families [251, 259, 260].  We then looked 
at our edgeR data (FDR adjusted p-value <0.05) for each drug to see if any of the SLC genes 
from the “amino acid transport across plasma membrane” pathway had significant differential 
expression after drug treatment (Table 4.5). In lithium treated cells, from the 28 genes, 6 genes 
were differentially expressed, of which all were upregulated. We also looked at the pathways 
from the other drugs to see if this particular pathway was enriched by them. In valproate treated 
cells, 12 genes were differentially expressed, of which 4 were downregulated and 8 were 
upregulated. In quetiapine treated cells 11 genes were differentially expressed where 8 of them 
were upregulated. These findings suggest that individually the BD drugs namely lithium, 
valproate and quetiapine tend to increase amino acid transport across the plasma membrane.  
Lithium has also been shown to affect the serotonergic system, which has long been thought to 
be involved in the pathophysiology of BD [169]. Multiple studies have shown that lithium 
increased the release of serotonin at the synaptic level, and this could lead to anti-manic activity 
in patients [169, 171] as well as anti-suicidal and anti-aggressive actions [261]. Moreover, 
lithium has been shown to increase the synthesis of serotonin and the uptake of tryptophan 
[261]. Therefore, these studies show that lithium could be attaining these therapeutic outcomes 
by affecting neurotransmitter-signalling pathways especially the serotonergic pathway. The 
SLC7A8 enoded amino acid transporter also transports tryptophan in the serotonergic system 
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[256] and this gene was also upregulated by lithium as mentioned previously. Therefore, the 
outcome that the amino acid transport pathway was enriched in lithium treated cells further 
attests to these above-mentioned findings. Consequently, it was interesting to see the amino 
acid transport pathway to be significantly enriched in lithium, and also in valproate and 
quetiapine treated cells denoting that this could be one of the mechanisms by which these drugs 
bring about efficacy.  
4.6.2 Antigen Processing and Presentation Pathway 
 
In the last decade, evidence is emerging to show that the immune system could indeed be 
involved in the pathophysiology of BD [115, 116]. A recent study showed that immune and 
neuronal signalling pathways are concordantly altered in SZ, BD and MDD [262]. Particularly, 
the MHC (Major Histocompatibility Complex) locus encoding MHC class I and II complexes 
are associated with BD [263]. MHC class I molecules mediate antigen presentation, and the 
class II molecules are found on the surfaces of antigen presenting cells (APCs) [264]. MHC 
class I and II molecules have similar function, where they deliver short peptides to the cell 
surface that are recognised by CD8+ and CD4+ T cells respectively.  In humans, MHC class 1 
molecules are encoded in the HLA (Human Leukocyte Antigen) complex that has HLA-A, 
HLA-B and HLA-C genes. Likewise, in MHC class II, the encoded genes are HLA-DR, HLA-
DQ and HLA-DP.  The expression of some of these genes located in the MHC have been shown 
to be downregulated in the brains of BD patients [265].  Moreover, in a study that looked at 
differentially expressed gene sets, it was found that in all mood disorders including BD, the 
MHC Class II antigen presentation gene set was downregulated [266]. In line with these 
findings, from our study it was found that valproate most significantly enriched for the “antigen 
processing and presentation pathway” (p<0.001; Table 4.1). This could mean that the antigen 
processing and presentation pathway is dysregulated in BD patients, and valproate may act to 
increase the expression of the genes associated with this pathway. However, an alternative 
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interpretation is that this pathway was not enriched by other BD drugs, and therefore it is 
possible that antigen processing and presentation is not pertinent to the pathophysiology of BD 
or to valproate’s therapeutic efficacy in BD. 
We then looked at our edgeR data (FDR adjusted p-value <0.05) to see if any of the genes from 
the “antigen processing and presentation” pathway had differential expression after each drug 
treatment (Table 4.6).  This pathway consisted of 61 genes in total. In lithium treated cells, 6 
of these genes were differentially expressed but downregulated. In valproate, treated cells 16 
genes were differentially expressed of which 11 genes were upregulated. In lamotrigine treated 
cells, there were no differentially expressed genes. In quetiapine treated cells, 15 genes were 
differentially expressed and 9 of those genes were upregulated.  This shows that valproate 
increases genes involved in the antigen processing and presentation pathway compared to the 
rest of the BD drugs. In valproate treated cells, HLA-A, HLA-B, HLA-DPB1 and HLA-DRB1 
genes were upregulated and contributed the most to the enrichment of the pathway (Table 4.6). 
Therefore, it is possible that valproate upregulates MHC genes that are usually downregulated 
in BD patients and it could be one of the mechanisms by which valproate brings about efficacy 
in BD patients.  
Moreover, valproate significantly enriched for many more pathways compared to other drugs 
after correcting for multiple testing (Table 4.1). This maybe because valproate is a potent 
histone deacetylase (HDAC) inhibitor, and modulates several biological processes such as cell 
proliferation, migration, cell cycle and differentiation [267, 268]. Therefore, it is expected that 
valproate will have more transcriptional effects on the cells compared to other BD drugs. In 
addition, there is increasing evidence that HDAC inhibition and the resulting changes in gene 
expression could be an important mechanism of action of valproate in the brain [269, 270].  
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4.6.3 CDK5 Pathway 
 
In quetiapine treated cells, the cyclin-dependent kinase-5 (CDK5) pathway was enriched (p-
value <0.001). CDK5 is a proline-directed serine/threonine kinase that is vital for various 
cellular functions including synaptic plasticity [271] and neurotransmitter release [272], which 
are some of the functions postulated to be affected in BD [273]. In total, this pathway consisted 
of 11 genes (Table 4.7). When we looked at these 11 genes in the edgeR dataset (FDR adjusted 
p-value <0.05) in quetiapine treated cells 4 genes were differentially expressed of which 3 were 
upregulated. However, CDK5 was not one of the differentially expressed genes. Therefore, we 
examined the raw dataset from quetiapine treated NT2-N cells, and found that CDK5 was 
downregulated (nominal p-value <0.05). It has been shown that inhibition of CDK5 activity 
through pharmacological or genetic means can potentiate presynaptic function on mammalian 
neurons denoting that this enzyme acts as a strong suppressor of neurotransmitter release [272]. 
Furthermore, antipsychotic medication including quetiapine has been shown to be related to 
the downregulation of CDK5 in SZ patients [274]. Therefore, given quetiapine downregulated 
the gene CDK5, it is possible that one of the mechanisms by which this drug brings about its 
efficacy is by downregulating CDK5 and thereby increasing neurotransmitter release, which is 
often dysregulated in BD patients. 
On the other hand, in lithium treated cells only one of the genes from this pathway was 
differentially expressed with an increased expression. In valproate treated cells 5 of the 11 
genes were differentially expressed of which 3 were upregulated. Lamotrigine treated cells did 
not affect any of the 11 genes.  
Although SZ, BD and MDD are clinically different, they have overlapping symptoms. This 
suggests possible common genetic aetiology, shared genetic risk factors and similar changes in 
gene expression in SZ, MDD and BD [275-278]. Therefore, looking at differentially expressed 
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genes in SZ or MDD subjects might also give an insight to the pathophysiology of BD. In the 
quetiapine treated NT2-N cells, in the CDK pathway the genes that mostly contributed to the 
enrichment of the pathway were NGFR and EGR1 (Table 4.7). In a post-mortem study of SZ, 
BD and MDD patients, it was found that EGR1 was significantly downregulated in SZ [276]. 
Furthermore, EGR1 has also been shown to be increased by lithium [279] and valproate [280] 
in mouse frontal cortex and neuronal stem cells respectively. These findings were replicated in 
our study (Table 4.7). Given that EGR1 is one of the key regulators of synaptic plasticity and 
neuronal activity [281], it is possible that quetiapine acts to increase the expression of this gene 
and thereby increase synaptic plasticity and neuronal activity, and lithium and valproate could 
also to some extent bring about efficacy through the regulation of EGR1.  
It is interesting that in the lamotrigine treated cells, no pathways were obtained from GSEA 
analysis, and edgeR analysis did not produce any significant differentially expressed genes 
either. It should be noted that the biological replicates (n=4) might not have been sufficient to 
capture the effects of lamotrigine, and this is applicable to the rest of the individual BD drugs 
as well.  
Another interesting finding from this study is that, as discussed in Chapter 3, the BD drugs as 
a combination regulated different pathways in NT2-N cells (steroid biosynthesis pathway) and 
rat brains (oxidative phosphorylation pathway) compared to the pathways regulated by the 
individual BD drugs. This leads us to speculate that the drugs when given as polypharmacy 
could give a complex summative effect that brings about efficacy in BD patients. On the other 
hand, in monotherapy, the drug could just target a few individual pathways and might not be 
as efficient as polypharmacy in controlling the symptoms of BD. Moreover, our group has 
recently shown that these BD drugs were generally anti-inflammatory when used in 
combination compared to individually [282]. This further attests that polypharmacy operates 
differently and via different mechanisms compared to monotherapy, and therefore has different 
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and possibly better efficacy in BD patients. However, interpretation of this finding should be 
dealt with cautiously as many a times patients are on different combinations of medications 
and with varying dosages. Furthermore, in a clinical setting, other confounding variables and 
environmental factors could influence how the drugs might bring about efficacy in patients. 
Therefore, further studies are warranted in post-mortem BD samples and in cellular models 
with varying treatment duration and drug dosages.    
Although the GSEA pathway analysis and edgeR analysis provide some insight into some of 
the pathways and functions regulated by the individual BD drugs and the understanding of how 
polypharmacy and monotherapy differ at the molecular level, this study is rather underpowered 
with a low number of biological replicates. Therefore, future studies with increased number of 
biological replicates are warranted to capture more meaningful biological information on the 
molecular mechanisms of the individual BD drugs.  
4.7 Conclusion 
 
In conclusion, the individual BD drugs regulated different pathways, except for lamotrigine, 
which did not appear to modulate any of the pathways assessed. Lithium regulated the “amino 
acid transport across the plasma membrane” pathway, while valproate and quetiapine regulated 
“antigen processing and presentation” and “CDK5” pathways respectively. However, the low 
number of biological replicates limit our interpretation of this study. 
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CHAPTER 5 
 
THE USE OF A GENE EXPRESSION SIGNATURE AND 
CONNECTIVITY MAP TO REPURPOSE DRUGS FOR 
BIPOLAR DISORDER 
 
5.1 Introduction 
5.1.1 Bipolar Disorder and Pharmacological Management  
 
Bipolar disorder (BD) affects up to 2% of the population in their lifetime and is one of the most 
debilitating and chronic mental health disorders. The disorder is characterised by alternating 
phases of mania and depression [168, 283]. Conventionally, BD treatment focuses on acute 
stabilisation of the patient, and follow-up where they are treated to symptomatic recuperation, 
and thereafter on maintenance therapy in order to prevent relapse [154]. As discussed in 
Chapter 1, although there are numerous medications available to treat BD, in reality, there are 
significant limitations to their efficacy [284]. The majority of patients undergoing BD treatment 
experience chronic and residual mood symptoms, polarity shifts, cognitive impairment and 
poor community function [285]. Moreover, treating the different phases of BD can also be 
challenging as the medications used to improve depression can induce mania or rapid cycling 
and vice versa [154].  
In addition, the vast majority of the BD patients are concomitantly on several medications, a 
practice known as polypharmacy or polytherapy [225, 226, 286]. In the treatment of BD, 
response to monotherapy is uncommon and polypharmacy is the rule rather than the exception 
[287]. Data emerging from the Systematic Treatment Enhancement Program for Bipolar 
Disorder (STEP-BD) shows that less than 20% of the patients studied received monotherapy 
[226, 288] while the rate of polypharmacy is on the rise in outpatient psychiatric practices 
[287]. This increased dependence on polypharmacy, however, does not necessarily translate to 
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improved chronic symptoms or functional outcomes in BD patients [289, 290]. Furthermore,  
polypharmacy lacks quality clinical trial based evidence [168], while adverse effects and 
medication non-adherence are also common [287].  
These factors make novel approaches in psychiatric drug discovery imperative as the need to 
develop novel, well-tolerated, efficacious and targeted therapies remains overt.  However, there 
has been a marked worldwide reduction in the pipeline for the discovery and development of 
new psychiatric drugs [291]. This is due in part to insufficient knowledge of the underlying 
pathophysiology and the lack of validated animal models, and hence pharmacological targets 
for BD [291]. However, recent years have seen a shift from conventional drug discovery 
methods to repurposing old drugs for new indications as a way of identifying new drugs for 
complex diseases.   
5.1.2 Drug Repurposing 
 
Traditionally, drug discovery involves identifying new drugs and validating them. This costs 
extensive amounts of time and money. Despite recent advancements in genomics and 
bioinformatics, the number of novel drugs that has been identified in the past decade has been 
significantly limited [292]. The average bench to bedside time required for  drug development 
is about 14 years [293]. Moreover, the average costs associated with developing a new drug 
have gone up as well, currently estimated to be USD 3-12 billion [294]. These impediments 
highlight why alternative tactics to drug discovery must be explored.  
One such approach that has gained popularity in recent times is drug repurposing or 
repositioning. Drug repurposing refers to discovering new indications for drugs that are already 
available and approved with known safety profiles [292, 295]. In recent years, 30% of the US 
Food and Drug Administration (FDA) approvals have been for repurposed drugs.  Sildenafil, 
a cyclic guanosine monophosphate - specific phosphodiesterase type 5 inhibitor, was first 
developed to treat coronary heart disease. In Phase II clinical trials it was found to have a side 
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effect of inducing penile erections [295]. Although it failed Phase II trials for treating angina, 
it became a successful treatment for erectile dysfunction in men. Likewise, thalidomide, a drug 
that was originally prescribed as a sedative, was found to cause birth defects, and was later 
repurposed as an anti-cancer drug [295]. According to the National Comprehensive Cancer 
Network, about 50-75% of biological therapies used in treating cancers in the USA are as off-
label indications [296]. 
Repurposing a drug does not require the first 6-9 years of the development process, as opposed 
to the traditional method, and the drug can directly enter pre-clinical testing and clinical trials 
[296]. This reduces the time and money spent on the process. Furthermore, in traditional drug 
discovery, if we are to reduce the time spent, then the risk of that drug failing increases. By 
repurposing, developers can circumvent this problem as many of the drug candidates already 
have safety and pharmacokinetic profiles that were tested for the primary indication [297]. 
Therefore, drug repurposing can accelerate development, reduce potential failure risks and 
ultimately the costs associated with drug development.  
5.1.3 Gene expression signature for drug discovery 
 
Genetic studies in recent years have provided a better understanding of the pathophysiology of 
psychiatric disorders, and are driving the identification of new targets. The Gene Expression 
Signature (GES) technology, a screening tool, is an innovative approach to repurpose drugs. 
This approach represents a significant step towards the development of novel therapeutics in 
psychiatry and other fields, and this atheoretical approach is a noteworthy break from the 
limitations posed by existing heuristic models. 
A GES can be defined as a single or combined genetic changes or expression pattern that are 
distinctive to a certain biological state or phenotype [298].  This is based on the notion that any 
biological state is mirrored in gene expression changes. The advent of high throughput 
technologies, namely microarrays and RNA sequencing, paved the way to generating gene 
125 
 
expression signatures for a phenotype or disease state [299]. These techniques enable us to 
concurrently study and analyse thousands of genes rather than just a few with conventional 
methods such as qPCR. From these numerous genes, we can segregate the genes that are 
differentially expressed between the different biological states, and link them to drugs and 
diseases related to the same biological process.  
In drug discovery, in order to obtain the genetic “fingerprint”, the first step is to acquire global 
gene expression data from at least two states of interest. For example, in order to discover drugs 
for BD, we must first understand how the current BD therapies affect gene expression. Given 
the popularity of polypharmacy in BD, a combination of commonly prescribed BD drugs was 
used to determine a GES that resembles what we can expect in BD patients.  In order to derive 
this GES, comprehensive molecular and genetic profiles with and without the drug exposure 
must be quantitatively measured in a cellular or animal model. The overall gene expression 
alterations brought about by the drugs provide insight as to how these drugs have therapeutic 
efficacy. This data can be generated by means of high-throughput techniques as described 
above.  Using complex statistical methodologies, a set of differentially expressed genes - the 
GES - can be filtered out, providing an outcome that best represents the overall cellular effects 
of the drugs.  
The GES can then be used to screen drugs that are already available on the market with known 
safety profiles and repurpose them for BD. For this we need to be able to screen thousands of 
compounds in a simple, robust and cost-effective way. Unlike the traditional drug discovery 
method, GES based drug screening does not focus on a known target, instead this technique 
analyses the overall biological effect as characterized by the resultant GES, and selects drugs 
from the library that act most similarly to the combination of BD drugs in terms of molecular 
mechanisms. The candidate drugs can then directly go into Phase II clinical trials, and their 
efficacy in BD patients can be determined. This cuts down on the time and money spent on 
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drug development. Moreover, this might avail us to find a monotherapy that has the same 
therapeutic effects as polytherapy, making this method even more attractive.  
Once a GES is discovered, we can also use computational methods, including BROAD 
Institute’s Connectivity Map (CMap) to repurpose drugs for BD. This method screens a 
database of gene expression data that has been gathered from cultured human cell lines treated 
with bioactive compounds, and allows us to establish links between diseases and genes, and 
potential drug therapies. In the case of the BD drug GES, CMap can be used to identify drugs 
that affect GES gene expression in a similar manner, highlighting drugs that can potentially be 
repurposed. 
5.1.4 Connectivity Map (CMap) 
 
As mentioned above, one of the computational methods used in drug discovery is the use of 
Connectivity Map (CMap; BROAD Institute), which is a publicly available database of 
transcriptome data compiled from cultured human cell lines treated with ~ 1,300 bioactive 
small molecules [219]. This pathway independent approach allows the screening of Food and 
Drug Administration (FDA, USA) approved compounds against gene expression profiles 
derived from human diseases, biological conditions or other benchmark drugs and thereby 
offers an alternative way to repurpose drugs  [300]. Moreover, CMap has also been widely 
used in target discovery and in understanding drug mechanisms [300].  
Therefore, here we explored a novel strategy for BD drug discovery by generating a gene 
expression signature (GES) as a proxy of the combined effects of four commonly prescribed 
BD drugs and used it to identify drugs that can be repurposed for BD using CMap.  
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5.2 Methods and Materials 
Detailed methods and materials for this chapter can be found in Chapter 2 of this thesis. 
5.2.1 Cell Culture  
Ntera2 human teratocarcinoma cells (NT2) were cultured and differentiated as previously 
described [208]. The differentiated neuronal-like cells (NT2-N) were treated with either the 
BD drug combination (2.5 mM lithium chloride, 0.5 mM valproate, 50 µM lamotrigine and 50 
µM quetiapine) or vehicle control (0.2% DMSO) for 24 hours (n=20 per group).  
5.2.2 Animal Study  
 
All animal procedures were approved by the ethics committee of Deakin University, Australia, 
and conducted according to the code of practice for the care and use of animals for scientific 
purposes (National Health and Medical Research Council, Australia). Eight-week-old male 
Sprague-Dawley® rats were either treated with the same BD drug combination as the NT2-N 
cells via intraperitoneal injection (lithium 10 mg/kg, valproate 50 mg/kg, quetiapine 2 mg/kg 
and lamotrigine 10 mg/kg) or vehicle (6% DMSO). The frontal cortex was dissected and snap 
frozen in liquid nitrogen 6 hrs after the injection as the Cmax for the drugs overlay at ~4 hrs with 
plasma half-lives between 7-24 hrs.   
5.2.3 RNA Isolation and Quality Control 
Total RNA was extracted from 20-30 mg of homogenized rat frontal cortex or harvested NT2-
N cells using TRIzol reagent and purified with RNeasy® mini kits (Qiagen). The quality of the 
extracted RNA from the NT2-N cells was determined using an Agilent 2100 Bioanalyzer and 
RNA 6000 Nano Kit (Agilent). The quantity of the RNA was assessed using NanoDrop 1000 
(Thermofisher Scientific). 
128 
 
5.2.4 Next Generation Sequencing (NGS) 
RNAseq libraries were prepared for all samples from 1 µg total RNA using an Illumina TruSeq 
RNA Sample Preparation Kit as per the manufacturer’s instructions and run on an Illumina 
HiSeq platform (HiSeq 2500 rapid 50bpSE; 1 flow cell) to measure genome wide mRNA. 
The raw data were obtained in fastq format and were aligned to reference genomes using 
Bowtie 2/TopHat 2. Genes with low counts were filtered out and the data set was normalized 
using the weighted trimmed mean of M-values. The differential expression of genes between 
the drug treated and vehicle groups in rats and NT2-N cells was assessed using edgeR in R. 
Genes with evidence for differential expression in both models were included in the GES for 
the purpose of this study.  
5.2.5 Pathway Analysis of GES Genes 
 
The identified GES genes were annotated using  using Database for Annotation, Visualization 
and Integrated Discovery (DAVID) Bioinformatics Resources V6.7 [218] (National Institutes 
of Health, Bethesda, Maryland, USA). DAVID employs a gene set based algorithm that 
identifies functionally connected genes in the input gene sets. This tool can examine 
functionally related genes based on the Gene Ontology terms, biological processes, cellular 
components and molecular functions. 
Firstly, the list of GES genes or their IDs were submitted to DAVID and converted to a 
compatible format. Using the functional annotation tools, enriched Gene Ontology (GO) terms 
were searched. GO terms that had a p-value of <0.05 following Benjamini correction for 
multiple testing were considered statistically significant.  
5.2.6 Real-time PCR 
Primer sequences for the genes MAL, TSPAN2, and PLP1 were designed using Beacon 
Designer ™ software, and supplied by GeneWorks, Adelaide, Australia. Reverse transcription 
was carried out for the NT2-N and rat frontal cortex RNA samples using Maxima H Minus 
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First Strand cDNA synthesis kit as per the manufacturers protocol (Thermo Fisher Scientific). 
Real-time PCR (qPCR) was conducted using Luminaris HiGreen Low ROX qPCR Master Mix 
(SYBR Green fluorescence; Thermo Fisher Scientific). The reactions were carried out in a 
PikoReal™ qPCR machine (Thermo Fisher Scientific) using the following protocol: 95°C for 
7 minutes, 40 cycles of 95°C for 30 seconds and 60°C for 1 minute followed by data 
acquisition, 60°C for 30 seconds; 55-95° data acquisition and 20°C for 10 seconds.  
Quant-iT™ OliGreen® ssDNA Assay Kits (Life Technologies) were used to quantify the 
cDNA concentration in each sample as per the manufacturer’s instructions. The plate was 
scanned in a Flex Station II 384 fluorescence plate reader (Molecular Devices, Australia) using 
excitation and emission wavelengths of 485 nm 538 nm respectively.  The data was used to 
produce a standard curve and calculate the relative cDNA concentration in each sample. Gene 
expression data from the qPCR was then normalized to the derived cDNA concentration of 
each sample. 
5.2.7 Differentially Expressed Genes in Participants with BD 
To validate the suitability of the GES genes for CMap analysis, we investigated whether they 
were associated with human BD by assessing their levels of expression in post-mortem brain 
samples (dorsolateral prefrontal cortex) of participants with BD and controls without any 
history of psychiatric disorders (n=30 per group).  A comprehensive literature review looking 
at the relevance to human BD was carried out for the rest of the genes that were not 
differentially expressed in the above study.  
5.2.8 CMap 
The GES genes were entered into CMap (build 2; publicly available at 
https://portals.broadinstitute.org/cmap/). For each gene in our GES, we identified the 
corresponding feature set ID from the 22,283 probe sets on the HG-U133A array that are 
recognized by CMap. These ID’s were collated into tag sets of “up” or “down” genes, where 
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“up” is genes whose expression was increased following drug treatment in both NT2-N cells 
and rat frontal cortex and “down” is the opposite, and analyzed using the CMap software. This 
tool measured the similarity between the input query GES and a reference microarray data 
containing human cell line derived expression profiles treated with approximately 1300 
compounds [219]. The similarity was reported as a connectivity score ranging from +1 to -1 
based on non-parametric rank ordered Kolmogorov-Smirnov statistics. When the connectivity 
score is positive, it denotes increased similarity or connection between the expression patterns 
induced by the compounds in the CMap database and the query GES. Negative connectivity 
score refers to an inverse similarity between reference profiles and query signatures. 
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5.3 Results 
5.3.1 Next Generation Sequencing 
 
We obtained a total of 255 million raw reads (mean of 6.4 million reads per sample) with 
12,998 million total bases (mean of 325 million bases per sample) from 40 libraries for the 
NT2-N cells treated with the BD drug combination or vehicle control. After filtering and 
trimming the dataset, a false discovery rate (FDR) adjusted p value cut-off of 0.001 was 
applied, which resulted in 7,614 differentially expressed genes of interest. Of these 
differentially expressed genes, 3,799 genes were upregulated and 3,815 genes were 
downregulated in the drug treated cells. 
On the other hand, a total of 273.8 million raw reads (mean of 17.1 million reads per sample) 
with 13,965 million total bases (mean of 873 million bases per sample) were generated from 
16 libraries from the frontal cortex of the rats treated with the BD drug combination or vehicle 
control. After filtering and trimming the dataset, data for 14,278 genes was obtained. Of those, 
7,272 were upregulated and 7,006 were downregulated in the drug treated rats frontal cortex. 
In the rat gene dataset obtained from the edgeR analysis, the p value cut-off of 0.001 did not 
yield any differentially expressed genes, therefore, a less stringent p<0.05 was used. This 
yielded 644 genes with nominal evidence of differential expression, of which 234 were 
upregulated and 410 were downregulated in the drug treated rats. Following correction for 
multiple testing by FDR, only one gene (Car3; carbonic anhydrase 3) was found to be 
differentially expressed in the rat frontal cortex. 
The resultant NT2-N genes with p<0.001 were aligned against the rat genes with p<0.05 and 
those genes with the best evidence of differential expression in both the cells and the rat brains 
were used in further analysis. We used the less stringent p<0.05 in rats so as not to omit any 
biologically valuable data, and also taking in to account the possible variability between the 
animals, which could have resulted in less significantly expressed genes.  A set of 88 genes 
was identified that showed evidence of differential expression in both NT2-N cells and rat 
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brains. These 88 genes were considered our GES for the purpose of this study. Of these, 24 
genes were upregulated and 64 genes were downregulated following the BD drug combination 
treatment (Tables 5.1 and 5.2). 
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Table 5.1.. Gene expression signature genes with increased expression after treatment with bipolar disorder drug combination in NT2-N cells 
and rat frontal cortex. 
Genes Rat Brains 
 
NT2-N Cells Function/Process 
logFC p-value logFC p-value 
Apip 0.36 1.99E-02 0.28 6.02E-03 Negative regulator of ischemic/hypoxic injury 
Bex2 0.16 3.52E-02 0.25 9.65E-16 Regulation of apoptotic process 
Fam103a1 0.24 4.25E-02 0.21 4.09E-02 RNA and protein binding 
Gadd45a 0.40 2.96E-02 0.14 2.67E-07 DNA repair and damage response 
Htatip2 0.28 3.51E-02 0.54 1.28E-16 Apoptotic process and cell differentiation 
Il4r 0.39 8.14E-03 0.18 4.00E-06 Inflammation 
Jun 0.14 4.66E-02 0.11 9.83E-08 Oncogene 
Mal 0.18 3.46E-02 0.64 3.82E-17 Myelination 
Nfil3 0.32 3.73E-02 0.14 2.81E-04 Immune response and circadian rhythm 
Nsmce2 0.36 8.16E-03 0.19 5.52E-03 Cell division 
Pcp4 0.32 3.03E-02 0.57 2.66E-18 Negative regulation of neuron apoptotic process 
Pex11a 0.27 2.81E-02 0.21 3.99E-03 Protein binding 
Phkg1 0.39 1.44E-02 0.72 6.17E-06 ATP and calmodulin binding 
Plp1 0.17 1.82E-02 1.11 2.61E-11 Structural constituent of myelin sheath 
Pmvk 0.21 1.07E-02 0.17 1.33E-05 Cholesterol biosynthetic process 
Postn 0.44 3.42E-02 0.20 5.39E-03 Neuron projection extension 
Ptp4a3 0.20 3.00E-02 0.15 1.57E-02 Notch signaling pathway 
Rsad2 0.86 4.53E-03 0.31 8.98E-03 CD4-positive, alpha-beta T cell activation 
Shisa4 0.15 4.14E-02 0.43 2.14E-11 Integral component of membrane 
Spon1 0.24 4.13E-02 0.29 4.66E-06 Cell adhesion 
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Genes Rat Brains 
 
NT2-N Cells Function/Process 
 logFC p-value logFC p-value  
Stmn4 0.15 4.47E-02 0.56 2.39E-103 Neuron projection development 
Tmem14a 0.26 6.81E-03 0.18 9.03E-07 Integral component of membrane 
Tppp3 0.36 1.96E-02 1.11 1.47E-94 Microtubule bundle formation and polymerization 
Tspan2 0.14 3.83E-02 0.20 4.03E-07 Axon development and myelination 
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Table 5.2. Gene expression signature genes with decreased expression after treatment with bipolar disorder drug combination in NT2-N cells 
and rat frontal cortex. 
Genes Rat Brains 
 
NT2-N Cells Function/Process 
logFC p-value logFC p-value 
Abca1 -0.29 1.79E-02 -0.26 1.01E-11 Cholesterol efflux 
Abcg2 -0.43 3.00E-02 -0.19 4.69E-07 Cholesterol efflux 
Ahnak -0.37 4.52E-02 -0.48 4.12E-37 Regulates cell proliferation and cell cycle 
Anxa2 -0.45 3.86E-02 -0.51 2.21E-155 Immune regulation 
Anxa5 -0.22 1.52E-02 -0.07 4.15E-04 Cellular signal transduction, inflammation, growth and differentiation 
Apln -0.37 1.90E-03 -0.75 4.50E-07 Immune response 
Arhgap5 -0.20 4.53E-02 -0.15 1.84E-05 Axon Guidance, Neurogenesis, Axonogenesis, axon extension, cell migration 
Arhgef40 -0.22 1.53E-02 -0.24 9.11E-25 Rho guanyl-nucleotide exchange factor activity 
Axl -0.20 1.55E-02 -0.51 3.28E-52 Neuroplasticity/neurogenesis 
Bcor -0.25 3.19E-02 -0.10 1.27E-05 Neurogenesis 
Cald1 -0.31 4.88E-02 -0.46 8.25E-73 Regulation of the actin cytoskeleton, modulation of cell movement 
Ccdc8 -0.44 6.28E-03 -0.12 7.72E-03 Microtubule cytoskeleton organization 
Ccdc80 -0.29 2.16E-02 -0.63 1.29E-101 Regulation of body weight and energy metabolism, tumor suppression 
Col3a1 -0.57 4.48E-02 -0.55 1.37E-59 Extracellular matrix 
Egfr -0.35 2.68E-02 -0.16 8.76E-04 Neural stem cell proliferation, circadian rhythm alterations 
Fam129b -0.24 7.95E-03 -0.07 3.06E-03 Cadherin binding 
Fbn1 -0.41 1.68E-02 -0.51 7.49E-67 Calcium ion binding 
Fgfr3 -0.18 9.21E-03 -0.48 3.68E-10 Developmental and regulatory processes and cell migration 
Foxo1 -0.29 1.95E-02 -0.46 6.01E-12 Apoptosis and cell survival 
Foxo3 -0.18 4.63E-02 -0.35 9.64E-17 Regulation of cell proliferation, apoptosis, metabolism, neurodevelopment 
Fstl1 -0.44 2.02E-02 -0.53 2.87E-111 Presynaptically secreted protein that directly activates Na+/K+-ATPase 
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Genes 
Rat Brains 
 
NT2-N Cells Function/Process 
logFC p-value logFC p-value 
Fzd2 -0.36 6.41E-03 -0.38 5.29E-32 G-protein coupled receptor activity 
Galnt1 -0.16 3.77E-02 -0.12 4.11E-04 Carbohydrate and manganese ion binding 
Hcfc2 -0.22 4.11E-02 -0.14 4.33E-04 Transcription coactivator activity 
Inppl1 -0.18 3.10E-02 -0.33 2.33E-43 Regulator of neuritogenesis and maintenance of neurite outgrowth 
Isoc1 -0.19 2.32E-02 -0.14 4.84E-02 Catalytic activity 
Kif13a -0.20 4.63E-02 -0.24 1.03E-10 Important for neuronal morphogenesis and function 
Loxl1 -0.43 1.75E-02 -0.47 1.12E-49 Cross-linkage of collagen and elastin, modulation of cellular functions 
Map3k2 -0.38 4.33E-02 -0.25 5.67E-17 Cell adhesion, proliferation 
Marveld1 -0.32 3.20E-02 -0.64 3.91E-61 Structural constituent of myelin sheath 
Mxra8 -0.33 3.52E-02 -0.60 2.46E-35 Establishment of glial blood-brain barrier 
Nacc2 -0.23 1.40E-02 -0.26 2.62E-30 Negative regulation of cell proliferation 
Notch2 -0.34 1.06E-02 -0.30 2.38E-26 Progenitor marker, neuronal differentiation 
Npas4 -0.38 4.81E-02 -1.91 8.52E-87 Cell differentiation 
Olfml3 -0.46 2.26E-02 -0.35 3.11E-57 Multicellular organism development 
Osr1 -0.58 4.16E-02 -0.41 1.49E-03 Cell differentiation 
Pcdhga10 -0.28 2.72E-02 -0.23 2.54E-03 Cell-cell signaling and cell adhesion 
Pcdhgc3 -0.19 1.92E-02 -0.17 7.59E-05 Cell-cell signaling and cell adhesion 
Pde3b -0.28 1.02E-02 -0.34 1.50E-04 Inflammation 
Pdgfc -0.34 2.19E-02 -0.10 4.60E-02 Platelet-derived growth factor receptor binding 
Plxnb2 -0.19 1.18E-02 -0.38 2.62E-98 Semaphorin receptor that acts on neuronal proliferation 
Ptch1 -0.20 4.26E-02 -0.47 6.97E-31 Sonic Hedgehog signaling 
Rassf2 -0.27 8.08E-03 -0.06 3.00E-02 Cell cycle 
Rgs16 -0.35 4.84E-02 -0.10 4.66E-02 G-protein coupled receptor signaling pathway 
Rhbdf1 -0.43 1.90E-03 -0.13 7.96E-03 Cell migration and proliferation 
Secisbp2l -0.17 4.28E-02 -0.14 4.78E-10 RNA and protein binding 
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Genes 
 
Rat Brains 
 
 
NT2-N Cells 
 
Function/Process 
logFC p-value logFC p-value 
Serpinh1 -0.29 1.69E-02 -0.19 4.19E-20 RNA binding 
Sfrp1 -0.49 4.25E-02 -0.23 5.74E-14 Wnt signaling pathway 
Slc1a2 -0.33 2.02E-02 -0.24 6.70E-13 L-glutamate transmembrane transporter activity 
Slc38a2 -0.25 2.24E-02 -0.44 5.30E-102 Amino acid transmembrane transporter activity 
Smad3 -0.18 2.89E-02 -0.25 3.83E-26 RNA polymerase II activating transcription factor binding 
Stard13 -0.29 3.03E-02 -0.22 5.93E-05 GTPase activator activity, endothelial cell migration 
Svil -0.36 1.73E-02 -0.05 2.47E-02 Actin filament binding 
Tagln -0.45 3.65E-02 -0.82 2.16E-130 Epithelial cell differentiation 
Tgfbi -0.52 4.79E-02 -0.19 2.22E-18 Cell adhesion, proliferation 
Tgfbr1 -0.17 4.38E-02 -0.30 8.86E-27 Activation of MAPKK activity 
Thbd -0.48 3.95E-02 -0.87 8.78E-09 Calcium ion and protein binding 
Timp3 -0.34 1.71E-02 -0.17 1.87E-05 Metal ion, protease and protein binding 
Ubn1 -0.13 4.93E-02 -0.08 8.53E-04 DNA and protein binding 
Vasn -0.29 2.90E-02 -0.99 1.06E-96 Cadherin and protein binding 
Vim -0.50 1.27E-02 -0.33 1.06E-156 Bergmann glial cell differentiation, astrocyte development 
Zbtb20 -0.51 4.70E-02 -0.39 4.22E-02 Regulation of transcription 
Zc3h11a -0.22 3.97E-02 -0.18 4.81E-13 RNA and metal ion binding 
Zic2 -0.33 4.38E-02 -0.37 1.67E-11 Cell differentiation, nervous system development 
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5.3.2 Pathway Analysis  
We used the Database for Annotation, Visualization and Integrated Discovery software 
package (DAVID, NIH) to test for enriched gene sets, and thereby identify modulated 
biological pathways, for the genes that were differentially expressed in both NT2-N cells and 
rat frontal cortex in response to treatment with the combination of BD drugs.  
The DAVID pathway analysis that was carried out with the 88 differentially expressed genes 
(GES) (Tables 5.1 and 5.2) revealed ‘structural component of myelin sheath’ to be the only 
pathway that was significantly regulated after adjustment for multiple testing (Adj.p= 0.04, 
Table 5.3). This finding was confirmed by real-time q-PCR, which showed three genes 
encoding structural constituents of the myelin sheath (MAL, PLP1 and TSPAN2) to be 
upregulated by the BD drugs in both NT2-N cells and rat brains (Figure 5.1). 
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Table 5.3. Top Gene Ontology Terms with evidence of differential regulation by the bipolar disorder drug combination. 
 
Gene Ontology Term Number of genes Nominal p-value Adjusted p-value* 
Structural constituent of myelin sheath 3 1.90E-04 0.04 
Extracellular matrix organization 6 1.20E-04 0.11 
Enzyme linked receptor protein signaling pathway 9 1.80E-04 0.082 
Collagen fibril organization 4 3.20E-04 0.098 
Response to organic substance 12 4.40E-04 0.1 
 
* Benjamini correction for multiple testing 
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5.3.3 Differential Expression of Myelination Genes in NT2-N cells and Rats  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.  Expression of structural constituents of myelin sheath in response to the 
combination of bipolar disorder drugs in NT2-N cells and rat frontal cortex measured by real-
time PCR. Mean ± SEM *p< 0.05 and ** p<0.001 
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5.3.4 Differentially Expressed Genes in Participants with Bipolar Disorder 
The data set consisting of differentially expressed genes in brains of participants with BD 
contained several genes (AHNAK, APLN, CCDC8, OLFML3, ISOC1 and PLP1) from our 88 
GES genes that showed evidence of differential expression (p≤0.05; Figure 5.2). Literature 
review also revealed several more GES genes with potential involvement in human BD (Table 
5.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Differentially expressed genes (AHNAK, APLN, CCDC8, OLFML3, ISOC1 and 
PLP1) in the post-mortem brains of healthy people and participants with bipolar disorder (Ctl- 
controls, BP- participants with bipolar disorder, n=30 per group; p≤0.05) 
142 
 
Table 5.4. Evidence of a role for gene expression signature (GES) genes in human bipolar disorder (BD) (GWAS – Genome wide association 
study, MDD-Major depressive disorder, iPSCs- Induced pluripotent stem cells and STEP-BD - Systematic Treatment Enhancement Program for 
Bipolar Disorder) 
Genes Evidence in Human BD 
ABCG2  Downregulated in the dorsolateral prefrontal cortex of subjects with BD (p<0.001; Akula et al. 2014) 
FBN1  Candidate gene for BD from GWAS studies in Norwegian (p<0.001) and Icelandic (p<0.05) populations (Djurovic et al. 2010)  
SLC1A2  Decreased expression in post-mortem hippocampus of  subjects with MDD (p<0.01) and BD (p<0.1; Medina et al. 2013) 
TAGLN Increased expression in iPSCs from subjects with BD (p<0.01; Vizlin-Hodzic et al. 2017) 
EGFR Candidate gene for BD from GWAS in STEP-BD and University College London sample collections (p<0.001; Sklar et al. 2008) 
FOXO3 Genetic variation associated with this gene seen in subjects with BD in Brazil (p<0.05; Magno et al. 2011) 
MAL  Decreased expression in post-mortem temporal cortex of subjects with MDD (p<0.01; Aston et al. 2005) 
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5.3.5 CMap Analysis 
 
Of the 88 GES genes, only 75 genes had corresponding feature set IDs from the 22,283 probe sets on the HG-U33A array (Affytag). These 75 
genes, which comprise the final GES, were analysed using CMap, which identified 10 drugs with positive CMap enrichment score of > 0 and 
PCMap-value of <0.001 (Table 5.5).  
 
Table 5.5. Top compounds that affect the expression of the gene expression signature genes in a manner similar to the bipolar disorder drug 
combination sorted by connectivity score.  CELL= Cell type, DOSE= Concentration of the drug, SCORE =Connectivity score. 
Drug P-Value Cell Dose (uM) Score 
Camptothecin 0.00054 PC3 11 0.793 
Chlorambucil 0.00362 PC3 13 0.743 
Flupenthixol 0.00873 HL60 8 0.712 
Valdecoxib 0.00749 PC3 10 0.703 
Rescinnamine 0.00771 MCF7 6 0.699 
GW-8510 0.00024 MCF7 10 0.672 
Cinnarizine 0.00939 MCF7 11 0.664 
Lomustine 0.00643 PC3 100 0.532 
Mifepristone 0.00543 HL60 9 0.515 
Nimesulide 0.00241 MCF7 13 0.510 
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5.4 Discussion 
 
When generating a GES, the first step is to segregate differentially expressed genes that are 
statistically significant.  Following that approach, we created a GES of 88 genes that represents 
the global gene expression changes in NT2-N cells and rat frontal cortex following treatment 
with four commonly prescribed BD drugs. This signature contains genes that putatively 
represent the combined mechanisms of action of the BD drug combination and is a proxy for 
biological pathways altered in BD. It should be noted that in the NT2-N cells a stringent p-
value of 0.001 was used, however, in the rats, none of the genes passed the cut off p-value of 
0.001; this could have resulted from the biological variability between the animals. Therefore, 
in the rats a less stringent p-value of 0.05 was used so as to not omit biologically meaningful 
data. However, in light of this limitation of the rat data, and to test the biological significance 
of the GES genes, we carried out pathway analysis and looked for evidence of association of 
the GES genes in human BD in a post-mortem study. 
In recent years, the use of various databases containing gene groupings based on signalling 
pathways or functions has become valuable in understanding differentially expressed gene sets 
derived from NGS or microarray studies. There are several databases available, and examples 
include Kyoto Encyclopaedia of Genes and Genomes (KEGG) and Gene Ontology (GO) 
Consortium [301]. The DAVID software incorporates several of these databases in the pathway 
analysis. Although this approach is valuable in obtaining biologically meaningful information 
about query gene sets, it should be noted that these analyses enfold many complex genes and 
functions into very high level, often vague pathways or GO terms. The reductionist nature of 
this approach, especially with GO terms, can limit the possible interpretation of the outcomes. 
However, presently it is the best method available to understand gene sets, especially in 
exploratory research such as in the case of BD, where prior knowledge of the pathophysiology 
is scarce. 
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When we carried out the pathway analysis on the GES genes using DAVID software, 
“Structural constituent of myelin sheath” was revealed to be a significantly altered molecular 
pathway upon BD drug combination treatment in NT2-N cells and rat frontal cortex. 
Oligodendrocytes, a type of glial cells, are involved in the myelination of naked or partially 
myelinated axons and myelin remodelling [302]. In BD, alterations are commonly reported in 
white matter, which is abundant in oligodendrocytes [303] and a decline in oligodendrocyte 
count and myelin have been shown to occur in BD patients [302]. A recent meta-analysis 
showed that white matter volume is decreased in the posterior corpus callosum extending to 
the cingulate cortex in BD patients [304]. Moreover, when the myelin sheath is degraded, 
neural connectivity, which is one of the hypothesized etiological mechanisms in BD, is affected 
[302].  Another recent study showed that white matter was reduced in patients after the first 
episode of mania compared to healthy controls, and progression was reduced significantly by 
lithium, which endows protection to white matter [305]. These lines of evidence suggest that 
the biological inference of this GES is significant and has potential association with BD. 
Moreover, in order to confirm differential gene expression of genes that are associated with 
myelination, we carried out qPCR, which revealed that MAL, PLP1 and TSPAN2, were 
increased by the BD drug combination in both NT2-N cells and rat frontal cortex, further 
validating the applicability of this GES in downstream analysis (Figure 5.1).  
Other than validating the GES, the finding that the BD drug combination increased the 
expression of myelination related genes, thereby potentially increasing myelination, is 
noteworthy. The expression of myelin related genes is upregulated during the myelination 
process in the post-natal period, and it is reduced afterwards, however still maintaining myelin 
turnover [306]. Nevertheless, in the event of nerve injury, the myelination genes are 
restimulated. As mentioned above, aberrations in myelination and white matter in BD patients 
have been widely reported. Consequently, this gives an insight into BD aetiology and the 
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mechanism of action of the BD drug combination, and potentially how these drugs bring about 
a clinical response in patients. Therefore, this GES is likely to be suitable for identifying 
monotherapies that act similarly to the BD drug combination via CMap.  
The second step in generating an ideal GES is demonstrating its association with the phenotype 
of interest. In order to corroborate the significance of the GES genes in human BD, we firstly 
carried out a literature search on PubMed. Many of the genes in our GES have previously been 
linked to BD and have established human relevance. For example, ANXA2, which exists as a 
heterotetramer with protein S100A10 (p11) [307], plays a role in the regulation of cellular 
growth and signal transduction pathways, and had increased gene expression in peripheral 
blood mononuclear cells of patients with BD [308]. The BD drug combination decreased the 
expression of ANXA2 gene in this study (Table 5.2). Moreover, FBN1, which is an extracellular 
matrix glycoprotein and a component of calcium-binding microfibrils, was also decreased by 
the BD drugs in this study. Three SNPs in FBN1 have been shown to be associated with BD 
and SZ in a Norwegian sample as well as an Icelandic cohort of participants with BD and SZ 
[309]. SLC1A2, is a gene that encodes a protein that primarily clears the excitatory 
neurotransmitter glutamate from the extracellular space at synapses in the CNS, which is 
essential to prevent neuronal damage [310]. This gene was increased by the BD drug 
combination in this study and has evidence of being decreased in BD and Major Depressive 
Disorder [311].  A rare variant of this gene was also found to confer susceptibility to BD and 
SZ [310].  Other genes in our GES that have been linked to human BD are GADD45A [312], 
ABCG2 [313], TAGLN [314], EGFR [315], FOXO3 [316] and the myelination genes MAL, 
PLP1 and TSPAN2 [317]. Moreover, in a post-mortem study carried out by our collaborators, 
six of the GES genes (AHNAK, APLN, CCDC8, OLFML3, ISOC1 and PLP1) showed evidence 
of differential expression in the brains of participants with BD (Figure 5.2). All of these 
findings support the validity and applicability of this GES in CMap based drug discovery for 
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BD. These findings increased confidence that the identified GES genes are a relevant set of 
genes for CMap analysis. With this optimal GES, we sought to identify compounds that alter 
gene expression in a similar manner to the BD drug combination using CMap. 
The CMap analysis revealed 10 drugs that act in a similar manner to our BD drug combination 
in terms of effects on the expression of the BD GES genes (Table 5.5 ). Interestingly, many of 
the known elements in the pathophysiology of BD are represented in the mechanism of action 
of these 10 agents. 
Flupenthixol, an established antipsychotic and one of the strongly correlated drugs 
(connectivity score of 0.712) identified in the CMap analysis, is widely used in treating mood 
disorders [318]. It has been found to prevent relapse in people with rapid cycling [319] and 
may possess anti-depressant properties and efficacy in the depressed phase of BD even at a low 
dosage [320]. However, in a small double blind placebo controlled trial it was found that 
patients were worse when they were being treated with flupenthixol compared to placebo [321]. 
Therefore, further investigations and larger clinical trials are required to determine the efficacy 
of flupenthixol in BD. Nevertheless, it is still encouraging that an empirical database such as 
CMap was able to recognize an established antipsychotic drug, which gives this method of 
drug discovery or repurposing further validity. 
GW-8510 is a 3’- replaced indolone that is thought to be a cyclin-dependent kinase 2 and 5 
(CDK2 and 5) inhibitor that regulates the cell cycle [322]. GW-8510 has been shown to induce 
neuroprotective effects in neurotoxin treated mouse cells and human neuronal cells, even at 
low concentrations, and also endowed protection against mitochondrial and endoplasmic 
reticulum stressors [322]. Given the mounting evidence for the role of mitochondrial 
dysfunction in BD [323], GW-8510 is an encouraging therapeutic lead that could potentially 
be repurposed for BD. 
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Two non-steroidal anti-inflammatory drugs (NSAIDs; Nimesulide and Valdecoxib), which are 
cyclooxygenase-2 blockers (COX-2), were also identified in the CMap analysis. There is an 
increasing body of evidence to show that inflammation plays a significant role in the 
pathophysiology of BD, and it is conceptualized to be a multi-systemic inflammatory disease 
[324]. Multiple studies have documented increased levels of circulating pro-inflammatory 
cytokines in different phases of BD [325]. Moreover, NSAIDs have been shown to have 
potential anti-depressant efficacy [326]. Furthermore, a recent study suggested that the 
adjunctive use of NSAIDs and other anti-inflammatory agents might be useful in the treatment 
of bipolar depression [327]. In a review by Berk et al. (2011), it was suggested that COX-2 
suppressors could potentially be efficacious in the treatment of BD [328]. Therefore, the use 
of NSAIDs in BD has good supporting evidence. However, given that only certain cytokines 
are altered in people with BD and not all studies have found inflammation to be significant in 
them, the use of NSAIDs in BD must be further explored [329]. 
Additionally, inflammation in mood disorders can also be regulated by the renin-angiotensin 
system in the central nervous system [330]. A drug repurposing study matched the Welcome 
Trust Case-Control Consortium genome-wide association data and drug profiles from three 
drug databases, finding two drug matches: imipramine, an antidepressant, and valsartan, an 
angiotensin antagonist [331]. Candesartan, also an angiotensin antagonist, has been shown to 
have anti-manic efficacy in an animal model and reversed amphetamine-induced alterations in 
glutathione, markers of lipid peroxidation (TBARS), inflammation (TNF-α) and neurotrophins 
(BDNF) [332]. More recently, an epidemiological study found evidence that  use of ACE 
inhibitors decreased the occurrence of mood disorders [330]. In this context, the ACE inhibitor 
from our CMap analysis, Rescinnamine, is a promising candidate drug for repurposing to treat 
BD.  
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The anti-glucocorticoid agent Mifepristone was identified in the CMap analysis. 
Hypothalamic-pituitary-adrenal (HPA) axis impairment has been associated with the 
pathophysiology of BD, and can lead to depressive signs and neurocognitive decrement [333]. 
Glucocorticoids are the final products of the HPA axis and are significant factors in the stress 
response [334]. Hypercortisolism can lead to impaired neurogenesis and dendritic atrophy 
[333], which are characteristics seen in people with BD. There is evidence for HPA 
dysregulation and changes in glucocorticoid responsivity in BD, raising the possibility that 
anti-glucocorticoids have the potential for therapeutic efficacy in BD [335]. Mifepristone has 
been proposed to improve neurocognition and act as an anti-depressant in people with BD and 
has been recommended for treating BD [333]. Therefore, this drug is one of the more promising 
drugs that could be repurposed for BD, further demonstrating the validity of this method. 
Another hypothesized pathophysiological factor in BD is dysregulation of glutamatergic 
transmission and neuroplasticity [336]. Glutamatergic disruption can be mediated by 
monoamines and also histamine. Activation of histamine 3 (H3R) receptors reduces the release 
of histamine and decreases the release of glutamate. Moreover, studies have provided evidence 
that H3R antagonists have anti-depressant properties [337] and improve cognition [338]. 
Furthermore, an anti-histamine, terfenadine, has been shown to avert N-methyl-D-aspartate 
(NMDA) mediated excitotoxicity and thereby inhibit neurotoxicity [339] thus making anti-
histamines such as Cinnarizine another interesting potential drug for BD. 
It is promising that CMap analysis has identified a number of drugs that could be repurposed 
for BD that are known to act on proposed pathophysiological mechanisms of BD. Given the 
shortcomings of polypharmacy and the currently used BD medications, this approach might 
pave the way to move away from polypharmacy and investigate monotherapies that could have 
the same or better efficacy as multiple drugs. This will also possibly increase medication 
adherence in patients, and reduce medication related costs. Although CMap does not provide 
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information for all cell types, it provides a viable basis for finding candidate drugs that may be 
repurposed for BD.  Moreover, the fact that several genes in the GES are associated with BD 
and have human relevance provides additional validity for this drug discovery method using 
CMap. Given the lack of new drugs in psychiatry, the use of CMap and GES warrants further 
investigation.  
Bearing in mind the complexity of psychiatric disorders, it is important to consider diverging 
from the traditional method to a new, broader perspective of drug discovery. Drugs identified 
through conventional methods are often not able to significantly modulate multiple signalling 
pathways, which is imperative in these pathologies. Moreover, given the lack of understanding 
of the pathophysiology and the mechanisms of action of currently used drugs, this question-
driven rather than hypothesis-driven approach to drug discovery seems highly plausible.  
One major advantage of this method is the absence of requirement for a highly specialized 
signal transduction assay, or prior knowledge of the protein to be targeted. The ability to 
convert any biological process or cell state into a completely generic GES that can be monitored 
in high throughput and at low cost is therefore attractive.  
It is important to highlight that this approach requires bioinformatics expertise to perform the 
complex statistical computational methods, making this a limitation of the process. Another 
limitation that should be taken into consideration is the need for a robust set of experimental 
conditions in order to generate the GES. Extended treatment times and different concentrations 
of the drugs could be considered as well in order to get a more comprehensive understanding 
of the effects of BD drug combination. 
The lack of significant differences in the gene expression in rats is an important issue in this 
study, which lead us to relax the p-value cut-off to 0.05 in the rat dataset. This issue could 
potentially be avoided by increasing the number of rats in each treatment group.  
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5.5 Conclusions 
 
In conclusion, the study described in this chapter shows the potential of matching gene 
expression signatures to atheoretical databases containing data of drug effects on gene 
expression profiles, which can be used to identify novel therapeutic agents for BD. Given the 
lack of understanding of the pathophysiology of BD and mechanisms of action of currently 
used BD drugs, this is an attractive method towards finding safe, cheap and efficient drug 
therapies for BD.  
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CHAPTER 6 
DRUGS USED TO TREAT BIPOLAR DISORDER ACT VIA 
MICRORNAS TO REGULATE EXPRESSION OF GENES 
 
6.1 Introduction 
6.1.1 BD pathophysiology  
BD is a debilitating and highly heritable mood disorder with poorly understood 
pathophysiology [340]. The majority of BD patients are treated with more than two drugs at a 
time, a practice known as polypharmacy [341]. BD is treated with mood stabilisers, 
antipsychotics and antidepressants in various disease phases and for prophylaxis. Many of the 
currently used drugs have been repurposed for BD, with the exception of lithium, which is the 
gold standard  treatment [342]. Regardless of the availability of these medications, the 
individual and combined drug mechanisms of action are still largely unknown owing to our 
poor understanding of the underlying biology of BD.  
Presently, our knowledge of the pathophysiological underpinnings of BD is sparse. However, 
many pathways and mechanisms have been postulated to be involved such as mitochondrial 
function, neurogenesis, apoptosis, intracellular signalling, glutamate activity, inflammation 
and neuronal plasticity [343]. Recently, dysregulation in microRNA (miRNA) expression has 
gained attention as a putative factor in BD, brain neoplasms, degenerative diseases and SZ 
[146, 344]. Therefore, by understanding which miRNA and mRNA molecules are specifically 
altered in BD and the treatment of BD, we will be able to unravel the mechanisms linked to the 
development of the disease and the mechanisms of action of the currently prescribed BD drugs. 
Ultimately, this could lead to the discovery of more effective therapeutics for BD. 
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6.1.2 Biogenesis of miRNAs 
miRNAs are 19-24 nucleotides long single stranded, non-coding RNA molecules that bind to 
complementary mRNA sequences and thereby post-transcriptionally regulate gene expression 
[345]. RNA polymerase II transcribes the MIR gene into long primary transcripts that contain 
hairpin structures (pri-miRNA), which are then processed by RNase III Drosha and DiGeorge 
critical region 8 (DGCR8) microprocessor complex in the nucleus in order to make 70-100 
nucleotides long precursor miRNAs (pre-miRNA) [345, 346]. These pre-miRNAs are 
transported into the cytoplasm by exportin-5 and further cleaved and converted to functional 
mature miRNAs by RNase III dicer (Figure 6.1) [346]. 
miRNAs function through cleaving mRNA or repressing protein synthesis in many tissues 
including the brain [139, 347]. When they anneal at the 3′ untranslated region of a target mRNA 
with complete complementarity, it leads to the degradation of the target [346]. On the other 
hand, miRNA annealing to targets with incomplete complementarity leads to the suppression 
of target genes  and thus inhibition of protein synthesis [346]. Every miRNA is predicted to 
have multiple target genes, and each gene could be regulated by several miRNAs [346, 348].  
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Figure 6.1. microRNA (miRNA) biogenesis. 
Transcription of MIR genes by RNA polymerase II. The synthesised primary miRNA (pri-
miRNA) transcript is long and contains a hairpin structure. Pri-miRNA is processed by RNAse 
III Drosha/DGCR8 complex, releasing a smaller hairpin structure comprising pre-miRNA.  
The pre-miRNAs are transported out of the nucleus into the cytoplasm by exportin-5. Pre-
miRNAs in the cytoplasm are cleaved by RNase III Dicer, which removes the loop structure 
and forms mature miRNAs. One of the mature miRNA strands then anneals at the 3′ 
untranslated region of a mRNA transcript with complete complementarity or incomplete 
complementarity leading to mRNA cleavage or repression of translation respectively (Image 
adapted from Mulrane [142] and Fries [349]) 
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6.1.3 miRNAs in BD 
miRNAs are involved in various pathways such as development, differentiation, proliferation, 
apoptosis and immune responses throughout the organism, including the nervous system [139-
141]. Neurons are rich in miRNA expression, and many neuronal and brain specific miRNAs 
have been reported [143, 144]. miRNAs play important roles in brain function, including 
neuronal differentiation, neurogenesis and synaptic plasticity [145, 146].  
Several promising studies suggest differential expression of miRNAs in the post-mortem brains 
of BD patients [147-149].  A recent study by Choi et al. (2017) found that miR-149 was 
increased in anterior cingulate cortex-derived (ACC) exosomes of BD patients. The same group 
has previously showed that miR-29c was highly expressed in the prefrontal cortex (PFC) of 
BD patients. Moreover, in another study on PFCs of BD patients, it was reported that miR-17-
5p, miR-579, miR-106b-5p and miR-29c-3p were upregulated while miR-145-5p, miR-485-
5p, miR-370, miR-500a-5p and miR-34a-5p were downregulated [149] 
Furthermore, studies have also shown that miRNAs are regulated by the commonly prescribed 
mood stabilisers, lithium and valproate, in humans and rats [152]. Chen et al. (2009) showed 
that lithium increased the expression of four miRNAs (miR-34a, miR-152, miR-155 and miR-
221) in lymphoblastoid cell lines derived from BD patients and their discordant siblings. In rat 
hippocampus, chronic treatment with lithium and valproate altered the expressions of 37 and 
31 miRNAs respectively, of which nine were affected by both drugs [152].  
Given that many miRNAs are highly expressed in the human brain, it is conceivable that 
dysregulation of miRNAs could be involved in the pathophysiology of BD. Therefore, 
exploring miRNAs in BD drug treated cells may facilitate better understanding of the molecular 
mechanisms of the drugs, and consequently the pathophysiology of BD. 
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6.1.4 miRNA Target Prediction  
As of January 2018, miRBase, the largest database of miRNA sequences, contains 1,881 
precursors and 2,588 mature miRNAs (www.mirbase.org). Many of the target genes of these 
miRNAs are predicted from bioinformatics approaches. However, to date only a relatively 
small percentage of miRNA-target gene interactions have been validated experimentally and 
of these miRNAs, only a few have been verified by more than one research group or in several 
cell lines and tissues [350]. 
Genome-wide results for miRNAs are usually further analysed by identifying their target genes. 
This analysis helps with understanding the functions and mechanisms of the miRNAs. 
Moreover, when these findings are coupled with pathway and gene ontology analyses, it allows 
one to acquire a deeper understanding of specific miRNA function. Using this method, disease 
specific functions of miRNA can also be established. Several studies have reported that 
miRNAs identified from post mortem brains of BD patients have been shown to be enriched 
for pathways related to nervous system function [145].  
Given the potential involvement of miRNA in BD, and also possibly in the mechanisms of 
action of BD drugs, in this chapter we describe how we profiled miRNAs in both a cell model 
and in the rat brain using next generation sequencing and the biological pathways they target 
in order to better understand the mechanism (s) of action of the drugs and the pathophysiology 
of BD. We used a subset of NT2-N cell samples treated with the BD drug combination 
containing lithium, valproate, quetiapine and lamotrigine from the study described in chapter 
2.  
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6.2 Materials and Methods 
Detailed methods and materials for this chapter can be found in Chapter 2 of this thesis. A 
subset of the same samples generated for chapter 2 were also used in the miRNA analysis. 
6.2.1 Cell Culture and Treatment for Next Generation Sequencing 
Ntera2 human teratocarcinoma cells (NT2) were cultured and differentiated as previously 
described (Pleasure et al., 1992). The differentiated neuronal-like cells (NT2-N) were treated 
with either the BD drug combination (2.5 mM lithium chloride, 0.5 mM valproate, 50 µM 
lamotrigine and 50 µM quetiapine) or vehicle control (0.2% DMSO) for 24 hours (n=20 per 
group). 
6.2.2 Animal Study 
All animal procedures were approved by the ethics committee of Deakin University, Australia, 
and conducted according to the code of practice for the care and use of animals for scientific 
purposes (National Health and Medical Research Council, Australia). Eight-week-old male 
Sprague-Dawley® rats were housed (21 ± 2°C, 40–70% humidity, 12-h light/dark cycle) with 
unrestricted access to food and water (n=8 per group). The drug treated group received the 
same BD drug combination as the NT2-N cells via intraperitoneal injection (lithium 10 mg/kg, 
valproate 50 mg/kg, quetiapine 2 mg/kg and lamotrigine 10 mg/kg) while the vehicle group 
was treated with 6% DMSO. The drug dosages were determined based on published literature 
describing the minimal effective doses needed to affect gene expression in the brains of rats 
and mice. The frontal cortex and hippocampus were dissected and snap frozen in liquid 
nitrogen 6 hrs after the injection as the Cmax for the drugs overlay at ~4 hrs with plasma half-
lives between 7-24 hrs.   
6.2.3 RNA Isolation and Quality Control 
Total RNA was extracted from 20-30 mg of homogenized rat frontal cortex/hippocampus or 
harvested NT2-N cells using TRIzol reagent and purified with RNeasy® mini kits (Qiagen). 
The quality of the extracted RNA from the NT2-N cells was determined using an Agilent 2100 
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Bioanalyzer and RNA 6000 Nano Kit (Agilent). The quantity of the RNA was assessed using 
NanoDrop 1000 (Thermofisher Scientific). 
6.2.4 Next Generation Sequencing (NGS) 
 
The cDNA library preparation was conducted in the Metabolic Research Unit, Deakin 
University. Briefly, the quality of the extracted RNA from the NT2-N samples (n=40) and the 
rats frontal cortex (n=16) was determined using Agilent 2100 Bioanalyzer and RNA 6000 Nano 
Kit (Agilent Technologies, USA). The quantity of the RNA was assessed using NanoDrop 
1000 (Thermo Fisher Scientific). For miRNA enrichment the TrueSeq® Small RNA Library 
Prep Kit (Illumina) was used. The same RNA samples that were used for the RNASeq library 
preparation were used for miRNA analysis. The first six NT2-N cell samples from the 20 
samples in each treatment group (n=6 per group) and all of the rat frontal cortex samples (n=8 
per group) were chosen for this analysis. The library preparation was carried out as per the 
manufacturer’s instructions.   The prepared libraries for NT2-N cells and rats were then 
analysed on an Illumina HiSeq platform generating 50 bp single-end reads (HiSeq 2500 rapid 
50bpSE; 1 flow cell).  
The output of raw sequence reads were downloaded in FASTQ format for bioinformatics 
analysis.  
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6.2.5 Data Analysis  
The raw sequence reads were filtered to remove technical sequences such as adapters and 
primers using the FastQC program 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Then the sequences were 
aligned to a reference genome using Bowtie 2/TopHat 2 
(http://ccb.jhu.edu/software/tophat/index.shtml). The differential expression of miRNAs 
between drug treated and vehicle groups was assessed using the software package DESeq 
(http://bioconductor.org/packages/release/bioc/html/DESeq.html) in R. An adjusted p value of 
<0.05 and total reads of >100 were used to identify miRNAs of interest. 
6.2.6 miRNA Target Prediction and Gene Annotation Enrichment Analysis 
Target prediction for the differentially expressed miRNAs was conducted by means of 
bibliographic search on PubMed and accessing the open source microRNA.org database 
(http://www.microrna.org/microrna/home.do). 
Using the resulting target genes for each miRNA, the potential individual and combinatorial 
effect of the miRNAs on regulation of biological pathways was studied by carrying out gene-
annotation enrichment analysis using Database for Annotation, Visualization and Integrated 
Discovery (DAVID) Bioinformatics Resources [218] (National Institutes of Health, Bethesda, 
Maryland, USA). 
6.2.7 miRNA TaqMan Assay 
The NT2-N cells were cultured as described in Chapter 2, and treated for 24 hours with 
individual drugs, drug combination or vehicle controls (n=6; 2.5 mM lithium chloride, 0.5 mM 
valproate, 50 µM lamotrigine and 50 µM quetiapine and DMSO or H2O).  The RNA was 
extracted as described in section 4.2.3 and stored at -80°C until use. 
To confirm and validate the differentially expressed miRNAs derived from sequencing data, 
Reverse Transcription (RT)-qPCR analyses of miRNAs (miR-128 and miR-378) were carried 
out using TaqMan microRNA assays (Applied Biosystems, Life Technologies, Australia). A 
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maximum volume of total RNA was used for the RT reaction. RT reactions were performed  in 
15 μl reactions with 0.15 μl of 100mM dNTP mix,  1.5 μl of 10X RTbuffer ,1 μl of 50U 
Multiscribe RT enzyme, 0.2 μl  of 20U RNAse inhibitor, RNAse-free water and 3 μl of  pooled 
1X primers (miR-128 – UCACAGUGAACCGGUCUCUUU and miR-378-
CUCCUGACUCCAGGUCCUGUGU) (Applied Biosystems, Life Technologies). RT 
reactions were performed at 16°C for 30 minutes, 42°C for 30 minutes, and 85°C for 5 minutes 
using a GeneAmp® PCR System 9700 thermocycler (Applied Biosystems, Life Technologies). 
The qPCR was performed with miRNA specific TaqMan miRNA Assay probes using 
PikoReal™ qPCR machine (Thermo Fisher Scientific) at 95°C for 10 minutes, followed by 40 
cycles of 95°C for 15 seconds and 60°C for 60 seconds. All samples were run in duplicate 
and included no template controls. Cycle threshold (Ct) values were automatically determined 
by the Pikoreal software.  
The expression of miR-128 and miR-378 was also confirmed in rat hippocampus following 
RNA extraction and carrying out the above-described miRNA TaqMan assay. In this case rat 
hippocampus tissue was utilised as we did not have enough rat frontal cortex tissue left.  
6.2.8 cDNA Quantification Using OliGreen Method 
The Quant-iT™ OliGreen® ssDNA Assay Kit (Life Technologies, USA) was used to quantify 
the cDNA concentration in each sample. The provided nucleotide standard (100µg/ml) was 
diluted in 1x Tris-EDTA (TE) buffer to prepare the oligonucleotide standards of 15, 12.5, 10, 
7.5, 5, 2.5, 1.25 and 0 µg/ml. 5 µl of each standard and cDNA samples were loaded in triplicate 
in an opaque 96-well plate (Greiner, Hamburg, Germany), into which 95 µl of 1x TE buffer 
and 100 µl of 1x ssDNA reagent were added.  The plate was covered with aluminium foil to 
protect it from light and incubated at room temperature for 5 minutes. Then the plate was 
scanned in a Flex Station II 384 fluorescence plate reader that is connected to a computer with 
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Softmax Pro v5 software.  Using this software, the protocol was configured to read the plate 
from the top with an initial mixing for 10 seconds followed by excitation at 485 nm and 
emission at 538 nm.  
The subsequent data was used to produce a standard curve and calculate the relative ssDNA 
concentration in each sample. miRNA expression data from the TaqMan assay was then 
normalised to the derived ssDNA concentration of each sample. This corrects for any deviance 
in gene expression that could result from total RNA concentration variability between samples. 
6.2.9 miRNA Inhibitors 
 
The NT2-N cells were cultured as described in Chapter 2  and seeded at a density of  475,000 
cells/well in coated 24-well plates, and transfected with 10μM miRCURY LNA microRNA 
inhibitors for hsa-miR-128-3p and hsa-miR-378a-5p simultaneously or negative control A 
(Qiagen) using Lipofectamine RNAiMAX reagent (Life Technologies) as per the 
manufacturer’s protocol. Briefly, the Lipofectamine RNAiMAX reagent and 10μM 
inhibitors/negative control (scrambled miRs) were diluted in Opti-Mem medium (Thermo 
Fisher Scientific). The inhibitor/negative control was added to the diluted Lipofectamine 
RNAiMAX reagent at 1:1 ratio and incubated for 5 minutes at RT. Then the inhibitor/negative 
control- lipid complex was added to the cells at a final concentration of 10nM in serum 
starvation media (DMEM with 0.2% (v/v) BSA) per well, and incubated for 24 hours.  After 
24 hours of transfection, the cells were washed with serum starvation media and the drug 
combination or vehicle treatments were applied for 24 hours (n=8).   
After 24 hours of drug treatment, the RNA was extracted using RNeasy® mini kits (Qiagen) 
as described in section 4.2.3, and stored at -80°C until use. 
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6.2.10 miRNA Inhibitors – Target Genes 
The extracted RNA from NT2-N cells transfected with miRNA inhibitors were reverse-
transcribed to produce cDNA using a Maxima H Minus first strand cDNA synthesis kit 
(Thermo Fisher Scientific, Australia). The reaction mixture (15 µl) in each thermocycler tube 
was made up with 1µl of 10 mM dNTP mix, 1 µl of  100 µM oligo (dT) 18 primer, 10 µl of 
RNA (1pg -5 µg total RNA) and 3 µl of nuclease free water. The tubes were then incubated at 
65°C for 5 minutes in a GeneAmp® PCR System 9700 thermocycler (Applied Biosystems, 
Life Technologies). After 5 minutes, the tubes were placed on ice briefly to stop the reaction, 
and spun briefly. In the meantime, a master mix of 5x RT buffer and Maxima H minus enzyme 
mix (4:1 ratio) was prepared and 5 µl was added to each tube. The contents (final volume of 
20 µl) of the tubes were gently mixed by pipetting and span briefly. The tubes were then 
incubated in the same thermocycler for 30 minutes at 50°C; 5 minutes at 85°C; 5 minutes at 
4°C. The resulting cDNA was diluted to 1:10 with nuclease free water, and stored at -20°C 
until use. 
6.2.11 Real-time PCR  
Primer sequences for the miRNA target genes genes NOVA1, GRIN3A  and VIM , which were 
used in Real-time PCR (qPCR) were designed using Thermo Fisher Scientific’s OligoPerfect™ 
Designer tool, and their complementarity and specificity were confirmed with Primer-BLAST 
(NCBI) (sequences given in Table 2.1 in Chapter 2). The designed primers were supplied by 
Integrated DNA Technologies (New South Wales, Australia). The primer pairs were optimised 
to ensure the amplification of the desired product as well as to determine the optimal template 
cDNA concentrations required for the reaction.  
qPCR was conducted using SYBR Green fluorescence. qPCR reaction mix was prepared for 
each primer pair, 0.11 µM of forward and reverse primers, 56% Luminaris HiGreen Low ROX 
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qPCR Master Mix (Thermo Fisher Scientific) and topped up with nuclease free water. This 
reaction mixture (9 µl in each well) was pipetted into a 96-well qPCR plate after which 1 µl of 
the diluted cDNA (1:10) was added in duplicate for each sample making the final volume 10 
µl. Duplicates of no template control (NTC) were also prepared. The prepared plate was sealed 
with an optical adhesive cover and spun briefly for 30 seconds. The reactions were carried out 
in a PikoReal™ qPCR machine with the following protocol: 95°C for 7 minutes, 40 cycles of 
95°C for 30 seconds and 60°C for 1 minute followed by data acquisition, 60°C for 30 seconds, 
55-95°C – data acquisition and 20°C for 10 seconds.  
The cDNA was quantified using the Quant-iT™ OliGreen® ssDNA Assay Kit as described in 
section 4.2.8. Gene expression data from the miRNA target genes was then normalised to the 
derived ssDNA concentration of each sample.  
6.2.12 Statistical Analysis 
All statistical analyses were carried out using Statistical Package for the Social Sciences 
version 24 (SPSS) software. Shapiro–Wilk tests were used to check whether the data were 
normally distributed. Levene’s Test was used to decide whether equal variances could be 
assumed between treatment groups. Drug treatment groups were compared to their 
corresponding controls using independent samples t-test for normally distributed data and non-
parametric tests for data not normally distributed (Mann-Whitney U test). Significance levels 
were set at p<0.05. 
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6.3 Results 
6.3.1 NGS 
6.3.1.1 Differentially expressed miRNAs in NT2-N cells 
 
Data for a total of 528 miRNAs was obtained with a total of 45 million raw reads. The data 
was filtered and usable data for 398 miRNAs (total reads>100) was obtained. From these 
miRNAs two (miR-128 and miR-378) were found to be differentially expressed (FDR adj. 
p<0.02; Figure 6.2) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. Differentially expressed miRNAs in drug treated cells relative to vehicle from the 
NGS data (* adj. p<0.02) 
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6.3.1.2 Differentially expressed miRNAs in Rats 
 
From the NGS data, we did not find any significantly differentially expressed miRNAs. 
However, we confirmed the expression of miR-128 and miR-378 in rat hippocampus. Both 
miR-128 and miR-378 tended to have an increased expression in the drug treated rats, however 
this was not statistically significant (Figure 6.3). 
 
Figure 6.3. Expression of miR-128 and miR-378 in BD drugs treated rat hippocampus 
compared to vehicle derived from qPCR. 
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6.3.2 miRNA Target Genes 
The target genes of the miR-128 and miR-378 were obtained through PubMed and 
MicroRNA.org databases. The top 50 gene targets with miRSVR score of < -1.2 were identified 
for each miRNA. The target genes were then compared to our genome wide mRNA sequencing 
data and only those genes expressed in the cells and downregulated in the data set were 
considered as target genes for each miRNA. This resulted in 39 and 48 genes for miR-128 and 
miR-378 respectively (Table 6.1)
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Table 6.1. Target prediction for miR-128 and miR-378, and the number of significant target genes obtained. 
miRNA Database Total number of 
predicted targets 
Number of 
genes expressed 
in NT2-N cells 
Number of genes 
with increased 
expression 
Number of genes 
with decreased 
expression  that 
have p>0.05 (not 
significant) 
Number of genes 
with decreased 
expression that 
have p<0.05 
miR-128 PubMed 54 46 22 8 16 
 Microrna.org 50 44 14 7 23 
Total number of targets of interest 39 
miR-378 PubMed 45 37 9 3 25 
 Microrna.org 50 45 17 4 22 
Total number of targets of interest 48 
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6.3.3 DAVID Gene Annotation Enrichment Analysis 
The target genes identified for each miRNA were used in the DAVID gene annotation 
enrichment analysis, which identified 36 and 37 IDs respectively for miR-128 and miR-378. 
The top pathways that were enriched in the miR-128 target genes were regulation of cell 
migration, locomotion, cell motion, neuron projection and axonogenesis (Table 6.2). Similarly, 
miR-378 target genes tended to be enriched in pathways associated with neuron projection 
development, differentiation, axogenesis and cell projection (Table 6.3). Because the BD drugs 
increase the expression of both miR-128 and miR-378, we repeated the gene annotation 
enrichment analysis using the target genes of both miRNAs. As shown in Table 6.4, the miRNA 
target genes were highly enriched for neuron projection development, cell projection 
organisation, cell motion and axonogenesis.  
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Table 6.2. Enriched pathways by the miR-128 target genes. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Enriched pathway Number of 
Genes 
P-Value Adj. P-Value 
Central nervous system projection neuron axonogenesis 3 0.00033 0.023 
Negative regulation of cell migration 4 0.0003 0.023 
Neuron projection development 6 0.0003 0.023 
Regulation of cell migration 6 <0.0001 0.029 
Regulation of cell motion 6 0.0001 0.018 
Regulation of locomotion 6 0.0001 0.027 
Cellular component morphogenesis 7 0.0002 0.024 
Cell projection organization 7 0.0002 0.021 
Cell motion 8 0.0001 0.016 
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Table 6.3. Enriched pathways by the miR-378 target genes. 
Pathway Number 
of Genes 
P-Value Adj. P-Value 
Neuron projection development 6 0.0004 0.09 
Cellular component morphogenesis 6 0.0029 0.17 
Axonogenesis 5 0.0013 0.17 
Cell morphogenesis involved in differentiation 5 0.0031 0.16 
Cell morphogenesis involved in neuron differentiation 5 0.0018 0.16 
Cell part morphogenesis 5 0.0037 0.17 
Cell projection morphogenesis 5 0.0032 0.15 
Neuron projection morphogenesis 5 0.0019 0.14 
Cell morphogenesis 6 0.0018 0.14 
Cell projection organization 6 0.0021 0.13 
Neuron development 6 0.0015 0.15 
Neuron differentiation 7 0.0007 0.11 
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Table 6.4. Enriched pathways by the miR-128 and miR-378 target genes. 
Pathway                                     Number of 
Genes 
P-Value Adj. P-Value 
Neuron projection development 12 3.30E-08 3.50E-05 
Cellular component morphogenesis 13 3.40E-07 6.10E-05 
Cell projection organization 13 1.50E-07 8.10E-05 
Cell motion 14 3.20E-07 8.70E-05 
Axonogenesis 10 3.30E-07 7.00E-05 
Cell morphogenesis involved in neuron differentiation 10 6.40E-07 8.60E-05 
Neuron projection morphogenesis 10 7.50E-07 9.00E-05 
Cell morphogenesis 12 9.00E-07 9.70E-05 
Neuron development 12 5.60E-07 8.60E-05 
Neuron differentiation 13 9.70E-07 9.50E-05 
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6.3.4 Expression and Function of miR-128 and miR-378 Target Genes 
As suggested by DAVID gene annotation enrichment analysis, the gene targets of miR-128 
and miR-378 obtained through PubMed and MicroRNA.org databases were enriched in 
pathways associated with neurogenesis and neurite outgrowth (Tables 6.2, 6.3 and 6.4). 
miRNAs generally decrease the expression of their target genes, and given these two miRNAs 
were increased by the drug treatment; we looked closely at the downstream target genes of 
miR-128 and miR-378 and their expression in the NGS data, and their functional roles through 
literature search. All of the target genes were downregulated, and many of them were inhibitors 
of neurogenesis  (RCOR3[351], NOVA1 [352], NAPIL2 [353], VIM [354] and NF1[355]) or 
neurite outgrowth (PAIP2 [356], PDLIM1[357], SYT1[358], EPHB1 and EPHB2,[359], PTEN 
[360], BICD1[361], CELSR3 [362], GRIN3A [363], PGR [364], UNC13C [365] and 
EHD1[366] (Figures 6.4 and 6.5).  
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Figure 6.4. Expression of some of the target genes of miR-128 associated with neurogenesis 
and neurite outgrowth, derived from the next generation sequencing mRNA data (*** p<0.001, 
** p<0.01) 
 
 
 
 
 
 
 
 
 
 
174 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. Expression of some of the target genes of miR-378 associated with neurogenesis 
and neurite outgrowth, derived from the next generation sequencing mRNA data (*** p<0.001, 
** p<0.01, *p<0.05) 
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We also tested whether the expression of the target genes was correlated with the expression 
of miR-128 and miR-378. In all instances, there is evidence of a negative correlation, which 
confirmed that the target genes of miR-128 and miR-378 are likely to be directly regulated by 
their respective miRNAs (Figures 6.6 and 6.7). 
 
 
Figure 6.6. Negative correlation between miR-128 and its target gene expression in BD drug 
treated NT2-N cells (p<0.05 for all genes) 
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Figure 6.7. Negative correlation between miR-378 and its target gene expression in BD drug 
treated NT2-N cells (p<0.05 for all genes) 
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6.3.5 miRNA TaqMan Assay  
The effect of the BD drug combination seen in the NGS data was confirmed and validated with 
qPCR. However, unexpectedly, the drugs when used individually had varying effects compared 
to the drug combination, and none of these results were statistically significant (Figures 6.8 
and 6.9). Valproate tended to increase the expression of both miRNAs and lithium tended to 
increase miR-128 but tended to decrease miR-378. Lamotrigine and quetiapine tended to 
decrease the expression of both miRNAs.  
 
 
 
 
 
 
 
 
 
Figure 6.8. Effects of individual and combination of BD drugs on the expression of miR-128 in 
NT2-N cells relative to vehicle. 
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Figure 6.9. Effects of individual and combination of BD drugs on the expression of miR-378 in 
NT2-N cells relative to vehicle. 
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6.3.6 Inhibition of miR-128 and miR-378 
Figure 6.10 shows that we successfully and significantly inhibited the expression of miR-128 (p<0.005) and miR-378 (p<0.001) simultaneously 
using miRNA inhibiters in NT2-N cells. 
 
Figure 6.10. Successful inhibition of miR-128 and miR-378 in NT2-N cells. * p<0.005, ** p<0.001
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6.3.8 Effects of BD drug combination on NOVA1, GRIN3A and VIM  
After confirming that the miRNA inhibiters were able to inhibit the expression of miR-128 and 
miR-378, we wanted to see the effect of the BD drugs when these miRNAs are inhibited. 
Therefore, firstly we inhibited the expression of miR-128 and miR-378 simultaneously in NT2-
N cells and then treated them with the BD drug combination to see the effect on some of the 
target genes of these two miRNAs. We measured the expression of NOVA1, GRIN3A and VIM 
in these cells (Figure 6.11). The BD drug combination tended to decrease the expression of the 
target genes when the two miRNAs were not inhibited, which was expected. However, when 
the expression of miR-128 and miR-378 were inhibited, the BD drug combination did not 
decrease the expression of the target genes.  
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Figure 6.11. Effects of BD drug combination on NOVA1, GRIN3A and VIM following simultaneous miR-128 and miR-378 inhibition in NT2-N 
cells. *p<0.05
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6.4 Discussion  
In order to elucidate the effects of a range of BD drugs on the expression of miRNAs 
in human neuronal cells and rat brains, we performed unbiased whole genome gene 
expression profiling.  One major finding of this study was that BD drug combination 
(lithium, valproate, lamotrigine and quetiapine) increased the expression of miR-128 
and miR-378 significantly in NT2-N cells as confirmed by NGS (Figure 6.2) and 
miRNA TaqMan qPCR (Figure 6.8).  These two miRNAs also tended to increase in rats 
treated with the BD drug combination as confirmed by miRNA TaqMan qPCR (Figure 
6.3). 
miR-128 is an intronic miRNA that is encoded by two isoforms miR-128-1 and miR-
128-2.  The pri-miR-128-1 gene is found in R3H domain containing protein 1 gene 
(R3HDM1) and pri-miR-128-2 resides in the cAMP-regulated phosphoprotein 
(ARPP21), which are conserved in the human, rat and mouse genomes [367]. miR-128 
has been shown to have anti-cancer activity in lung [368] and breast [369] cancers.  In 
the brain, miR-128 appears to be expressed specifically in neurons and is one of the 
most copious and enriched miRNAs in the cortex and cerebellum [370]. This miRNA 
is associated with neural tissue differentiation and is involved in cortical migration 
[371]. miR-128 might also be essential for the evolution from migration to outgrowth 
in neurons, which in turn stimulates neuronal maturation [372]. miR-128 has been 
implicated in SZ and major depressive disorder where it has been shown to have 
increased expression in human post-mortem brain samples and anti-depressant treated 
MDD subjects [373-375]. Moreover, in rats treated with an antipsychotic drug, 
haloperidol, miR-128 expression was found to be increased, however this effect was 
not extendable to human schizophrenic patients in this study [376]. Therefore, this 
miRNA is thought to be involved in the pathophysiology of various psychiatric 
disorders as well as in the mechanism of action of psychiatric drugs.  
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miR-378 is another intronic miRNA that is embedded in the first intron of the ppargc1b 
gene that encodes PGC-1β [377]. miR-378 has also been shown to be upregulated in 
BD patients, and is thought to be involved in lipid metabolism, cell growth and cell 
differentiation [378-380]. Furthermore, miR-378 overexpression increased cell 
viability and reduced apoptosis, whereas its knockdown led to neuronal injury in mice 
[371]. In addition, miR-378 directly inhibits the expression of vimentin (VIM) which in 
turn increases neurogenesis [354, 381]. From our mRNA sequencing data and the 
experiment with miRNA inhibitors (Figure 6.11), VIM was found to be downregulated 
when the NT2-N cells were treated with the BD drug combination, concurring with this 
finding. Moreover, agreeing with the conclusions of Meganathan et al. (2015), in our 
study valproate increased the expression of miR-378, thereby potentially 
downregulating VIM. Therefore, it is indeed possible that one of the mechanisms of 
action of valproate in BD patients could be to increase neurogenesis via regulation of 
miR-378. 
Neural plasticity or the ability to adapt to new challenges such as environmental 
changes and brain lesions is disrupted in BD patients [382]. At a cellular level, 
disruption of neural plasticity can be characterized by structural changes in the brain 
network such as reduced dendrite and neurite outgrowth and neurogenesis [134]. 
Another key finding of this study suggests that downstream target genes of miR-128 
and miR-378 are associated with neurogenesis and neurite outgrowth. To identify 
affected pathways, we carried out DAVID pathway analysis. The pathways of these 
miRNAs, when target genes were analysed separately or together, did not change 
greatly which denote that they might have coordinated effects on the pathways. Both 
the miRNAs affected pathways linked to neuron differentiation, projection and 
development, axogenesis and morphogenesis. Furthermore, a trend towards a negative 
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correlation between the target genes and miRNA-128 and miR-387 was also seen. 
These findings together suggest that the BD drugs may increase neurogenesis and 
neurite outgrowth through regulation of these miRNAs. 
In order to validate and confirm the NGS findings, we also performed miRNA TaqMan 
assays with individual and combined drugs. Unexpectedly, on their own the drugs had 
varying and sometimes opposite effects to the combination effect seen in NGS. These 
findings reflect that the drug combination increased the expressions of miR-128 and 
miR-378, however, independently the drugs had unpredictable effects. It is established 
that polypharmacy is considered more effective than monotherapy in BD (Sachs, Peters 
et al. 2014). However, the mechanisms underlying the efficacy of polypharmacy are 
not well understood. Therefore, the findings from the TaqMan assays were interesting 
and might go some way towards explaining the extensive use of polypharmacy in BD. 
It is possible that when BD patients are on monotherapy, maybe they are not efficiently 
treated to relieve their symptoms. However, when treated with several drugs, the 
synergistic effects of the drug combination may enhance the clinical response in 
patients. However, in order to prove this, further studies with a variety of drugs and 
doses are warranted. 
We also showed that miR-128 and miR-378 could be successfully inhibited using 
miRNA inhibitors (F).  In the negative control treated cells, where the miRNAs were 
not inhibited, upon treatment with the BD drug combination, the target genes (GRIN3A, 
NOVA1 and VIM; Figu) tended to be downregulated. However, in the cells where the 
miRNAs were inhibited, the BD drugs did not have the same effect. In other words, the 
expression of the target genes did not decrease in the presense of miRNA inhibiters. 
These target genes are either inhibitors of neurogenesis or neurite outgrowth. Therefore, 
when not downregulated, they will act to inhibit neurogenesis and neurite outgrowth, 
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which are affected in BD patients. Therefore, these findings further attest that the BD 
drug combination could indeed act via these miRNAs to bring about efficacy in BD 
patients by downregulating the target genes that inhibit neurogenesis and neurite 
outgrowth.  
The pathways affected by the miRNAs were related to neurite outgrowth and 
neurogenesis, which reinforce the previous findings described in chapter 3, where we 
measured neurite outgrowth in combination and individual BD drug treated cells. It was 
found that the BD drug combination tended to increase neurite outgrowth, whereas 
individually the drugs had no effects. This was an interesting finding as it relates well 
to the expression of miR-128 and miR-378 in individual and drug combination treated 
cells. Moreover, the variable effects of the drugs on miRNA expression and neurite 
outgrowth when in combination or used alone in this study add to the phenomena of 
polypharmacy and its clinical efficacy seen in BD patients. However, further studies 
are needed to elucidate the mechanisms driving these findings.  
Although we lack a complete understanding of the pathophysiology of BD, 
accumulating evidence suggest that neuronal degeneration may play a role in the 
disease. Post-mortem studies have consistently showed reduced brain volume, number, 
size and density of glial and neuronal cells [383]. Therefore, given that the drugs 
increased the expression of miR-128 and miR-378, it is plausible that these miRNAs 
are functioning together to affect genes that are associated with neurogenesis and 
neurite outgrowth in order to overcome the worsening of neuronal loss in BD patients. 
It is also possible that miR-378 increases cell viability and induces the cells to produce 
more cholesterol given its involvement in lipid metabolism, which is essential for 
neurite outgrowth, while miR-128 promotes neurogenesis and neurite outgrowth. 
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Moreover, these findings also give some insight into the mechanisms of how 
polypharmacy might bring about efficacy in BD patients.  
6.5 Conclusion  
In conclusion, here we show that a combination of four commonly prescribed BD drugs 
change the expression of a group of genes in neuronal cells that contribute to increased 
neurite outgrowth or axogenesis and neurogenesis, which are essential to renew 
degenerated neurons seen in BD patients. It is possible that this effect is mediated, at 
least in part, through modulation of the expression of miR-128 and miR-378. 
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CHAPTER 7 
CONCLUSIONS AND FUTURE DIRECTIONS 
7.1 Conclusions 
As discussed in chapter 3, we characterised the global transcriptional effects of the BD 
drug combination in NT2-N cells and rat frontal cortex using next generation 
sequencing. Using the differentially expressed genes in pathway analysis, we found that 
the BD drug combination upregulated the steroid biosynthesis pathway in NT2-N cells, 
and thereby increased the expression of all of the genes in the cholesterol biosynthesis 
pathway. In rats treated with the same BD drug combination, we found that the 
cholesterol biosynthesis pathway genes tended to be upregulated as well. Furthermore, 
it was also found that the synthesised cholesterol was being retained within the NT2-N 
cells and the ABCA1 gene, which is involved in the efflux of cholesterol was 
downregulated by the BD drug combination. When we quantified neurite outgrowth in 
the NT2-N cells, it was found that the BD drug combination increased the length of the 
neurites compared to individual BD drugs, which did not have any effects on neurite 
length. Therefore, this study showed that the BD drug combination may increase the 
biosynthesis of cholesterol in the brains of BD patients and the synthesised cholesterol 
is possibly used to elongate and protrude neurites to make more connections between 
neurons, thereby increasing neuronal plasticity. We believe that this mechanism 
perhaps underpins the clinical efficacy in BD patients treated with polypharmacy. 
In chapter 4, we explored the transcriptional effects of individual BD drugs in NT2-N 
cells, once again with the use of next generation sequencing. Using the same drugs as 
in chapter 3, but individually rather than in combination, we looked at the differentially 
expressed genes and also pathways the drugs regulate. We found that lithium regulated 
the “amino acid transport across the plasma membrane” pathway, while valproate and 
quetiapine regulated “antigen processing and presentation” and “CDK5” pathways. We 
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also looked at the expression of the genes involved in these pathways in the edgeR 
derived differentially expressed gene sets. However, this study was likely 
underpowered due to the low number of biological replicates. Therefore, the findings, 
although biologically meaningful to some extent, cannot be extrapolated as possible 
mechanisms of action of the individual BD drugs.    
The fifth chapter of this thesis looked at generating a GES as a proxy for the 
transcriptional effects of the BD drug combination in NT2-N cells and rat frontal cortex, 
and which genes also had evidence of differential expression in individuals with BD.  
We identified a total of 88 genes, which showed evidence of differential expression 
upon treatment with the BD drug combination in both models, and therefore comprised 
the GES. Six of these genes showed evidence of differential expression in post-mortem 
brains of individuals with BD. After validating the human relevance of the GES genes, 
we used it to find new drugs that can be repurposed for BD using CMap. The CMap 
analysis identified 10 compounds that produced transcriptional changes on the GES 
genes in a similar way to the BD drug combination. This study showed that GES and 
CMap can be used as tools to repurpose drugs for BD, and that this method is valuable 
in identifying drugs in psychiatry where the pathophysiology of the disorders are not 
well understood.  
The sixth chapter of this thesis explored the identification of differentially expressed 
miRNAs in BD drug combination treated NT2-N cells and rat frontal cortex. The BD 
drug combination increased the expression of miR-128 and miR-378. We obtained 
putative target genes of these miRNAs via microRNA.org and PubMed searches 
databases and used them in DAVID pathway analysis. The target genes of miR-128 and 
miR-378 affected pathways such as “neuron projection development” and 
“axonogenesis”. When we looked at the expression of the target genes in our next 
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generation sequencing data, we found that many of them were differentially expressed 
following treatment with BD drug combination. We conclude that the BD drugs affect 
a number of genes at a transcriptional level that would increase neurite outgrowth and 
hence neural plasticity, and that this is mediated (at least in part) by modulation of the 
expression of two key miRNAs. 
In conclusion, the BD drugs combination increased mitochondrial function and 
biosynthesis of cholesterol compared to individual BD drugs. This in turn increased 
neurite outgrowth, which is required for maintaining neuronal plasticity. It is possible 
that this effect of BD drug combination is mediated, at least in part, through modulation 
of the expression of miR-128 and miR-378. This could be a possible mechanism by 
which polypharmacy brings about its therapeutic efficacy in BD patients and why 
monotherapy is not always effective. Moreover, using CMap, there is an exciting 
prospect to identifying or repurposing drugs for BD, which could be an attractive 
method towards finding safer, cost effective and efficacious drug therapies for BD 
7.2 Future Directions 
While this thesis has demonstrated the potential of understanding the molecular 
mechanisms of BD drugs using NT2-N cells and rats in order to understand the 
pathophysiology of BD, many opportunities for extending the scope of this thesis 
remain. This section presents some of those avenues. 
One of the acknowledged limitations of this study is the suitability of NT2-N cells and 
rats as models to understand the molecular mechanisms of BD drugs. These two models 
do not represent the phenotype nor genotype of BD. However, they are reasonable 
models to understand the transcriptional effects of the BD drugs in neuronal cells and 
brains given the lack of validated animal models for BD. Nevertheless, for a more 
comprehensive understanding of how these drugs act in the brains of BD patients we 
could use induced pluripotent stem cells (iPSCs) technology. We believe it would be 
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interesting to validate the findings of this study in iPSCs derived from BD patients and 
controls.  
Moreover, the scope of this thesis was also limited to a single dosage of the drugs and 
duration of the treatment. While the dosages and time of treatment were determined 
empirically and from previously published data, it would be interesting to see the 
transcriptional effects of the BD drugs at different dosages and time points, which might 
help us to understand the chronic and acute drug mechanisms.  
In addition, when we measured neurite outgrowth in the NT2-N cells, we found that the 
measurements could be quite subjective and therefore could be biased. However, new 
technologies such as the use of real-time cell analysis could enable us to measure neurite 
outgrowth in real-time and at different time points with fewer chances for human error. 
When we quantified free cholesterol in NT2-N cells and rat brain, we used a 
fluorometric method. However, several other methods are available for quantification 
and visualisation of free cholesterol such as the use of filipin dye that binds to free 
cholesterol. These methods could not be explored due to time constraints; however, 
they offer interesting opportunities for future research.  
Finally, this research provides exciting prospects for drug screening and clinical trials. 
In this study we employed a GES with 88 genes to screen the CMap database to find 
drugs that could be repurposed for BD. However, this GES could be further reduced to 
6-7 genes, which could be used to screen drug libraries to identify drugs that can be 
repurposed for BD. Furthermore, this smaller GES could also be used in CMap analysis 
to identify drugs to treat BD. Following validation of this GES and a drug screen in 
iPSCs, the identified drug(s) could go into clinical trials to be repurposed for treating 
BD.  
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7.3 Summary 
BD is a chronic and debilitating mental health disorder that affects about 2% of the 
population around the world. The current medications used in treating BD have their 
limitations in improving the symptoms and present with several side effects. In order to 
develop better and more efficacious BD treatments, the pathophysiology of BD must 
be better elucidated. However, there is a paucity in the understanding of the 
pathophysiology of BD as well as the mechanisms of some of the currently prescribed 
BD medications. Therefore, one of the ways to understand the pathophysiology of BD 
is by reverse engineering where you first understand how the currently used BD drugs 
work at molecular level by identifying the transcriptional effects they induce.  
Therefore, in summary, this thesis has presented an approach that can be used in drug 
discovery in BD. We have analysed the molecular mechanisms of some of the BD drugs 
in human neuronal cells and rat frontal cortex. The ideas from this analysis lead to new 
avenues where by generating a GES we can screen large drug libraries to identify drugs 
that can be repurposed for BD. This will cut down the cost and time involved in the 
drug development pipeline as the drug libraries to be screened contain already approved 
drugs. We believe this approach will enable us to discover more efficacious, safer and 
cheaper drug therapies for BD. This method will also be promising in other psychiatric 
disorders such as SZ and MDD where the pathophysiology is not elucidated.  
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